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Abstract
This thesis describes human immunodeficiency virus type 1 (HIV-1) infection in
Kenyan infants. Paediatric HIV-1 infection causes rapid disease progression in the
absence of antiretroviral (ARV) therapy. African cohorts have reported the highest
rates of mortality, from 20-50% at 2 years of life. Understanding the pathogenesis in
HIV-1 infected children is important to the design of prevention, treatment, and
vaccination strategies. A cohort of 476 Kenyan children born to HIV-l infected
women was studied longitudinally from the time of birth to 24 months. Despite the
provision of ARVs to prevent mother-to-child transmission, 19.4% of infants became
infected with HIV-1. Infant HIV-1 infection resulted in persistently high levels of
viraemia and rapid CD4 depletion. Cumulative mortality at 2 years was 54%. Peak
and set-point HIV-1 viral load, and CD4% at 6 months were predictors of 2-year
mortality. Co-infection with cytomegalovirus (CMV) before the age of 1 month was
also associated with increased risk of death. Infants with HIV-1 infection had poorly
contained CMV viraemia in comparison with HIV-1 exposed uninfected controls.
Multicolour flow cytometry was used to describe the phenotype of T cells during
primary viral infection. Both CMV and HIV-1 infection resulted in dynamic
redistribution of T cell populations. High frequencies of activated, apoptotic
vulnerable, differentiating CD8 T cells were observed concurrent to acute infection
with either HIV-l or CMV. Co-infection with both viruses resulted in even more
profound changes in cellular phenotype. CD4 T cell phenotype was also affected by
acute viral infection, but at a much lower magnitude than observed in the CD8 subset.
HIV-l specific CD8 T cells were studied in a subset of infants using IFN-y ELISpot
assays and tetramer staining. Very high frequencies of HIV-1 specific CD8 T cells
were identified with tetramer staining, and these cells resembled adult T cell
responses in magnitude and phenotype. ELISpot assays revealed weak responses in
infants less than 6 months old that increased with age. These data suggest that HIV-l
specific CD8 T cell responses can be generated during acute infection in infants, but
IFN-y production is lower compared to adult cells. Reduced functional capacity may
explain the inability of infant T cell responses to contain HIV-1 viral load.
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CHAPTER 1: INTRODUCTION
SECTION I. THE IMMUNE SYSTEM
The major functions of the immune system are the discrimination of self from non-
self and elimination of foreign pathogens. This section reviews basic concepts in
immunology pertinent to the study of HIV -1 infection in infants.
The lymphoid organs
The primary lymphoid organs are the locations of lymphocyte development and
selection. B cells are produced in the foetal liver and then migrate to the bone
marrow where they continue to differentiate and undergo selection. T cells are
generated in the bone marrow and mature and undergo selection in the thymus. With
age the thymus shrinks, the cortex may disappear completely but the medullary areas
persist, enabling low levels ofT cells to be generated during adult life (147, 148).
The secondary lymphoid organs and tissues function to concentrate antigen and
maximise APe and T cell interaction. The spleen maintains surveillance and defence
against blood borne antigens. Lymph nodes (LN) are sites for cells to survey antigens
found in the lymph that have entered through the skin or mucosal surface. The LN
contains B cell areas (cortex) and the T cell areas (paracortex). The central medulla
consists of T, B, macrophages, and plasma cells. Antigen presenting cells carry
antigen into the LN, where they interact with T cells. The lymph nodes are located at
junctions of lymphatic vessels to form a network that eventually drains into thoracic
duct and into subclavian vein and back into the blood circulation. High endothelial
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vessels (HEV) allow traffic of lymphocytes out of circulation and into the LN.
Integrins on the endothelial cells (VCAM-I, MadCAM-I etc) mediate adherence to
the endothelium and facilitate lymphocyte trafficking into lymphoid tissue.
Cytokines and chemokines
Cytokines work in an interconnected network to co-ordinate all aspects of the cellular
immune response, and provide a bridge between the innate and adaptive arms of the
immune system. They are signalling molecules that act in an autocrine or paracrine
fashion. Cytokines include the interleukins (IL), interferons (IFN), tumour necrosis
factor (TNF), growth factors (GF), colony stimulating factors (CSF) and the
chemokines (82). Cytokines may activate cells by engaging their receptors thereby
initiating signal pathways involving Src and JAK kinases. IL-I(a and (3),IL-2, TNF-
a. and TNF-(3help activate T cells. Conversely, IL-lO and TGF-(3decrease cytokine
synthesis. IL-2, IL-7, and IL-IS stimulate proliferation of T cells, IL-7, IL-I4, and
IL-IS stimulate proliferation of B cells. Other cytokines have anti-proliferative
function: IFN-a, IFN-(3, and IFN-y (Thl cells). IL-7 and IL-IS support the
maintenance of memory cell proliferation and survival (IL-7 and IL-IS) (38) (480).
IL-4 and IL-S produced by CD4 T cells determine antibody isotype switching in B
cells. The CSFs induce differentiation, proliferation and migration of granulocytes,
macrophages and their precursors. IFN-y, a, and (3increase class I MHC expression
to augment antigen presentation during viral infection. IFN-y binding to T cells
results in activation of the JAK-STAT pathway, and alters transcription of genes to
support anti-viral defences, including the development and proliferation of Th cells
and their effector functions (593).
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Chemokines are a subset of the cytokines that mediate cell migration. Chemokines
have two receptor binding sites, one to bind the epithelium, one to bind the ligand on
the tethered lymphocytes. In this way, cells expressing the correct chemokine
receptor are recruited to areas of inflammation. Cytokine receptors are classified
based on spacing of cysteine residues, c-chemokines (CXC), l3-chemokines (CC),
XCRl, and CXC3Rl. CCR5 and CXCR4 receptors are co-receptors for the human
immunodeficiency virus (HIV). Chemokines can thus compete for receptor binding
with viruses and mutations in chemokine receptor genes can inhibit viral entry (106).
Toll-like receptors
Toll-like receptors (TLRs) also provide an important link between the adaptive and
innate immune systems. Phagocytes have pattern recognition receptors (PRR) that
bind to pathogen associated molecular patterns (PAMPs) - conserved structures
common to many microbes. TLRs are an important part of the system, and are
expressed on the cell surface or in the cytoplasm on membrane-bound organelles.
Binding of TLRs activates adaptor proteins that initiate signal transduction to recruit
NF-KB(361). The cellular response depends upon the TLR ligated and the adaptor
protein, and can result in cellular activation, cytokine production, phagocytosis, or
apoptosis. Ten TLRs have been identified in humans. TLR4 was the first identified, it
recognises LPS. TLR2 recognises peptidoglycan, TLRs 3, 7, 8, and 9 nucleic acids,
and TLR-5 recognises flagellin (529).
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Innate immunity
Innate immune responses are generated rapidly and have no immunologic memory.
Components of the innate arm of the immune system recognise highly conserved
motifs common to extracellular pathogens and their specificity does not change upon
secondary challenge.
Complement
Complement was first described in 1901 by the Belgian immunologist Jules Bordet as
agents in the serum ("alexine") that had the ability to complement the lytic effects of
antibodies against bacteria (59). The complement system is composed of -30 serum
proteins that control inflammatory reactions to extracellular organisms. Their
functions include chemotaxis, clearance of immune complexes, cellular activation,
and direct antimicrobial defence. The complement system is regulated by the short
half-life of the component proteins and the activity of complement regulatory proteins
bind C3b and prevent it from triggering downstream reactions. The complement
system functions through three pathways working in a signal cascade, so a small
number of interactions can initiate a large response. In the classical pathway, Cl
protein binds IgG or IgM coupled to antigen(438). The alternative pathway is
activated by microbial cell wall components that lack complement regulatory
components DAF and Mep. The lectin pathway is activated by the interaction of
microbial carbohydrates with the lectins: mannose binding lectin (MBL), ficolin H, or
ficolin L (191). The three pathways converge to activate C3 protein. C3 protein binds
to bacteria, viruses, and fungi, and initiates phagocytosis by binding to receptors on
monocytes, macrophages, and DC. Fragment C3a activates phagocytes and mast cells
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and C3b can opsomse microbes. Phagocytes have receptors for complement
fragments; these fragments diffuse away from the site of infection and stimulate
chemotaxis toward the affected area. C3 activation results in the sequential activation
of proteins C3-C9, polymerisation of C9 protein to form the membrane attack
complex (MAC), which mediates lysis of target cells by inserting itself into the lipid
bi-layers of bacteria or viral envelopes.
Granulocytes
The majority of granulated phagocytes (95%) are polymorphonuclear leucocytes
(PML), also known as neutrophils, which recognize protein fragments released when
complement is activated (C5a), factors from fibrinolytic and kinin systems, products
of other leucocytes and platelets, and bacterial products. Microbes are sequestered
within phagosomes that fuse with lysosomes, resulting in destruction of the microbe.
Granulocytes can also degranulate if activated through their Fcy receptors and act as
cytotoxic cells. Basophils and mast cells comprise about 0.2% of leucocytes.
Degranulation of basophils enhances the inflammatory response against parasites but
can also cause allergy. Eosinophils comprise 2-5% of blood leucocytes. Though
capable of phagocytosis, their primary function is defence against large pathogens
that cannot be phagocytosed (such as helminths and schistosomes) via degranulation.
Eosinophils also have a regulatory role in the immune response, the release of
histamine and aryl sulphatase inactivates mediators of inflammation.
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Monocytes and macrophages
Monocytes have several functions which transverse both the innate and adaptive arms
of the immune system. Monocytes and macrophages (monocytes which have
migrated into extravascular spaces) express PRRs that which recognise PAMPs.
Macrophage PRRs include TLRs, CD36 scavenger (which recognises bacterial
antigens and apoptotic cells), CDI4 (recognises lipopolysaccharide - LPS),
complement receptors, and FeR.
Phagocytosis results in degradation of the microbe, and shuttling of microbial proteins
into the antigen processing and presentation machinery of the cell, making them
important antigen presenting cells (APC) for lymphocytes. When activated by their
receptors, monocytes produce cytokines (ILl-, IL-12, IL-18, TNF-n) that activate
other cells of the immune system and chemokines (RANTES, MIP-I c, MIP-I13)that
attract cells to the site of inflammation.
Dendritic cells
Dendritic cells (DC) are professional antigen-presenting cells. There are two main
lineages, the myeloid (mDC) which share a common progenitor with monocytes and
expresses CD11c+ and the plasmacytoidllymphoid (PDC) which differentiates from
the common CD34+ progenitor and is CDIIc-. mDC are potent stimulators ofnaYve
T cells, and secrete IL-I2, pDC produce high levels ofIFN-n. Immature DC express
low levels of class II MHC and have a high endocytotic capacity. They migrate to the
non-lymphoid tissues, and are found in areas exposed to the external environment
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such as the skin (Langerhans cells) and mucosa where they encounter antigen.
Immature DC take up antigen through macropinocytosis, phagocytosis, or via PRRs
such as TLRs and mannose-binding C-type lectin receptors, and migrate to the lymph
nodes (LN). En route to the lymph nodes they undergo maturation, begin to secrete
IFN-a, and interact with naive precursor CD4+ T cells to initiate the cellular immune
response. As DCs mature, they begin to express higher levels of MHC class II and
become highly efficient antigen presenting cells. The HIV-l envelope gp120 binds
CD209 (DC-SIGN) on DCs and is transported to LNs to facilitate dissemination and
infection of T cells (202).
NK cells
Natural killer (NK) and NK T cells are derived from a common progenitor cell in the
thymus. NK cells comprise 15% of blood lymphocytes in adults. NK can be
identified by the absence of CD3 and the expression of CD16 and/or CD56. At least
two phenotypically and functionally distinct groups of NK cells have been identified,
the CD56brightCDl6_subset, which secretes high levels of cytokines (lFN-y, TNF-a)
and CD56dimCDI6+ cells which have high cytotoxic activity and can kill targets
without prior sensitisation in a non-MHC restricted manner. NK cells mediate
cytotoxicity via two main mechanisms. NK cells recognise targets coated with IgG
via CD16 (FcyRIII receptor) and are activated to secrete cytokines or degranulate, this
process is called antibody dependent cellular cytotoxicity (ADCC).
In the second mechanism, NK cell activity is regulated by a balance of activating and
inhibitory signals mediated through surface receptors. Engagement of activating
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receptors and activation of immunoreceptor tyrosine-based activating motifs (ITAMs)
results in cytokine secretion, degranulation, and induction of apoptosis. However,
engagement of inhibitory receptors results in the recruitment of cytoplasmic
immunoreceptor tyrosine-based inhibitory motifs (lTIMs) to block activation signals.
NK cells express killer immunoglobulin-like receptors (KlRs) containing 2 (KlR2D)
.or 3 (KlR3D) extracellular Ig-like domains. KlRs with short cytoplasmic tails
activate NK cell function and those with long cytoplasmic tails inhibit NK cell
function (556). The ligands for KlRs are class I MHC molecules, and recent studies
suggests their recognition may also be peptide-specific (533) (228). Other NK
activating receptors include CD16 (FcyRIII), CD94INKG2C (ligand is HLA-E), NCR,
and ILT-1 (Ig-like transcript 1). The inhibitory receptors include ILT-2 (ligands are
HLA-A, -B and G), CD941NK2GA (ligand is HLA-E). Viruses and tumours down-
regulate or modify class I MHC as a mechanism to avoid cytotoxic T cells (CTL) and
NK recognise virus-infected and tumour cells by their suspicious lack of class I MHC
molecules (''the missing self'). If class I MHC are present, the NK cell receives an
inhibitory signal and moves on without killing.
NKTcells
NK T cells are found in low numbers throughout the circulation and tissue. NK T
cells express NK lineage markers and have an a.~ T cell receptor (TCR). The NK T
cell receptor repertoire is much more limited than the CD4 and CD8 T cell TCRs, and
is restricted by CDId bound to glycolipids. There are two main subsets ofNK TCRs,
the Va.14 and non- Va.14. Va.14 recognise a marine sponge derived a-
galactosylceramide (aGalCer), microbial a.-glycuronylceramides and the self antigen
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isoglobotrihexosylceramide (jGb3). Epitopes for non-Va.14 TCRs have not been
identified. NK T cells super-activate resting DC, causing an upregulation of class I
and class II MHC and CD40 expression. NK T cells become activated themselves by
the interaction, upregulate CD40L expression, and produce very high levels of both
Thl and Th2 cytokines, including IFN-y, IL-4 and IL-13.
Adaptive immunity
The adaptive arm of the immune system prevents disease upon re-infection by
generating immunological memory. During primary infection with a pathogen, narve
precursor cells are activated by specific antigens and undergo clonal expansion as
they acquire effector functions. Upon clearance of the pathogen, a number of the
effector cells persist in the host as slowly proliferating, long-lived memory cells.
Memory cells respond rapidly upon secondary stimulation with antigen, providing
rapid clearance of the pathogen. The adaptive immune system can be divided into
humoral immunity, which is mediated by B cells and antibodies, and cell-mediated
immunity, which is mediated by T lymphocytes.
Humoral Immunity
B cells are produced in the foetal liver and then migrate to the bone marrow where
they continue to differentiate and undergo selection. The humoral system consists of
antigen-specific molecules that clear antigen in the blood. B cells comprise between
5-15% of lymphocytes and are defined by expression of the B cell receptor (BCR)
and CDI9, CD20, and CD22. The BCR is immunoglobulin (Ig), most B cells express
IgM and IgD, much fewer express IgA, IgE, IgG. Accessory molecules of the BCR
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are CD79a and CD79b, which participate in cell-signalling. Most B cells express
MHC II enabling them to act as APC for CD4 T cells. B cell activation and homing
are facilitated by ligation of complement receptors for C3b, C3d. B cells proliferate
upon activation and acquire effector functions. Plasma cells are terminally
differentiated B cells which have lost surface Ig but secrete large amounts of Ig
(antibodies). Antibodies are vital to acute antiviral defences, and are able to provide
sterilising immunity.
The basic structure of the antibody is two identical light chains and two identical
heavy chains, one light chain is attached to each heavy chain and the heavy chains are
attached to each other. Each of the antibody chains consists of repeating units of
amino acids which fold independently into globular motifs known as immunoglobulin
(Ig) domains. Both the light and heavy chains have variable (VL and VH) and
conserved domains (CLand CH). Both light and heavy chains contain hypervariable
regions in the N-terminus called complementarity-determining regions (CDRs).
CDRs are presented as projecting loops with highly variable amino acid sequences,
and the CDRJ regions form the antigen binding site. Proteolytic cleavage of Ig
monomers revealed distinct fragments with different binding properties(107).
Digestion with papain cleaves Ig before the disulphide bond which links the two
heavy chains, resulting in two identical fragments each retaining the ability to bind
antigen (Fab = Fragment, antigen-binding). These were formed by the combined light
and heavy chains and contained both variable and constant domains of each. The
third fragment, formed by the CHdomains, crystallised into a lattice (Fe = fragment,
crystalline). The Fe portion of Ig is conserved between antibody classes (isotypes)
and mediates many of the effector functions of antibodies. Digestion of Ig with
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pepsin cleaved after the disulphide bond, resulting in a large F(ab')2 fragment which
contained the two Fab regions. The Fe region was cleaved into small peptides. In
summary, each monomeric antibody was determined to have 2 Fab and one Fe region.
Generation of antibody diversity
Stimulation of cells with antigen was shown to result in the expansion of cells
producing antibodies against the antigen (550). The germ line was too small to
account for this level of diversity on a one gene, one protein basis (535). Comparison
of heavy and light chains from different mouse tumour cell lines revealed that half of
the chains was always identical within antibody classes, whilst the other was unique,
and in 1963 Dreyer and Bennett put forth the hypothesis that the genetic material
adjacent to the common part of the antibody was subject to a "genetic scrambling
process" during the differentiation of specific cells (152), and that this could be
achieved by multiple crossovers during recombination (507). It was later discovered
that both heavy and light chains undergo somatic rearrangement. Antibody diversity
is achieved by two mechanisms, V(D)J recombination during B cell ontogeny, and
somatic hypermutation in response to antigen binding. Multiple genes encode the
variable and constant regions of the Ig protein. The light chain variable region is
encoded by multiple variable (V) and joining (1) genes and the constant region is
encoded by constant (C) genes. The heavy chain variable region is encoded by V, J,
C and D (diversifying) gene segments. Somatic rearrangement of the Ig genes begins
with joining of D and J genes in the heavy chain locus and deletion of intervening
DNA(20). One V gene is joined to the DJ complex to create VDJ. All D segments 5'
to the rearranged D are deleted. Following transcription the intron between VDJ and
C is spliced out, giving rise to the functional VDJC transcript of the heavy chain. The
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light chain follows the same pattern of VJC arrangement, following translation the
light chain assembles with the heavy chain and is transported to the cell surface.
Recombination of the Ig loci is mediated by recombination activating genes 1 and 2
(RAG-l and RAG-2) which recognise recombination signal sequences (474) (356) in
the introns between the genes. Combination of different heavy and light chains adds
another layer of diversity to the Ig repertoire, there are 5 heavy (o, 6, E, y, u) and two
light chain loci (A, K). Finally, junctional insertions and deletions during
rearrangement can further add to diversity. Antigen dependent somatic
hypermutation of Ig follows ligation of antigen. Point mutations are induced into the
V region of the antigen binding site, creating an Ig variant with enhanced affinity for
the antigen. B cells expressing Ig for self antigen are deleted in the bone marrow,
become anergic, or undergo additional light chain rearrangements to alter antibody
specificity (210) (239).
Antibody class is determined by structure of the heavy chain. In secreted form the
tails of the heavy chains interact with one another though a 15 kD polypeptide to form
multimeric Ig molecules, IgM forms a pentamer and IgA forms a dimer. When bound
to the cell membrane all antibodies are monomeric. IgG comprises 70-75% of
immunoglobulins and is a monomer in secreted form. IgG is the major Ig involved in
secondary immune responses. IgG promotes ADCC by opsonisation, binds Fe
receptors on macrophages and neutrophils, and activates the classical pathway of
complement. IgM in pentameric, it comprises -10% of serum Ig and is important in
the response to blood-borne infectious organisms, especially during acute infection.
IgA forms 15-10% of Ig and exists as a monomer or dimer. IgA protects mucosal
surfaces and is abundant in saliva, colostrum, breast milk, and tracheobronchial and
24
genitourinary secretions. IgD forms <1% of serwn Igs, but is a major B cell surface
component and is involved in B cell differentiation. IgE is also found in low
concentration in the serum «1%), it is a component of surface membrane of
basophils and mast cells. IgE is involved in the sensitisation of mucosal surface cells
on conjunctival, nasal, and bronchial mucosae and may prevent helminth infection.
IgE is also involved in the generation of allergic reactions.
Affinity maturation and class switching
The processes of affinity maturation and class switching are important in primary and
secondary immune challenge (394). In the early stages of the immune response,
antibodies have low affinity for antigen. During the course of the immune response
the average affinity of antibodies increases in a process called affinity maturation.
Two mechanisms mediate this, somatic hypermutation and antigen driven selection
and expansion of B clones expressing higher affinity antibodies. The predominance
of higher affinity antibodies allows a more rapid, efficient clearance of pathogen upon
secondary challenge. Antibody class switching also occurs during B cell
proliferation. Though each B cell produces only one type of VL chain, somatic
recombination and differential splicing of the heavy chain constant (C) genes enable
variation in the heavy chain. Hence a cell once producing one type of antibody (such
as IgM) can switch to producing another class (lgG) of antibody with the same light
variable chain and same epitope specificity.
Together, affinity maturation and class switching enable the adaptive immune system
to generate a more efficient secondary response to challenge. The primary response
to viral challenge occurs after a time lag, characterised by appearance of high IgM
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and low IgG titres, with mixed low and high affinity. The secondary response occurs
much more quickly than the primary challenge, antibody titres may be >1O-fold
greater, antibodies are of higher avidity, and primarily IgG-type.
Antibodies in the foetus
Though B cells are present in the developing foetus, antibody production is greatly
reduced in the neonate (230). IgM cannot cross the placenta, and is produced by the
neonate. IgA production is very low in the newborn, it also does not efficiently cross
the placenta and must be acquired though breast milk. Though neonates cannot
synthesise IgG, high levels are acquired through placental transfer. By 9 months of
age, IgG synthesised by the infant has usually has replaced maternal antibody (5), but
prolonged breastfeeding can mean the persistence of maternal antibody. By 12
months of age, the infant produces 80% of adult level IgG, 75% of IgM, and 20%
IgA.
T lymphocytes
T cells are produced in the bone marrow from and migrate to the thymus where they
differentiate and undergo positive and negative selection. T cells are identified by
their expression of CD3, CD45 and the surface T cell receptor (TCR). The TCR is a
disulphide linked heterodimer of two subunits, either aJ3 (95% ofT cells) or yb chains
(-5% of T cells). yb T cells protect the mucosal epithelia, their TCRs recognize
glycolipids and lipids and do not appear to require APC. Most yb in the blood are
CD4-CD8-, in tissues they are usually CD8+. aJ3 T cells are the main mediators of
cellular immunity against viral infection. Each subunit chain contains two Ig-like
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domains, a and f3, each of which has a variable (V) and constant domain (C) (198).
The a and f3 chains are anchored to the plasma membrane and have a short
cytoplasmic tail. Each of the V regions contains 3 complementarity-determining
regions (CDR) that bind the peptide and MHC. The TCR is expressed at the cell
surface in association with the CD3 molecule. CD3 is necessary for TCR expression
at the cell surface and for signal transduction upon TCR ligation. CD4 and CD8
proteins expressed on the T cell form part of the binding complex to recruit tyrosine
kinases that phosphorylate CD3, and initiate T cell activation.
T cells are produced in the bone marrow and mature in the foetal thymus. The
expression of Notch-l results in commitment to aT cell lineage (581). Diversity in
the TCR repertoire is generated by similar mechanisms as the Ig genes and somatic
recombination is mediated by RAG-I and RAG-2. Genes are rearranged during
lymphocyte differentiation in the thymus while the cells are CD4-CD8-. The a chain
genes are located on chromosome 14 and is composed of V, J and C segments and the
f3 chain is composed of V, J, C and D segments on chromosome 7. There are two j3
chain loci and one a chain locus. The 13 chain is arranged first, D is joined with J then
the DJ complex is joined with a V segment to form VDJ. Splicing of mRNA results
in joining with a C gene segment (there are two and selection of which one seems to
be random). Rearrangement of the a chain locus is similar, V is joined with J, and
following transcription, VJ mRNA is joined to C to make VJC. Only one of the two f3
chain loci are expressed in the T cell, the productive arrangement of one locus inhibits
rearrangement of the corresponding locus on the other chromosome by allelic
exclusion. TCR diversity is thus achieved through the use of multiple VD and J
segments, the combination of different V, D and J genes during rearrangement, and
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the pairing of diverse a and ~ chains. Junctional diversity is also generated through
N-region diversification of both the a and ~ chains which is catalysed by
deoyribonucleotidyl transferase (TdT) (288). This includes the random addition of
nucleotides that are not part of the genomic sequence at VD, DJ, and VJ junctions and
imprecise joining of gene segments. In addition, many ~ chain D segments can be
translated in all three reading frames. By the combination of these processes, it is
estimated that _1011different TCR CDR3 arrangements are possible.
"Double positive" CD4+CD8+ al3 T lymphocytes undergo selection in the thymus
following TCR rearrangement. During positive selection, antigen is presented by
DCs and macrophages of the cortical epithelium of the thymus. Lymphocytes with
TCR that recognise self-MHC are given a survival signal, those that fail to recognise
self MHC undergo apoptotic death (death by neglect). During negative selection
TCRs with high affinity for self MHC/peptide complexes are deleted. The majority
of self-reactive T cells are deleted during this process, and only a small fraction of the
original TCR repertoire survives the process to enter the circulation. Based upon their
recognition of class I or class II MHC and the strength of signal received, CD4 or
CD8 is lost from the double positive thymocytes, and the mature cells express CD4 or
CD8 (252, 404).
T cell subsets
Though they share a common progenitor, CD4 and CD8 T cells have distinct
properties. CD8 T cells recognise infected cells by the presentation of viral antigen
complexed to class IMHC molecules. Once activated, CD8 T cells proliferate and
mature into effector T cells. Mature cytotoxic CD8 T cells (CTL) can kill virus-
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infected cells via Fas or perf orin-mediated pathways. CD8 T cells also release
cytokines which promote their own proliferation (IL-2) and limit viral infectivity
(IFN-y). Cells of this phenotype are called Tel. Alternately, CD8 T cells may
produce suppressive eytokines (Tc2 cells) such as IL-IO which inhibits cellular
proliferation and activation by down-regulating cytokine synthesis.
CD4 cells can also be cytotoxic but primarily support the adaptive immune response
via the production of cytokines that stimulate CD8 T cells, B cells and DC, hence the
name "T -helper" cell. CD4 recognise APC expressing class II MHC. CD4 are
further categorised by their production of IFN-y (Thl) or IL-4 (Th-2). The
polarisation of naive CD4 into Thl or Th2 cells is determined at the time of priming
by the strength of TCR-MHC peptide engagement and cytokine signalling (530,531)
(400). CD4 can be induced into a Thl phenotype by stimulating naive cells in the
presence of IL-l2 (in vivo this comes from DCs), and Th-2 type can be induced by
stimulation in the presence of IL-4. Polarisation to a Thl phenotype is mediated by
the action of STAT4 and T-bet which induce the IFN-y gene (527) (383). Alternately
STAT6 signalling and GAT A3 induce the IL-4 gene resulting in a Th2 phenotype cell
(314). Thl cells are important in defence against intracellular pathogens, their IFN-y
activates macrophages, and binding of CD40L on T cells to CD40 activates DCs.
Thl cells also produce IL-2, which stimulates cellular proliferation. Th2 type cells
produce IL-4, IL-5, IL-6, and IL-IO. Th2 cells are active against extracellular
pathogens, they mediate inflammation and stimulate B cells to proliferate and secrete
antibodies. Follicular B helper T cells (TFH) are a distinct subset of CD4 T cells that
support the development of memory B cells in lymphoid follicles (557). TFH express
CXCR5 and thus home to germinal centres of B cell proliferation. TFH may develop
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from Th2 type cells, or may form a separate lineage; commitment to the TFH
phenotype is believed to be determined by the expression of transcription factor BCL-
6. TFH from the follicles of the tonsils express the inducible T cell co-stimulator
(lCOS), Ox40 (C0134), C040L, and secrete IL-lO and IL-21, which together support
B cell survival and development. ICOS ligation stimulates T cells to proliferate and
produce IL-lO, which with IL-21 enhances B cell proliferation. B cells failing to
interact with T cells undergo apoptosis, but ligation of C040 results in survival.
OX40 binding is required for the development of memory plasma cells, somatic
hypermutation and antibody class switching. The presence of TFH in B cell germinal
centres may thereby enhance B cell proliferation, survival, and development into
long-lived memory plasma cells. Additional C04 T cell subpopulations have been
defined by their ability to secrete high levels of TGF-f3 (Th3), and IL-17 (Th17)
(232). Th3-type cells have suppressor function, and Th17 are important in
inflammatory responses at mucosal surfaces(283).
C04 T cells also have suppressive functions that are important in the maintenance of
peripheral tolerance and down-regulation of the adaptive immune response(463).
These regulatory T cells (Tregs) can be divided into naturally occurring (nTreg) and
induced (iTreg). Both have the ability to down-regulate C04 and C08 activity,
including the production of IFN-y and proliferation. nTreg express high levels of the
IL-2 receptor a (C025), glucocorticoid-induced TNF receptor (GITR), and C0152
(CTLA-4), are C012iow and are dependent upon IL-2. nTreg are committed in the
thymus to a regulatory function by induction of the FOXP3 gene (a fork head/winged
helix family gene) transcriptional regulator(199, 280). This subset functions in a non-
antigen-specific manner, though signalling through the TCR may be involved in their
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activation. nTreg are important in maintaining peripheral tolerance to self-reactive T
cells that have escaped thymic selection; in the mouse model their absence results in
autoimmunity and adoptive transfer has been show to restore peripheral
tolerance(464). The suppressive mechanism of nTreg activity is not yet well defined.
In vitro, nTreg appear to require cell-cell contact, but suppressive cytokines (IL-I0
and TGF-B) may also be involved. iTreg are generated during the adaptive immune
response, and arise from naive CD4 T cells via induction of Foxp3. The generation of
iTregs is antigen-specific, and requires the participation of cytokines including TGF-
13. The iTreg subset is more heterogeneous than the n'Ireg, and includes CD4 cells
producing IL-l 0, and TGF-13.
MHC restriction
The importance of cytotoxic T cells in antiviral immunity was revealed during the
early 1970s with the demonstration that splenocytes isolated from mice infected with
lymphocytic choriomeningitis (LCM) or ectromelia (mouse pox) viruses could reduce
viral titres when adoptively transferred into mice or used in vitro lytic assays (51-53,
373). Anti-6 serum reduced or ablated the effect suggesting the transferred cells were
derived from the T cell lineage. Experiments by Zinkernagel and Doherty revealed
that histocompatability between at least one H-2 allele of the effector and the target
cells was required for the lytic activity (601, 602). This lead to the "altered self'
hypothesis that the transferred cells recognised either virus-modified H-2 or virus
complexed with H-2 (601), though it was still a matter of debate as to whether there
was one or two receptors (one for the virus, one for the MHC) involved in the signal.
In humans HLA restriction was confirmed using influenza virus (360). The final
pieces of the puzzle were assembled with the crystallisation of the HLA-A2 molecule
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(48) (49) and the demonstration that T cells recognise epitopes on viral protein
fragments presented by HLA molecules(541) (539,540).
The human HLA locus is located on chromosome 6 and encodes several genes
involved in the immune response. The class I genes encode HLA-A, B, C, E, F, G.
The class II genes encode HLA-DRA, DRB, DPA, DPB, DQA, and DQB genes. The
class III genes encode several diverse genes, many of which are involved in
immunity; these include complement proteins, 1NF-a, heat-shock proteins and
proteins involved in antigen processing (TAP). HLA-A, B, and C present small viral
peptides to the CDS T cell receptor. HLA-C, E and G are NK cell ligands, the
expression of HLA-G on the placenta inhibits NK-mediated rejection of the
foetus( 451). The class II HLA molecules present viral peptides to the CD4 T cell
receptor.
Class I HLA molecules are expressed on nearly all nucleated cells. The class I MHC
molecule is a heterodimer composed of a heavy 45kDa chain and the non-covalently
bound, light invariant fhmicroglobulin chain( 469). There are three extracellular
domains, a1 (N terminal), 0 2, 0 3 and a cytoplasmic tail. The 03 domain interacts
with CDS on the T cell and is invariable. Together a1 and 02 together form the
antigen-binding groove that holds the viral peptide. The peptide-binding cleft is
formed by two alpha helices atop a (3-pleated sheet, residues in both the helices and
the sheet are polymorphic and differ between HLA-types. These variations form the
3-D structure of the groove and determine what peptides may bind there. The floor of
the peptide-binding groove has recessed pockets with amino acid motifs enabling the
binding to specific amino acid side chains. There are two pockets in the binding
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groove that are critical for stable peptide binding, these bind "anchor residues" at
position 2 and 9 of the peptide(309, 524). Though each individual HLA molecule
may have the potential to bind multiple peptides, the array of peptides that bind there
is limited by the anchor residues. Changes to anchor residues in the peptide are most
likely to inhibit binding. Peptide side chains point upwards away from the HLA
molecule and these are recognised by the TCR. Changes in amino acid sequences that
lie at anchor residues, or contact the TCR can impede binding to the HLA or the TCR,
and is one of the mechanisms by which HIV-1 escapes from CTL responses. The
class I peptide binding groove is closed on its ends so the length of peptides binding
there is limited to 9-11 amino acids. Class II MHC are expressed on a limited number
of cells including macrophages and DC. Class II MHC are heterodimers of 2 heavy
chains, comprised of ol, a2, fU, and 132extracellular domains; there is no
132microglobulinsubunit attached. The overall structure of the peptide binding cleft is
similar to the class I molecule, but the antigen binding cleft is open on the end,
enabling it to accommodate larger peptides over 20 amino acids long(522).
Antigen processing and presentation to T cells
Antigen presentation via class I and II MHC requires "processing" of foreign proteins
to generate peptides of the appropriate size. Though any cell expressing class I or II
MHC has the potential to be an antigen presenting cell (APC), some cell types are
particularly efficient at processing antigen and presenting it to T cells. These are
known as "professional" APC; these include B cells, macrophages, and DC. DCs are
the most effective APC, and unlike B cells and macrophages their primary function
appears to be antigen presentation.
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Antigens for class I MHC are cellular proteins produced endogenously within the
APC. Sources of endogenous protein include viral and host proteins synthesised
within the cell, alternative transcripts and defective proteins. Peptides have been
found with post-translational modifications suggesting that stable proteins can also be
presented through the endogenous pathway. Proteins are targeted for degradation by
ubiquitination and degraded within the barrel-shaped proteasome by the LMP2 and
LMP7 subunits(99, 538). Following egress from the proteasome, peptides are further
trimmed at the N-terminus by cytosolic peptidases. TAP proteins 1 and 2 stabilise the
peptides to prevent degradation in the cytosol while being transported to the lumen of
the ER. In the ER more trimming may take place via ERAAP or ERAP1 peptidases.
Chaperone proteins calnexin, calreticulin and ERP57 associate with the class IMHC
molecule while awaiting assembly. TAPASIN is involved in quality control for
MHC/peptide assembly, it mediates selection of peptides for loading based on their
half-life, retains unstable complexes in the ER, and may retrieve unstable complexes
that have already exited the ER(243, 416). TAPASIN forms a bridge between TAP
and the MHC until the peptide is able to associate with class I. B2microglobulin
attaches to the MHC, and peptide is loaded before disengagement of chaperones.
More peptide editing may take place after loading on the MHC. Association of all
three components, heavy chain, j32microglobulin and peptide, are required for
expression at the cell membrane (537). The assembled peptide-MHC complex is
transported through the Golgi to the plasma membrane.
T cell pnmmg of class I MHC to exogenously derived antigen has also been
described(46). This so-called "cross-presentation" enables the presentation of
antigens which do not infect the APC, and is particularly important in immunity
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against twnour antigens. DC and macrophages are both capable of cross presentation.
Antigen endocytosed via FcyR, phagocytosis or macropinocytosis is exported to the
cytosol for proteasomal degradation (294) then escorted by TAP for loading onto
class I MHC in the ER or in specialised phagosome-ER compartments (221).
The class II pathway presents proteins that have been endocytosed by phagocytosis,
macropinocytosis or receptor-mediated endocytosis, and processed in endosomes. In
addition to microbial antigens, apoptotic cells also enter into the class II system in this
way. Following translation, the aj3-heterodimer is inserted into the ER membrane
and complexed with an invariant polypeptide (Ii) which serves as a placeholder until
peptide loading (115). Class II MHC are assembled in a specialised compartment
called the MIIC. The Ii fragment is cleaved into smaller fragments, one of these the
CLIP (class II associated invariant peptide) sits in the peptide-binding groove of the
class II molecule until it is replaced by peptide. It is not yet known whether proteins
are degraded before or after loading onto the MHC (491). The HLA-DM molecule
binds to the class II MHC, altering its binding properties and enabling release of CLIP
and allowing peptide to take its place (567). The entire complex is then transferred to
the cell membrane for presentation.
The immunological synapse and cellular activation
The immunological synapse is formed by contact between an APC and an effector
cell. The TCR is angled at 45-80° across the MHC binding site. The CDR3 loops of
the Vj3chains form the peptide binding site and the CDRI and bind the MHC (41)
(139). Only a few amino acids of the peptide are contacted by the TCR at the
interface, between 5-7 on class I and 6-7 on class II peptides. Changes to the peptide
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amino acid sequence can greatly alter binding at the interface; altered peptides may
fail to load onto MHC or contact TCR (no delivery of activation signal), may have
reduced avidity for TCR (delivering a weakened signal) or may act as antagonists,
inhibiting T cell activation. T cell activation corresponds to the "tightness" and the
duration of the binding (118).
The participation of other molecules is also crucial for delivery of an activating
signal. During TCR-MHC engagement, the microtubule organising centre (MTOC)
becomes polarised to a location underneath the synapse. Other molecules within the
T cell membrane are recruited to the area of TCRlMHC interaction by the movement
of lipid rafts. A "bulls-eye" pattern is formed with the TCR and associated molecules
forming the supramolecular activation complex (cSMAC) at the centre, surrounded by
adhesion molecules and CD45 (244). Adhesion molecules on the APC (ICAMs -1
(CD54) ICAM-3 (CD50)) interact with LFA-I (CDllalCDI8) and talin on the T cell
to increase the duration of interaction between the two cells. Complete T cell
activation requires delivery of a secondary signal after TCR-MHC interaction, this
signal is provided by co-stimulatory molecules. CD28 on T cells interacts with B7-1
& B7-2 (CD80 & CD86) on DCs or monocytes. Alternatively, CTLA-4 can interact
with B7 molecules to deliver an inhibitory signal. Co-stimulation via CD28 greatly
augments the activation phenotype of the cell, particularly IL-2 production. If no
second signal is delivered, T cells do not respond optimally to antigen, and
antagonism can result.
The process of cellular activation proceeds from the secondary receptor engagement
through intracellular motifs. CD3 is associated with the TCR at the cell membrane
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and its tail contains an immunoreceptor tyrosine activating motif (ITAM). When
TCR is engaged, the ITAM is phosphorylated by p56 Lck, and results in the
recruitment ofZAP-70. Zap-70 phosphorylates downstream proteins to begin a signal
transduction cascade. This cascade ultimately results in the release of Ca2+ ions from
intracellular stores and translocation of transcription factors (NF -AT and NF -KB) to
the nucleus (174). NF-AT activates IL-2 transcription, which has both autocrine and
paracrine function to initiate cellular proliferation.
Mechanisms of cytotoxicity
Cytotoxic T cells (CTL), NK, and cytotoxic CD4 can all participate in the cytotoxic
response. Cytotoxicity can occur via direct cell-to-cell signalling or via soluble
intermediaries. All pathways involve cellular differentiation into effectors (activation,
proliferation & formation of cytolytic granules), unidirectional delivery of a death
signal, and initiation of apoptosis in the target cell. CTL and NK are serial killers,
with cell-cell interactions occurring within a few minutes, whereas killer CD4
maintain a single cytotoxic synapse for several hours. Two main pathways
predominate in the adaptive cytotoxic immune response, the Fas and granule-
mediated pathways (267). Activated CD4 and CD8 T cells upregulate expression of
Fas ligand (FasL), enabling delivery of a death signal to cells expressing Fas receptor
(CD95). FasL may be stored in cytolytic granules (and secreted) or expressed at the
cell surface. TNF receptor 1 (TNFR-l) pathway is triggered by TNF and
lymphotoxin, which are stored in the vesicles of CTL, NK and macrophages. Like
Fas-FasL signalling, the death signal is delivered when TNF or lymphotoxin
encounter the receptor on the target cell. Though different receptors and ligands are
involved, the signalling pathways overlap. Receptors are trimerized after ligation and
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an intracellular death-inducing signalling complex (DISC) is formed as death domains
within the target cell associate with other proteins that recruit and activate caspases 8
and 10.
Granule-mediated killing occurs through the formation of a cytotoxic synapse
between killer and target cell. Upon activation of the killer cell, cytotoxic granule
formation increases. Downstream signalling in the effector cell results in the
mobilisation of Ca2+ and reorganisation of the cytoskeleton. Granules become
polarised in the effector cell toward the target cell membrane. The final step in
formation of the synapse is fusion of cytotoxic granules with the cell membrane and
Ca2+ -dependent exocytosis. Several proteins are contained in the cytotoxic granules
that enable unidirectional cytotoxicity. Perf orin polymerises in Ca2+ -dependent
manner and forms pores in cell membranes (594). Calreticulin binds perf orin and
may protect perf orin-mediated damage to the effector cell (189). Cathepsin B
degrades membrane-bound perforin and may protect the effector cell from membrane
damage (34). Granzymes are serine proteases that enter the target cell cytosol to
activate apoptosis. Though it was previously believed that granzymes entered the
target cell through perforin channels in the cell membrane, this is now thought
unlikely because granzymes are much larger than the pore formed by perf orin (72).
Further experiments suggested that granzyme and perf orin are likely to be
endocytosed by the target cell and perforin then facilitates the release of granzyme
into the target cell cytosol by disrupting the membrane of the endosome. Granzyme
A then translocates to the nucleus to directly initiate apoptosis via the SET, a complex
of multiple proteins which interact with granzyme A to nick DNA. Granzyme A also
disrupts the nucleosome to make DNA more susceptible to degradation by DNAses.
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Granzyme A can also cleave lamins A-C to disrupt the nuclear lamina. Granzyme B
induces apoptosis differently, utilising the apoptotic pathways within the target cells.
Its substrates are anti-apoptotic proteins, and their cleavage releases cytochrome c
from the mitochondria. Cytochrome c initiates formation of the apoptosome and
initiates a cascade of events culminating in activation of caspases and DNA
fragmentation.
Changes in T cell phenotype during viral infection
The activation of T cells results in the acquisition of functions that enable the
clearance of viral infection. T cell activation and maturation into effector cells can be
observed by the differential expression of cellular proteins during the immune
response.
Cellular activation
CD69 is the earliest glycoprotein upregulated on the cell surface after T cell or NK
activation. CD69 is an activating receptor and its ligation increases Ca2+
mobilisation, cytokine and cytokine receptor synthesis. Its expression is transient and
its natural ligand has not yet been identified. CD38 is expressed on NK, B and T cells
and is upregulated upon cellular activation (18, 439). CD38 is constitutively
expressed upon neonatal T cells, and its presence on a T cell is not in itself an
indicator of activation(341, 497). CD38 has multiple functions that support cellular
activation. The enzymatic activity of CD38 produces products involved in the
regulation of cytoplasmic calcium levels. CD38 catalyses the conversion ofNAD+ to
nicotinamide (NAm) and cyclic ADP-ribose (cADPR), and the degradation of cADPR
to ADP-ribose (ADPR)(363). CD38 may be directly involved in signalling.
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Interaction of the cytoplasmic tail with lck results in the mobilisation of Ca2+ and the
production of cytokines (32). CD38 also functions as an adhesion molecule between
leucocytes and endothelial cells by interacting binding CD31 (124).
CD95
Engagement of the T cell receptor results in spontaneous apoptosis of T cells in the
absence of "rescue" stimuli, in a process called activation-induced cell death (AICD)
(17, 73, 133, 266). Apoptotic death is important during the contraction phase of
immune responses to limit inflammatory responses that could become dangerous to
the host. T cells also express CD95 (Fas) on the surface following activation, making
them susceptible to apoptosis upon encounter with the Fas ligand (FasL, CDI78).
Additionally, the down-regulation of anti-apoptotic factor Bcl-2(242) is involved in
the Fas apoptotic pathway (251, 592). During the contraction phase of viral infection,
high frequencies of cells are detected expressing CD95, with down-regulation of Bel-
2 and these are highly susceptible to apoptosis(64). CD95+ cell frequencies are
elevated in patients with HIV-1 infection.
Co-stimulatoIy molecules
Changes in the expression of co-stimulatory molecules occur following cellular
activation. CD28 delivers a second signal during activation through the TCR via
interaction with its ligand CD80 (or CD86). CD27 is a TNF receptor family molecule
required for T cell effector and memory cell development. The ligand of CD27 is
CD70, which is expressed upon T cells, B cells and DCs. In a mouse influenza
model, CD27-CD70 signalling promotes the survival of activated T cells, increasing
the number of effector cells at sites of infection (238). CD27 is also important in
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generating a secondary response to stimulation of memory CD8 T cells (237). During
viral infections in humans, CD27 and CD28 have been used together to describe the
effector and memory status of virus-specific CD4 and CD8 T cells. CD4 and CD8
cells are proposed to follow a unidirectional pathway of maturation from a naive to
effector and memory phenotype that can be tracked by the expression of CD27 and
CD28. Naive or early effector phenotype cells are CD27+CD28+, stimulation with
antigen results in the sequential loss of CD27 and CD28 to a double negative "late"
CD27-CD28- phenotype. CD4 lose CD27 expression first, followed by CD28, and
CD8 lose CD28 expression first followed by CD27, and these single positive cells
have thus been called "intermediate". Comparison of antigen-specific CD8 T cells
during acute infection with HIV-l, Epstein-Barr virus (EBV) and hepatitis C virus
(HCV) has revealed that most responding cells are CD27+CD28+, low in perf orin
content, high in activation markers, low in Bcl-2 and proliferating (26). In contrast,
during chronic infection the virus-specific cells were enriched in different subsets.
EBV and HCV-specific CD8 were primarily early (CD27+CD28+), HIV-l-specific
CD8 T cells were primarily intermediate (CD27+CD28-) and cytomegalovirus
(CMV)-specific CD8 were predominantly late (CD27-CD28-) phenotype cells.
Though expression of CD27 and CD28 was different for these viruses, all appeared to
be effector T cells capable of cytokine secretion and cytotoxic activity. However,
HIV -1 specific CD8 appeared to be less functional than other virus-specific T cells;
HIV -1 specific CD27+CD28- were able to secrete cytokines, but had low levels of
perf orin and were less capable than CMV -specific CD8 T cells in lytic assays (27).
Selective expansions of CD27/CD28-subpopulations of cells have also been observed
in the CD4 subset. In CD4 T cells, EBV -specific CD4 T cells are predominantly
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early phenotype, and CMV-specific CD4 T cells are a mixed phenotype of
intermediate and late (24).
Proliferation
Cellular proliferation results in the clonal expansion of virus-specific effector T cells.
Brief exposure to antigen results in cellular proliferation, the development of full
effector function, and the development of memory. However, persistent stimulation
results in clonal exhaustion, loss of effector function, and apoptosis. The impairment
of CD4 proliferation during persistent immune activation is believed to play an
important role in the pathogenesis of HIV-1 infection. Cellular proliferation can be
measured in a number of ways.. The gold standard assay to measure CD4
proliferation is the measurement of H3-Thymidine incorporation into dividing cells in
a short-term culture. More recent methods involve staining cells with Carboxy
Fluoroscein Succinimidyl Ester (CFSE) which is divided equally between daughter
cells during mitosis. Alternately the synthetic nucleoside Bromodeoxyuridine (5-
bromo-2-deoxyuridine, BrdU) is an analogue of thymidine and gets incorporated into
cells during division. BrdU can be labelled with fluorescent antibodies and used to
detect cellular division in culture. Proliferating cells can also be detected by the
measurement of surrogate molecules that are upregulated during cell division. These
markers have been useful in quantifying proliferating cells ex vivo. Protein Ki67
(pKi67) is a nuclear protein which is required for cell proliferation (reviewed in (71»
but its precise function is still poorly understood. It is expressed when cells enter G1
phase of the cell cycle, but is not found in resting cells(203, 204). pKi67 continues to
be expressed during G1, S, G2 and M phases, but is highest during DNA
synthesis(335). Ki67 staining has been used extensively in HIV-I(29, 108) and
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cancer studies(71) to quantify proliferating cells. The protein is expressed in the
nucleus and nucleolus, so intracellular staining is necessary for its detection. The
transferrin receptor 1 (CD71) also has also been used to identify proliferating cells.
Iron is also required for DNA synthesis and progression through the cell cycle
(reviewed in(312». CD71 regulates intracellular iron levels and is required for the
uptake of Tf-Fe3+ into cells(15, 257). It is undetectable on resting lymphocytes, but is
upregulated during their proliferation(138, 536, 543). IL-2 receptor (CD25)
expression is required for CD71 expression, and this sequential induction is required
for DNA synthesis in lymphocytes(392).
CD57 is expressed on B cells, T cells, NK cells, and NKT cells but its functions are
not well defined. The expression of CD57 on CD8 T cells is indicative of extensive
proliferation leading to senescence(68) (409). Though cells expressing CD57 are
unable to divide, they have been shown to maintain most of their other effector
functions, including the secretion of IFN-y and capacity for cytotoxicity (313).
CD57+ cells have been shown to accumulate during HIV-l and CMV infection (161).
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SECTION II. THE HUMAN IMMUNODEFICIENCY VIRUS
Viral classification
The human immunodeficiency virus type-I (HIV-I) is member of the family of
human retroviruses (Retroviridae) (287). HIV-I is an enveloped virus with a genome
that consists of two single strands of sense RNA, of approximately 9.2 kb in size.
HIV-1 is classified as a lentivirus because of the long incubation period common
before the onset of disease (lenti = slow). HIV-1 shares features common to the other
lentiviruses. These include the ability to infect non-dividing, terminally differentiated
cells, the encoding of regulatory proteins in the viral genome, and a high rate of
mutation. All known lentiviruses establish persistent chronic infection by the
integration of viral genes into the host genome. Lentiviral infections begin with an
acute phase of infection characterised by high viral loads, followed by rapid
dissemination of virus and a long period of latent infection, followed by later
reactivation accompanied by immunopathology. Other lentiviruses include the simian
immunodeficiency virus (SIV), which infects a number of primates, and feline
immunodeficiency virus (FIV) which infects cats.
Organisation of the HIV -1 genome
The HIV-1 proviral genome is organised into structural, regulatory and accessory
proteins. The structural proteins are composed of Gag, the Gag-Pol precursor, Pro,
RT, In, and Env. The regulatory proteins are Tat and Rev, and the accessory proteins
are Nef, Vpr, Vpu, and Vif.
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Gag
The Gag protein (p55) is a 55kD precursor protein expressed from unspliced viral
RNA. Its N-terminus is myristoylated which allows it to associate with the
cytoplasmic side of cell membranes(212). Gag recruits viral genomic RNA into
budding virions. After budding, the p55 protein is cleaved into 4 smaller fragments,
the matrix (pI7 MA), capsid (P24 CA), nucleocapsid (p8 NC) and p6. The pI7
fragment retains the myristoylated fraction and remains tethered to the inner surface
of the membrane to stabilise the virion. It is also participates in the escort of the viral
DNA to the cell nucleus enabling HIV-I to infect non-dividing cells (192, 193). P24
forms the conical core of the viral particle. P24 interacts with cyclophilin A (CyA),
which facilitates the uncoating of the HIV-1 capsid during the early stages of viral
infection (66, 500). Ne recognises the HIV-I packaging signal, to incorporate RNA
into virions. This helps to condense viral RNA for packing(532). The p6 polypeptide
is involved in the release of budding virions off the cell membrane and aids in the
incorporation of Vpr into virions.
Gag-Pol Precursor
The Gag-Pol Precursor protein is formed by differential translation of the viral
mRNA. It is generated by a ribosomal frame shift triggered by a cis-acting RNA
motif(413). Ribosomes shift to translate the Gag-Pol Precursor approximately 5% of
the time, resulting in a 20:1 ratio of Gag to Gag-Pol Precursor. The Precursor is a 160
kD fusion protein containing Protease (Pro, plO), Integrase (In, p3I), RNAse H (P15),
and Reverse Transcriptase (RT, p50) (253).
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Pro is an aspartyl protease expressed as a dimer, it cleaves the Gag-Pol precursor, and
Gag into the component pr.oteins(31, 179). The protease inhibitors form an important
class of drugs active against HIV-1 infection, which work by blocking Pro, resulting
in the formation of defective viral particles(127).
RT has both RNA and DNA- dependent polymerase activity, and lacks proofreading
activity. The lack of proofreading results in a very high rate of mutation and several
point mutations are introduced into each new gen.ome(336, 419). This results in
considerable viral diversity that enables the virus to adapt to evade host innate and
adaptive immune defences. RT is the target of antiretroviral drugs from the
nucleoside analogue RT inhibitor (NRTI) and non-nucleoside RT inhibitor (NNRTI)
classes. NRTIs are nucleoside analogues, which get inc.orporated into the newly
synthesised DNA strand. Because they lack a 3' hydroxyl group to form bonds with
incoming bases, strand elongation is terminated. 3' -azido-2', 3' -dideoxythymidine
(AZT), a thymidine analogue, was the first drug of this type appr.ovedfor use against
HIV-l infection. NNRTIs inhibit RT by binding at regions other than the nucleoside
binding site(120).
The In protein mediates the insertion of viral DNA into the host genome in 3 stages
(74, 80). Exonuclease activity trims duplex viral DNA. Double stranded
endonuclease activity cleaves the host at the integration site. Ligase activity joins the
viral and host DNA. Local host enzymes fill in the ligation site. It is believed that
accessibility to DNA rather than specific signal sequences determine the site of
proviral integration, Open stretches of DNA that are being actively transcribed are
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thus hot spots for integration, and integrating at these sites also increases the
likelihood of proviral transcription(437, 483).
Env
The envelope Env protein (gp160) is cleaved into gp41 and gp120. Together gp41
and gp120 are expressed as a trimer forming the virion envelope(43). Gp41 forms the
transmembrane domain of Env (307). Gp120 contains the binding site for the Hlv-I
receptor CD4. Glycosylation of Env with 25-30 carbohydrate side chains improves
binding to the HIV-1 receptor and shields epitopes from neutralising antibodies(569,
589) (440). Gpl20 has 5 hypervariable regions, the V3 loop determine whether HIV-l
uses CCR5 or CXCR4 as a co-receptor(129, 173, 245). The V3 loop is also the
primary target for neutralising antibodies (nAb); binding this region prevents
attachment to the HIV-1 receptor (213). Viruses that bind CCR5 are macrophage-
tropic and non-syncytium-inducing (NSI), viruses that utilise the CXCR4 receptor are
T cell tropic, and syncytium-inducing (SI). During the course of HIV-I disease the
virus may change tropism and begin to utilise an alternate receptor, the switch from
CCR5 to CXCR4 tropism is associated with accelerated disease progression (110).
Tat
The transcriptional activator (Tat) protein is expressed in two forms either 72 or 101
amino acids in length, depending on differential mRNA splicing (459). Both forms
activate transcription and bind RNA. Tat binds a stem-loop structure called the
transactivation response element (TAR) at the 5' end of viral RNA and activates
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transcription from the LTR(172) and increases transcription. Tat binding also
promotes elongation at the transcription phase so that full-length transcripts can be
synthesised (171, 272).
Rev
Rev (regulator of viral expression) is a 13 kD RNA binding protein that induces
transcription. Rev binds the response element (RRE), a bubble formed in the dsRNA
helix created by G-G base pairs(37). RRE binding facilitates the export of
incompletely spliced RNA and unspliced RNA from the nucleus to the cytoplasm, this
mechanism is important in the regulation of HIV-1 late gene expression(342).
Ne!
Nef (negative factor) is a 27 kD myristoylated protein. It was originally named
negative factor because it was originally thought to down-regulate transcription but it
is no longer thought that Nefregulates gene expression. Nefis the first HIV-l protein
detected following infection, this may be one of the mechanisms explaining the
immunodominance of Nef responses in many individuals(281). Nef has several
functions that increase viral infectivity. Nef down-regulates CD4 expression on the
cell surface by interacting with the cytoplasmic tail of CD4, which is subsequently
endocytosed and degraded in lysosomes(197, 282). Nef also down-regulates class I
MHC expression on the cell membrane, to reduce CTL recognition(484). However
Nef does not decrease HLA-C expression, which is a ligand for inhibitory NK cell
receptors(14). Nefalso increases the expression ofFasL on the infected cell, making
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it possible to kill approaching CTL that express Fas (590, 597). Nef also activates
protein kinases by binding to SH3 domains of Src family tyrosine kinases, allowing it
to alter signalling the cell(504).
Vpr
The viral protein, regulatory (Vpr) is homologous to the Vpx protein in SIV. Vpr
enables HIV-1 to infect non-dividing cells by tethering the viral genome to the
nuclear pore. Vpr also facilitates HIV-I viral replication by causing arrest in the G2
phase, when LTR are most active(448).
Vpu
The viral protein, unknown (Vpu) is a 16 kD protein which localises at the inside of
the target cell membrane. Vpu is necessary for virion budding(286). Vpu is also
involved in the decrease of CD4 expression; CD4 and gp120 can adhere to one
another in the ER, trapping them inside. Vpu enables separation of the two proteins
by triggering ubiquitin-mediated degradation ofCD4(579).
Vif
The viral infectivity factor (Vif) inhibits the cellular protein APOBEC3G (498).
APOBEC3G is incorporated into HIV-1 virions and is thus transferred to a newly
infected cell (16, 525). During HIV-1 reverse transcription in the new cell
APOBEC3G causes deamination of cytosine resulting in the accumulation of uracil
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bases in the newly synthesised strand of viral DNA (233). The uracils are matched
with adenosines resulting in a G ~ A "hypermutation" of the viral DNA which
results in long stretches of adenine bases which interfere with viral viability (258)
(598). Vif subverts APOBEC3G function by causing ubiquitination of the protein,
thus diverting it to the proteasome for degradation (595).
Regulation of HIV-1 genome expression
The regulation of HIV -1 genome expression is mediated though differential splicing
and regulatory proteins. Long terminal repeat sequences (LTR) are positioned at the
end of the RNA genome. Transcription from the 5' LTR forms a 9kb transcript that
encodes all of the HIV -1 genes. The primary transcript can be spliced into more than
30 different mRNAs or incorporated as genomic RNA into new virions (485).
Incompletely spliced RNA encodes the proteins Env, Vif, Vpu, Vpr, and Tat. The
fully spliced products encode Rev, Nef and Tat. Rev binds proteins with introns
allowing nuclear export of unspliced RNA that would normally be trapped in the
nucleus. Threshold levels of Rev are thus required before unspliced or incompletely
spliced protein products can be produced. Thus, the "early" HIV -1 proteins are those
made from completely spliced RNA (Rev, Nef, Tat) and are Rev-independent. The
"late" genes require Rev production for their expression (Gag, Pol, Env, Vpr, Vpu,
Vif).
The LTRs sequences contain 3 sub-regions that regulate HIV-I transcription, U3, R
and US. The LTR contain cis-acting DNA sequences for binding of cellular
transcription factors. These includes binding sites for cellular transcription factors
NF-KB, SP-I, Ets, NF-AT and AP-I (389). Binding of these DNA sequences
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enhances HIV -1 transcription. The LTR also contains the TAR and the site of
initiation for transcription.
The HIV -1 life cycle
The life cycle of HIV -1 begins with viral binding and entry. Env fuses with the host
cell membrane at CD4, inducing a conformational change in gp120 that exposes the
co-receptor binding site for CCR5 or CXCR4(303). Binding induces a conformational
change in gp41, bringing together the HRI and HR2 regions of the protein to form a
6-helix bundle that draws the virion and cell together forming the fusion pore (91,
348,364). Following fusion the contents of the virion are released into the target cell.
A class of ARVs called fusion inhibitors has been developed to block viral fusion
(344). HIV-I can also be endocytosed but this does not result in productive infection
and usually results in lysosomal degradation (347). In the cytoplasm CyA, Nef and
Vif participate in the uncoating of the virion associated with the plasma membrane.
Reverse transcription occurs in the cytoplasm to create double stranded viral DNA,
tRNA Lys acts as a primer for RT. RNase H cleaves RNA-DNA hybrids, removing the
reverse-transcribed strand to allow synthesis of complementary DNA. HIV -I proteins
and the viral dsDNA form the pre-integration complex (PIC), which is transported to
the nucleus. The viral genome is compacted in the PIC and crosses the nuclear
membrane with the aid of In, MA, and Vpr. Integration of viral DNA into the host
chromosome is mediated by In, which cuts both viral DNA, host chromosome, and
then joins the two together. Integration can lead to active or latent infection of the
cell. Proviral DNA not being actively transcribed can persist in cells as a viral
reservoir. Viral latency makes complete eradication of the virus unlikely using
antiretrovirals. Engagement of transcription factors at the LTR initiates proviral
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transcription and is greatly enhanced by the binding of Tat to TAR. Viral transcripts
are generated and transported to the cytoplasm in a Rev-dependent or -independent
manner. Virion assembly occurs adjacent to the plasma membrane. MA anchors the
assembling complex to the membrane. Gag, Gag-pol, Vpr, and genomic RNA are
packaged into the virion by the co-operation of viral and cellular chaperone proteins.
(
Budding occurs through hijacking of the cellular export machinery. The p6 protein
binds the cellular protein tumour-suppressor gene 101 (TSG101) and exits the cell by
budding in a way similar to the formation of exosomes (209).
The early history and epidemiology of HIV·l
The first cases of AIDS were identified in the early 1980s when doctors from New
York, Los Angeles and San Francisco reported cases of Pneumocystis jirovecii
pneumonia (formerly P. carinii) (PCP) and Kaposi's sarcoma (KS) in young
homosexual men and injection drug users (3, 7, 352). Because the first cases were
identified amongst homosexual men, the condition was for a time called Gay-related
immune deficiency syndrome (GRIDS). Soon there were similar reports in injecting
drug users and haemophiliacs, and Haitians with no reported homosexual behaviour
(8, 352). All of the affected subjects had severely depleted CD4 counts. The first
reports of AIDS in an infant was in the setting of blood transfusion (494), but it soon
became clear that the infectious agent could be transmitted vertically (486) (114)
(515) (97) (329). Together these case reports suggested the infectious agent was a
blood-borne pathogen that could also be transmitted sexually. In 1982 the CDC
adopted the name acquired immune deficiency syndrome (AIDS) and published its
first case definition (9). The virus responsible for AIDS was first isolated in 1983 by
Francoise Barre-Sinoussi and was called lymphoid associated virus (LAV) (36), but it
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was not known at the time to be responsible for AIDS. In 1984 two laboratories
independently published reports identifying the virus causing AIDS, and these were
called HTLV-III (human T lymphotropic virus) and AIDS associated retrovirus
(ARV), respectively (194, 322). In 1986 the International Committee on the
Taxonomy of Viruses established the name human immunodeficiency virus (HIV).
HIV-2 was discovered in 1986, and the original virus was renamed HIV-1 (100,224,
270).
In Europe and North America, rates of HIV -1 infection continued to climb in the
1980s and early 1990s, particularly in high-risk groups of homosexual men, injection
drug users and commercial sex workers. The screening of blood transfusion products,
public health awareness, and risk reduction in high risk groups greatly contributed to
control of the epidemic in resource-rich nations. Treatment of HIV -1 with multiple
antiretroviral drugs began in 1996, (highly active antiretroviral therapy, or HAART).
HAART is able to reduce levels of viraemia to undetectable levels, but the presence
of a reservoir of latent provirus makes it unlikely that HAART will ever clear virus
completely (586) (98) (178). HAART greatly increased survival in people living with
HIV -1, and dramatically reduced the number of AIDS cases and opportunistic
infections (2). Though HIV -1 was first identified in the US and Europe in the 1980s,
it soon became clear that the virus was already well established in sub-Saharan Africa
(471,551) (296). Over the next 20 years HIV-l prevalence continued to grow in sub-
Saharan Africa and this region continues to carry the highest prevalence.
In sub-Saharan Africa, HIV -1 infection occurs predominantly through heterosexual
and mother-to-child transmission (MTCT). The latest WHOIUNAIDS Epidemic
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estimates 39.5 million people are infected with Hl'V-I globally, with 24.7 million in
sub-Saharan Africa (547). Globally, 2.3 million children under the age of IS, and 18
million women are infected with HIV-1. There were 4.3 million new infections in
2006, and 530,000 of these occurred in children under the age of 15. Overall, 2.9
million deaths were attributed to HIV-I and 380,000 of these were among children.
At the 2005 GS Summit and the September 2005 United Nations World Summit, the
leaders of the world's nations committed to a massive increase in HIV-l prevention,
treatment and care. A goal was set to provide universal access to HIV-1 treatment for
all who need it (575, 576). Several governments, non-governmental organisations,
and private charities have donated billions of dollars and drugs for HIV-1 treatment in
less developed countries. However, poor health care infrastructures and the lack of
experienced health professionals are major hurdles to meeting this goal. Stigma
continues to be a barrier to HIV-1 testing and partner notification, many HIV-l
infected people fail to access public services because they do not yet know they are
infected.
Origins and diversity of HIV
HIV-l sequencing and phylogenetics have traced the likely origins back to sub-
Saharan Africa. HIV-1 is most similar to the simian immunodeficiency virus (SIV)
virus found in chimpanzees (196), and mV-2 appears to be closely related to SIV
isolated from sooty mangabeys (95) (225). HIV-2 is endemic in West Africa and
regions once colonised by Portugal. The earliest confirmed HIV-1 specimen was
isolated from a plasma sample taken from a man in the Democratic Republic of
Congo in 1959 (600). Phylogenetic analysis of the viral sequence placed the
specimen nearest to the ancestral nodes of B and D subtypes. Based on sequence
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variation and phylogenetic relationships of different subtypes, the jump from
chimpanzees into human beings probably occurred in central Africa around the 1930s
(±10 years) (289) (465) (555).
HIV-l is organised into subtypes based on sequence similarity. HIV-I is organised
into 3 main groups, M, which accounts for the majority of viruses circulating in the
global pandemic, 0, which is found in low prevalence in west and central Africa and
N which is rare and found only in Africa The M group is divided further into
subtypes (also called clades) A-K (there are no E and I subtypes), and several
circulating recombinant forms (CRFs) that comprise viruses clearly originating from
the recombination of two SUbtypes. Subtypes A and F are further divided into AI,
A2, F1 and F2. Sub-Saharan Africa contains the most diverse collection of subtypes,
A, C, D and CRF02_AG. Subtype B is responsible for the epidemics in Europe,
Australia, and the Americas, though other subtypes are becoming more frequent.
Subtype C is the most common in southern Africa and India, and is accountable for
nearly half of infections globally. Subtype A (-70%) and D (-21%) are the most
frequently isolated in Kenya and intersubtype recombinants comprise at least 2% of
infections (393).
HIV-2
HIV-2 shares 30-60% homology with HIV-1, and utilises the same co-receptors and
target cells as HIV-1. HIV-2 infection also leads to AIDS, hut long-term survival is
more common (271, 349, 351). mV-2 is also transmitted vertically, though less
frequently than HIV-1, and is associated with increased risk of mortality compared to
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HIV-negative children(476). HIV-2 patients in chronic infection typically have
proviral loads comparable to HIV-I infection, but plasma viral load is much lower
than observed in HIV-I, even in the absence of therapy. CD8 T cell responses of
similar magnitude are detected against HIV-l and HIV-2. However, CD4 T cell
proliferation and cytokine production appear to be much stronger against HIV-2
(153), and NK cell activity may be greater (397). Early reports suggested HIV-2 may
confer protection from HIV-1 infection, but this has not been confirmed in subsequent
studies. Dual infection is common and results in disease progression similar to that
observed in HIV-I infected individuals (475).
Transmission of HIV·l
Transmission of both HIV-I and HIV-2 occurs through the transfer of free virions or
infected cells across mucosal surfaces. HIV-l is also found in blood, semen (297,
368), vaginal and cervical secretions (295) (101), breast milk (391) (454) and
amniotic fluid (384). The likelihood ofHIV-l transmission is influenced by a number
of factors. Transmission is most likely to occur if the infecting person has a high viral
load, particularly in acute infection (176) (137). The presence of STDs, and genital
ulcers in particular increases the risk of HIV-I acquisition (83) (503).
Though the person-to-person risk for sexual transmission of HIV-1 is low (0.1% -
0.4% for sexual transmission) (217, 458) the risk of MTCT is very high, with
estimates between 25-40% in breast-feeding populations (390) (11). MTCT of HIV-l
can occur in utero, during delivery, or through the ingestion of breast-milk. It is not
always possible to discriminate the timing of transmission, but it is thought that most
infections occur intrapartum through exposure to maternal cervical and vaginal
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secretions and/or blood(122, 155). Maternal plasma viral load has consistently been
correlated with the risk of MTCT (137) (375) (513). Women with detectable HIV-l
shedding in the genital tract are also more likely to transmit virus to their infants
(263). Chorioamnionitis, prolonged rupture of membranes, and genital tract
infections are also associated with increased risk of transmission (528) (516) (374).
Caesarean section reduces the risk of HIV-1 transmission by preventing exposure to
the maternal cervical mucosa, but carries additional risks for the mother(343).
Acquisition of HIV-1 in utero is also common. HfV -1 has been detected in amniotic
fluid, (384) the placental trophoblast, and Hofbauer cells (a macrophage) of the
chorionic villous(92, 324, 367). However placental infection does not correlate with
transmission, and HIV-1 replicates poorly in trophoblast cells in vitro(33, 350, 354,
376). The placenta appears to be a fairly good barrier against MTCT, and
transmission probably occurs via transcytosis of cell-associated virus (304) or perhaps
through the use of DC-SIGN (509). Though infection can happen as early as 8 weeks
in gestation(324), most transmissions occur late in gestation, within a month of
delivery(70, 455).
Breast-feeding poses an additional risk of infection to the infant, especially during the
first month of life when the breast milk contains high levels of cell-associated
virus(390, 391, 552). Risk of acquisition after the first month is lower but constant
over time and related to the duration of breastfeeding(113). Viral load in the breast
milk correlates with plasma viral load, but is approximately 2-3 logs lower(454).
Breast milk contains epithelial cells, lymphocytes and macrophages that can all be
carriers of HIV-l. It is thought that transmission via breast-milk occurs across both
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the oral mucosa(187, 188) and the gut mucosa (23) (56). Levels of maternal plasma
and breast milk viraemia are strong predictors of transmission (317). Mastitis and
sub-clinical mastitis during lactation were shown to further increase the risk of HIV-I
transmission by increasing breast milk HIV-I viral load (490) (580).
A number of interventions have been shown to reduce the risk of MTCT. The overall
strategy of these interventions is to reduce the exposure to maternal virus. If an infant
escapes transmission in utero and during delivery, breast milk transmission can be
eliminated by replacement feeding. However, in most African nations breastfeeding
can be nearly ubiquitous for various cultural, economic, and nutritional reasons. The
choice not to breastfeed is essentially a revelation of one's HIV-I status to family and
community. Furthermore, breastfeeding is important to the health of the infant, and
its benefits must be weighed against the risks imposed by HIV-1. In a Kenyan study,
formula-fed infants not acquiring HIV-1 had rates of mortality comparable to those
with HIV-1(390). In addition to the nutritional benefits, neonates acquire all of their
IgA from breast milk, and additionally benefit from maternal IgG. The preparation of
safe breast milk substitutes makes replacement feeding dangerous for women without
access to clean water, increasing the chance of infection with water-born pathogens.
Several studies have shown that exclusive breastfeeding reduces the risk of HIV-I
acquisition compared to mixed feeding (112, 247). In many communities, giving the
infant water and soft foods is begun within the first few weeks of life. The premature
introduction of food and water-borne pathogens may initiate inflammatory reactions
in the neonatal gut, thereby creating a mucosal environment facilitating HIV-l
entry(449). The WHO thus recommends avoidance of breast-feeding only where it is
acceptable, feasible, affordable, sustainable and safe. If the mother is known to be
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HIV -1 infected it is recommended that exclusive breastfeeding continue until 6
months, followed by re-evaluation of the risks and benefits with continued breast
feeding(577).
The provision of antiretrovirals (ARVs) to the mother and/or infant greatly reduces
the risk of MTCT. The earliest intervention trials used AZT monotherapy initiated
between 14-34 weeks of pregnancy and provided a high intravenous dose during
delivery, and AZT treatment to the infant for 6 weeks post partum (l09). The
intervention reduced the risk of transmission by -70%. A subsequent study in
Thailand showed that short course regimens during pregnancy in the mother alone
significantly reduced risk of in utero and intrapartum transmission( 492). The current
gold-standard for prevention ofMTCT is HAART during pregnancy, followed by the
avoidance of breastfeeding. Elective Caesarean may be beneficial if complete viral
suppression cannot be achieved in the mother. Together, these interventions have
reduced the risk of transmission to < 2% in resource rich settings( Ill). Current
WHO guidelines recommend a two-part approach for ARV prophylaxis in resource-
poor settings. If the mother requires treatment for herself, the WHO recommends use
a nevirapine (NVP) based combination therapy plus prophlyaxis for the infant. If the
mother does not require treatment for her own health the WHO recommends short-
course combination therapy plus single-dose intrapartum and neonatal NVP (117)
(575). Though these interventions greatly reduce the risk of MTCT, these
interventions are still unavailable to most women in resource-poor settings. In Kenya,
where HIV -1 prevalence among pregnant women is currently estimated to be 6.1%,
only 9.3% currently benefit from interventions to prevent MTCT.
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The natural history of HIV -1 infection
HIV-l infection in adults
Acute infection with HIV-1 is often asymptomatic, though a proportion of people
experience a seroconversion illness characterised by flu-like symptoms resembling
infectious mononucleosis. During this time virus is disseminated from the site of
infection to the lymphoid tissues. Viraemia peaks at about 3 to 4 weeks post infection
and is followed by a period of decline and it is thought HIV-1 specific CD8 T cell
responses are responsible for this reduction in viral load(292, 402, 560). Antibodies
to HIV-l are generated 2-3 months post-infection, resulting in a "window period"
when the newly infected person may be infectious but still seronegative. CD4 cells
drop rapidly during acute infection, and then partially recover their numbers as viral
levels decline. It is now known that the majority of CD4 depletion occurs in the gut
associated lymphoid tissues (GALT) and persists here even following the partial
recovery observed in the blood (69).
Following acute infection, an equilibrium is reached between host and virus in which
relatively low levels of viraemia are maintained for many years in most individuals
before the onset of AIDS (411). In the absence of ARV therapy, mean time to AIDS
is approximately 8-10 years in adults, though this is influenced by age, and may be
significantly shorted in resource poor settings (256, 460). During this time the host is
usually asymptomatic, though viral replication continues, and CD4 T cells are steadily
depleted. Levels of viraemia in early infection are highly predictive of the rate of
disease progression (310, 366, 399, 521). Lower viral loads during acute infection
result in more limited destruction of the CD4 subset and more slowly progressive
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disease (162, 379, 431). CD4 T cells are progressively depleted during the
asymptomatic period, until a critical threshold is reached. The loss of CD4 help
disables the immune response allowing the invasion of opportunistic pathogens, the
onset of AIDS, and ultimately death.
Many of the infectious organisms causing severe disease in immunosuppressed
patients are present in immunocompetent people without causing disease, hence the
pathogens cause "opportunistic infection" (01) (353). Ols vary greatly by
environmental exposure to pathogens and CD4 count. Mycobacterium tuberculosis
(TB), KS, PCP, CMV, toxoplasmosis, and B cell lymphomas associated with Epstein-
Barr virus (EBV) infection are common globally. Ols may also disseminate beyond
their usual reservoirs to cause systemic disease or pathology in multiple organs. A
good example is CMV, which asymptomatically infects most of the world's
population. In immunosuppressed patients CMV becomes reactivated, and causes
symptomatic disease. In HIV-1 infection CMV can cause severe retinopathy,
gastrointestinal disease, and infection in the central nervous system.
T cell responses inHIV-1 infection
There is a wealth of evidence supporting the importance of CD8 T cells in the control
of HIV-1 replication. HfV-1- specific CTL appear during acute infection prior to the
emergence of HIV-1 antibodies, peak with viral load, then inversely correlate with
viral load during post-acute infection (292, .387, 402). Blocking of CTL with
antibodies during acute SIV infection results in uncontrolled viraemia (481) (261).
The importance of CTL is further supported by the emergence of "CTL escape
variants," mutations in the HIV-1 genome that affect antigen processing, MHC
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binding, or TCR recognition (62, 292, 315) (150, 421, 435). The emergence of
escape has in some cases been associated with increased viral replication and disease
progression (215). Two selective forces thus act upon the virus, the need to maintain
replicative fitness and to escape CTL(250, 319). The detection of HIV-1 specific
CD4 proliferation has also been strongly correlated with slow disease progression in
HIV-1, though in the majority of HIV-1 infected subjects, these responses are low or
undetectable(268, 388, 450). Despite the low frequency of proliferative responses,
HIV-1 specific CD4 T cells can be detected in many individuals by the secretion of
cytokines (lFN-y, IL-2), and their frequencies decline with time during chronic
infection (426).
The characterisation of subjects with slowly progressive disease suggests that the
"quality" of the T cells generated during the adaptive immune response is an
important factor in the control of viraemia During chronic HIV-1 infection, the
frequency of HIV-l specific CD8 measured by IFN-y are not consistently correlated
with viral load and survival(10, 44, 154,201). Long-term survivors have been shown
to generate CTL with multiple effector functions in addition to cytotoxicity, including
the secretion of one or more cytokines and proliferation (45) (19). The maintenance of
CD4 help is important for the sustained function of CTL during chronic infection
(326) (229). CD4 help may be vital to the generation of functional effector cel1s. In
the mouse LCMV model, virus-specific CTL can be generated in the absence of CD4
T cells, but lack the ability to secrete cytokines or to kill(596). CD4 help appears to
be maintained in HIV-2 patients who typically experience slow disease
progression(153).
62
There is also accumulating evidence of that the lack of effector function of CTL
during chronic HIV-l infection is due to "exhaustion". HIV-l specific CD8 T cells
acquire CD57+ expression, indicative of senescence (68). In addition to decreased
proliferative capacity, there is good evidence for the progressive loss of other CTL
functions during disease progression (27) (493) (290). The recent identification of the
cell surface molecule programmed-death-l (PD-l) on HIV-1 specific CD8 T cells is
associated with an exhausted phenotype, characterised by a lack of cytokine secretion,
killing, and proliferation (542). In a cohort of HIV-I infected patients, frequencies of
PD-l + cells and the level of PD-l expression were strongly correlated with HIV-l
viral load and progression (119). The blocking of PD-l with antibody was shown to
reverse the effects and restore effector function, and this has generated interest in the
therapeutic possibilities of targeting the molecule.
Mechanisms of CD4 depletion
CD4 T cells are the main targets of HIV-1 infection, however macrophages may also
be productively infected and may be important reservoirs in the tissues. Despite the
rapid and progressive depletion of CD4 T cells, it is now clear that only a subset is
actually infected, and a large number of cells die thorough mechanisms other than
direct cytopathic effects of the virus. The progressive depletion of T cells is thought
to progress by a combination of 1) direct cytopathic effects on infected cells 2) killing
of innocent bystander cells 3) impaired CD4 proliferation (in infected and uninfected
T cells) 4) dysregulation ofhaemopoiesis and production of naive cells.
Proliferation is impaired in HIV-1 infected CD4 T cells, and they are more likely to
undergo apoptosis than uninfected cells (235, 415, 501, 585). CD4 activation is not
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impaired, and a number of infected cells are also depleted by AICD. Memory cells,
and HIV -1 specific CD4 T cells in particular are preferentially targeted for HIV-l
infection, further reducing the pool of effector cells available to fight infection (145).
The expression of HIV-I viral proteins Tat, Nef, and Vpr can also induce apoptosis
(573). Depletion of CD4 occurs primarily in bystander cells which are not infected
with virus (177, 386). Bystander cells can be eliminated by the formation of syncytia
(240,470), AICD, and the induction of apoptosis by cells bearing FasL(17, 142) (64).
T cell haemopoiesis is also dysregulated by HIV -I infection. Naive CD4 and CD8 T
cells are also depleted during the course of HIV-I (447). Signal-joint TCR excision
circles (TREC) generated during TCR rearrangements are diluted with successive
cellular divisions, and can be used to monitor the relative proliferation of T cells.
HIV -1 infected subjects have lower levels of TRECs in comparison to HIV -1 negative
age-matched controls, and had lower frequencies of recent thymic emigrants (RTEs),
suggesting impaired thymic function (148). Treatment with HAART increased TREC
levels and the frequency of naive T cells. CD34+ progenitor cells have also been
found to be infected with HIV -1 (345, 520) and express high levels of CXCR4,
suggesting HIV-1 infection may also have the potential to disrupt haemopoiesis (128).
Host genetic factors influencing the control of HIV -1
Host genetic factors have been shown to contribute significantly to the risk of HIV -1
acquisition and disease progression. Mutations in chemokine receptor genes have
also been shown to influence the risk of HIV-I disease progression. A 32 bp deletion
in the CCRS exon (CCRSa32) results in a lack of CCR5 expression on the cell
surface (331) (466). Subjects homozygous for this mutation are unable to be infected
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by strains with R5 tropism. Subjects heterozygous for the mutation can be infected
with R5-tropic viruses but infection is less likely than in the absence of the mutation.
However, the cells of these patients can still be infected with X4-tropic HIV.
Additional mutations in the chemokine receptor genes have also been identified that
provide reduced risk of HIV-1 infection or disease progression: 59356Crr CCR5
promoter, CCR2-64I, SDF-l 3'A, and RANTES (25, 262, 264, 330, 523). The
possession of several class I HLA molecules has been associated with the risk of
HIV-1 acquisition or disease progression (86). Homozygosity for class I alleles has
also been associated with bad outcome (85), but homozygosity for HLA-Bw4 appears
to be protective (180). In MTCT, the sharing of more than 3 class I HLA alleles has
also been shown to increase the risk of MTCT (340, 433).
Paediatric HIV-l infection
Paediatric HIV-1 infection results in an accelerated course of disease compared to
adults. In untreated infants, viral loads are maintained at very high levels during the
first two years of life, and at this time there are high rates of mortality (382, 496)
(410). US and European cohorts have reported 2 year mortalities of -2-20% (50)
(216) (6). Studies from sub-Saharan Africa have reported much higher rates of
mortality (395). A study in West Africa reported 60% mortality at 18 months (116),
and studies from East Africa have reported'20%-52% (355, 401) (160). The greatest
risk of AIDS appears to be during the first year of life, those children surviving the
first year are able to establish control of virus and survive even in the absence of ARV
(50) (216) (134). This observation suggests strong selection factors during the first
few months of life may influence survival.
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Correlates of mortality
As in adult infection, HIV-1 viral load during early infection is a strong indicator of
disease progression and mortality in infants (136) (453) (443) (67). Various studies
have used mean, peak, or baseline viral load to predict survival. In utero transmission
and early peri partum infection have been associated with increased morbidity and
mortality in MTCT (318) (355). Maternal health is also a very strong predictor of
infant survival, particularly during the first year of life, whether or not the infant
becomes infected with HIV-1. Maternal HIV-1 viral load, CD4, and mortality have
been shown to predict infant mortality (249) (401) (443). Breastfeeding, though a
risk factor for HIV-1 infection, is important in infant health and the prevention of
respiratory and diarrhoeal illnesses in both HIV-1 infected and uninfected children (1,
495).
The most common causes of death during the first year of life in HIV-1 infected
infants in resource-poor settings are diarrhoeal and respiratory disease. Repeated
episodes of infection with Candida albicans, oral hairy leucoplakia, and pneumonias
(often PCP) and non-specific gastrointestinal illness are very common in HIV-l
infected infants.
Treatment
Though a staggering number of children are currently infected with HIV-1, there is a
lack of data informing treatment guidelines. Because untreated HIV-1 is known to
follow such an aggressive course in infants, in resource-rich nations it is now standard
to treat children immediately following confirmation of HIV-1, regardless of CD4 or
viral load. However, the optimal regimen for neonates, and whether treatment can be
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safely discontinued at an older age is unknown. In sub-Saharan Africa, these
problems are especially pressing due to the great numbers of infected children.
Additionally. rural and resource-poor areas may lack diagnostic facilities to identify
HIV-l in infants. Subsequently. many areas rely on clinical indicators to diagnose
HIV-1 infection in infants. Many ARVs are not provided in paediatric formulations.
those that are available as liquids require refrigeration, and this is a problem if
patients do not have electricity. A recent report by the CHER study group in South
Africa has demonstrated that ARV therapy initiated in the first 12 weeks of life can
substantially reduce morbidity and mortality during the first year of life (558). The
frequency of treatment failure and severe adverse effects were low in the infants and
treatment compliance was very high. This report suggests that the treatment of very
young infants with HIV-1 is viable and beneficial. Several other clinical studies are
currently underway in sub-Saharan Africa to optimise HAART in children (166)
(398) (452) (561). Several medical interventions besides HAART have also been
shown to benefit infants with HIV-1 infection. The WHO recommends all children
with suspected HIV-1 infection be given trimethoprim sulphamethoxazole (TMP-
SMX) prophylaxis for the prevention of Pneumocystis jiroveci pneumonia (PCP) (88).
Vitamin A supplementation is also recommended for the reduction of infant morbidity
and mortality (168).
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Immune responses during paediatric HIV-l infection
Innate immune responses
NK responses to HIV-1 have been demonstrated in HIV-1 and HIV-2 infection (397).
Increased NK activity and release of IFN-y has been correlated with HIV-1 infection,
though their overall frequency may be reduced (21). NK cells release ~-chemokines
MIP-l a, MIP-l ~ and RANTES that compete for the CCR5 receptor and thus have the
ability to block HIV-1 entry into target cells(405). High levels of chemokines in
breast milk have been associated with reduced risk ofMTCT(163). ADCC antibodies
directed against HIV-1 have been identified in adult and infants with HIV-1 infection.
IgG ADCC antibodies are obtained through placental transfer, but have not been
associated with protection from transmission(259). Furthermore although ADCC
antibodies could be detected in infants these were not associated with disease,
progression, and children less than a year old were unable to make ADCC responses
against HIV-l(259). CD8 antiviral factor (CAP) activity has also been associated with
delayed disease progression and has also been detected in infants exposed to HIV-
who escaped infection(323). Secretory leukocyte protease inhibitor (SLPI) is a mucin
that may prevent HIV-l entry, SLPI levels in saliva and vaginal fluids have been
shown to correlate with reduced transmission(165, 424), but may not protect from
breast milk transmission.
Humoral immune responses
Overall HIV-1 specific IgG titres correlate poorly with transmission. Neutralising
antibodies (nAb) correlate better with protection from transmission than overall IgG
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titres and have been promising in animal vaccine models(135, 226, 285, 472, 554).
IgA nAb against HIV -1 have also been found in HIV -1 infected patients and in
exposed seronegatives (ESN) (l02, 132). In MTCT viral species that have escaped
maternal antibody responses are preferentially transmitted to the infants, suggesting
that selective pressure from infant nAb is involved in the selection of transmitted
variants(588). However, the sites of Env which contain nAb epitopes are easily
mutated by HIV -1. Glycosylation of gp 120 results in further shielding of neutralising
epitopes(569). The search for antibodies that can broadly neutralise many primary
viral isolates has produced few strong candidates.
T cell responses to HIV-J
HIV -l-specific T cell responses are less frequently detected in neonates and
infants(338, 339) (96, 337) (423) (76) (487) (333) (506) (534). In contrast, infection
with CMV results in the expansion of very high frequencies of CMV -specific CTL
that have a mature phenotype and function similar to those observed in adults (94)
(346) (206, 372). The CD4 response to CMV however, appears to be less than fully
functional than it is in adults with lower production of IFN-y (87) (546). These
responses are sufficient to enable most children acquiring CMV post partum to
remain asymptomatic, although viral shedding may persist for years (265) (13) (517).
In contrast CTL responses from neonates and infants fail to control HIV -1. In most
infants viral loads are maintained at persistently high levels for at least a year, and
mortality is very high during the first two years of life(382, 410, 496).
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In general, infant HIV-l-specific T cell responses resemble those generated by adults
with rapid progression. Infant CD8 T cell responses against HIV-1, measured by
cytotoxicity assays or cytokine production, are less frequently detected and weaker in
magnitude than responses detected in adults (338, 339) (337) (423) (76) (487) (333)
(506) (534). The frequency of IFN-y producing cells has not been shown to be
associated with viral load or disease progression in infants, though in older children
there are reports of positive and negative associations with disease progression (77,
79, 333, 446, 489). Early treatment with HAART has been shown to decrease the
magnitude and breadth of IFN-y responses in children compared those treated later in
life, and detection of HIV-1 specific CD8 is associated with incompletely suppressed
viraemia (61, 78). Env-specific IFN-y responses are more frequently detected in
infants compared to older children(76, 534).
As observed in adult infection, CD4 responses, including proliferation(370) and
cytokine production, appear to be particularly impaired in paediatric HIV-I infection
(298, 564). The maintenance of Thl responses has been associated with sustained
CTL responses and slow disease progression in children with HIV-I(90, 301, 534,
566). Infant CD4 responses may be preferentially skewed toward a Th2-type
response in CMV and HIV-I infection, which is not optimal for antiviral responses
(434, 546, 564). However, infection Bordetella pertussis or pertussis vaccination
results in the generation of Thl type responses in neonates (462) (461). In those
children surviving the first year months of life, T cell responses grow in frequency
and magnitude(78, 333,467).
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Factors contributing to impaired HIV-I responses in infants
Many factors may contribute to lower T cell responses in infants. Several studies
have reported Th-2 skewed responses, or weak IFN-y production in CD4 T cells
during viral infection. IFN-y responses may be suppressed in the foetus to prevent
placental damage (568). These responses continue to be impaired during neonatal
life, and are observed as a skewing toward a Th2 type T cell response to viral
infections (434). Down-regulation of IFN-y synthesis is thought result from hyper-
methylation of CpO sites within and adjacent to the IFN-y promoter (574). Hyper-
methylation of the IFN-y gene was observed in CD4+CD45RO- when compared to
adults. However methylation of the IFN-y gene of CD8+CD45RO- and NK cells
were similar to that observed in adults, and corresponded to similar levels of IFN-y
production. Methylation of other cytokines promoters IL-4 and TNF-a were similar
between neonatal blood and adult DNA, suggesting a selective mechanism for down-
regulation of foetal IFN-y in CD4 cells. This selective regulation of IFN-y may
explain the reduced Thl responses observed during HIV-I and CMV infection in
neonates.
Additionally, HIV-I has been shown to infect the thymus (70), and HIV-I induced
destruction of developing lymphocytes may affect T cell responses. In vitro, human
and mouse neonatal T cells ~e less responsive to stimulation through the TCR. Cord
blood and neonatal CD4 T cells require more co-stimulation in order to produce IFN-
y and IL-2 and to proliferate, but the provision of adult APC and co-stimulation can
generate adult-like responses(l2). Neonatal T cells have lower expression of TCRs
and adhesion molecules LFA-l (CDlla), LFA-3(CD58), and CD2 (468) (278), which
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could result III lower signalling through the TCR, and a greater need for co-
stimulation.
Genetic similarity of mother and infant may result in the transmission of virus pre-
adapted for efficient replication in the new host. CTL escape mutations have been
detected in infants(214). De novo CTL escape mutations have also been detected in
infants (170) (425) suggesting that although CTL responses may be weaker during
infant life, they have sufficient function to exert selection pressure on the virus to
mutate.
Exposed uninfected individuals
HIV -1 specific CD4 and CD8 T cell responses have been detected in subjects with
persistent exposure to virus who remain uninfected. These groups include
commercial sex-workers (CSW) (183 {Kaul, 2001 #49, 184, 275, 276, 456),
discordant couples (223) and infants born to infected mothers(105, 299, 300, 316,
457). Long-term follow-up of CSW suggests that these responses may be indeed
protective and not just an effect of exposure(277). The mechanism underlying the
generation of these responses in the absence of infection is not known. Cross-
presentation of defective virions, viral proteins, or apoptotic cells by DCs may explain
CTL responses in the absence of infection. Occult infection may also explain some of
these cases, recent ultra-sensitive PCR has revealed several exposed seronegatives to
be infected with virus at very low levels (599).
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Development of an HIV -1 vaccine
The development of a safe, effective, affordable vaccine against HIV -1 is the best
hope for containing or ending the pandemic. Initial strategies focused on generating
nAb responses to the HIV -1 Env, but these have failed to protect in phase III trials
(181, 427). The flexibility of the viral envelope in subverting nAb responses via
mutation and glycosylation suggest this may not be effective as a single strategy
(445). The strong evidence supporting the protective role of CTL in prevention of
HIV -1 acquisition and delayed disease progression has focused much of the current
research on the development of a vaccine to induce cellular immune responses against
HIV -1. An optimal vaccine may indeed elicit both humoral and cellular responses.
Viral diversity has been the main challenge in the design of a vaccine. Heterogeneity
between different viral subtypes may necessitate the development of subtype-specific
or vaccines. Alternatively a polyvalent vaccine may be optimal for regions with
multiple subtypes, such as Kenya where subtypes A and D are circulating at high
prevalence(393). In addition to viral heterogeneity, host HLA alleles differ greatly
between different regions and this must also be considered in evaluating
immunogenicity .
Safety issues have precluded the development of inactivated or live attenuated HIV-l
as a vaccine. A strategy adopted by several groups is the inclusion of HIV -1 genes in
a viral vector with limited replicative ability, such as vaccinia, adenovirus, Semliki
forest virus or canarypox. These have been shown to be immunogenic alone or
combined in a two-step prime-boost with a DNA-vector. A novel approach has been
to include HIV-l genes in a Bacillus Calmette Guerin (BCG) for the simultaneous
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immunisation of neonates against HIV-1 and TB (248). Choice of HIV-1 genes for
inclusion will also be important to immunogenicity; it may be best to target the most
abundantly expressed structural proteins (Gag, Env), or regulatory genes expressed
early (Rev, Nef, Tat). Another strategy has been to select individual epitopes targeted
by resistant individuals (exposed seronegatives) on the assumption that these
responses may confer protection. The use of adjuvants and different routes of
inoculation can also greatly improve immunogenicity.
Though a prophylactic vaccme is the holy grail of vaccine design, sterilising
immunity may not be possible in the absence of an antibody component. However,
several vaccine/challenge experiments in primate models indicate that a vaccine
might improve survival even if it cannot confer protection from infection. Such a
vaccine may limit CD4 destruction by reducing viraemia during acute infection,
resulting in better long-term containment of viraemia (320). Additionally, a
therapeutic vaccine would be of great benefit to those who are already infected. This
strategy focuses on vaccination to enhance the immune responses of those already
infected with the virus, in order to enable better long-term viral containment and
. possible cessation of antiretroviral therapy (143) (144).
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SECTION III. CYTOMEGALOVIRUS AND HIV-!
Classification and epidemiology
Cytomegalovirus (CMV) is a linear double-stranded DNA VIruS from the
betaherpesvirus family (human herpesvirus-S, HHV -5). The receptor and co-receptor
for CMV have recently been identified as epidermal growth factor receptor (EGFR)
and integrin avb3(562. 563). CMV infects a wide array of cell types including
endothelial cells. neutrophils, and lymphocytes (287). Its main reservoir in the blood
is the monocyte. CMV infects the majority of the world's population and prevalence
is higher in areas of low economic development (195).
CMV is the leading cause of congenital viral disease globally. affecting
approximately 0.1-2% of all births (185) (200) (479). In developing nations. CMV
may infect a large percentage of children during the first year of life (40). CMV is
transmitted through contact with infected secretions. the incubation period is 2-3
weeks after which virus can be detected in blood. saliva. genital secretions. urine. and
breast milk (559) (227) (517). Most symptomatic congenital infections occur in
settings where the mother is experiencing a primary CMV infection. Transmission is
less likely during latent maternal infection and the majority of these are asymptomatic
(58. 186). Symptomatic CMV is more likely in the setting of detectable CMV
viraemia (306). Symptoms of congenital CMV are both immediate and long term.
Immediate symptoms may include hepatomegaly. splenomegaly. microcephaly.
jaundice. thrombocytopenia or petechial rash. Long-term effects of congenital CMV
include deafness, vision impairment, mental and growth retardation (35.57,414).
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Chronic infection and immunosuppression
Though the immune system effectively contains CMV replication, persistent latent
infection is established for the life of the host. Most healthy people will never
become symptomatic, but there is a growing body of evidence suggesting that long
term infection with CMV may compromise immune responses in the very old (334,
406) (417). CMV may become reactivated during treatment with immunosuppressive
drugs or during HIV -1 infection. CMV infection causes disease in different organs
depending upon the underlying basis ofimmunosuppression(158}. CMV in transplant
recipients may cause fever, hepatitis, gastrointestinal tract inflammation (Gl), retinitis,
pneumonitis and myelosuppression. In HIV -I infected adults, CMV retinitis is the
most common syndrome associated with CMV disease, but dissemination to the 01
and central nervous system tissues is also common. HIV -1 infected infants with
congenital CMV may have GI disease and failure to thrive. HAART has greatly
reduced CMV-associated morbidity during HIV-I infection (125) (408).
CMV in HIV·l infected infants
The risk of CMV infection is increased in HIV -1 infected infants; the prevalence of
congenital infection in HIV-! infected infants may be as high as 20% (149). This
may be the result of increased CMV reactivation in HIV -I infected mothers, or as a
result of HIV -I induced immunosuppression in the infant. CMV infection during
primary infection with HIV -1 in neonates is associated with an accelerated course of
HIV -I disease, and increased risk of mortality (93, 284, 293). CMV may contribute
to HIV -1 disease progression in direct and indirect ways. CMV may broadly activate
the immune system, providing a larger pool of activated cells that could be targets for
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HIV-1 infection. CMV may also directly act as a co-factor for HfV-1 at the
molecular or cellular level by activating latent provirus or altering HIV-1
tropism(218). The US28 gene of CMV encodes a protein homologous to CCR5 and
may provide an additional co-receptor for HlV-1 infection. Though this has been
demonstrated in vitro there is no evidence showing this occurs in vivo.
In adults, CMV viral load strongly predicts disease progression and mortality, and the
effect was shown to be independent ofHIV-1 viral load (159, 512). The relationship
between CMV viral load and survival has not been evaluated in HIV-1 infected
infants. The mechanism by which CMV may modify HIV-1 disease progression is
unknown.
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STUDY QUESTIONS AND SPECIFIC AIMS:
The natural history of infant HW-J infection
Paediatric HIV-1 infection causes rapid disease progression In the absence of
antiretroviral (ARV) therapy. African cohorts have reported the highest rates of
mortality, from 20-50% at 2 years of life. Understanding the pathogenesis in HIV-I
infected children is important to the design of prevention, treatment, and vaccination
strategies. A cohort of 476 Kenyan children born to HIV-l infected women was
studied longitudinally from the time of birth to 24 months.
Specific aims for Chapter 2:
Determine the prevalence and timing of HIV-I transmission in a cohort of
breastfed infants born to women receiving short course antenatal AZT.
Describe the natural history of HIV-1 infection in a cohort of Kenyan infants
infected though mother to child transmission by sequential viral load
measurements and CD4 percentages.
Determine correlates of infant mortality in the cohort.
CMV infection in a cohort of HIV-J exposed Kenyan infants
The acquisition of CMV is common during infancy in sub-Saharan Africa In regions
of high HIV-1 prevalence, infants are at a high risk for co-infection with both
pathogens. HIV-1 infected infants co-infected with CMV have an increased risk of
mortality, though the mechanism governing this observation is unknown. CMV viral
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load predicts death in adults co-infected with HIV-1. This relationship has not been
determined in infants.
Specific aims for Chapter 3:
Determine the prevalence of CMV infection in Kenyan infants born to HIV-1
infected women.
Determine if HIV-1 infection influences the timing of CMV acquisition.
Compare CMV viral loads longitudinally over time in infants with HIV-l
infection and uninfected infants.
Examine the correlation between HIV-1 and CMV viral load.
Determine if timing of CMV acquisition, or the magnitude of CMV viral load
predict mortality in HIV-1 infected infants.
Lymphocyte distributions in healthy and HW-l exposed Kenyan infants
T cell phenotype can be described by the detection of cellular proteins using flow
cytometry. Lymphocyte distributions change in response to age, environmental
factors, and infection. The establishment of age-normal values for T cell phenotypes
is important in understanding the effects of viral infection. The study of cellular
phenotype can enable a better understanding of viral pathogenesis in infants.
Specific aims for Chapter 4:
Using multi-colour flow cytometry, describe the phenotype of CD4 and CD8
T cells in healthy HIV-1 negative and HIV-1 exposed uninfected Kenyan
infants.
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Compare phenotypic frequencies before and after detection of CMV.
Examine the correlation between CMV viral load and frequencies of activated
cells during acute and chronic CMV infection.
HIV-l induced lymphocyte redistribution in Kenyan infants
The study of HIV-1 induced changes in lymphocyte subsets IS valuable to the
understanding of HIV-1 pathogenesis in infants.
Specific aims for Chapter 5:
Using multicolour flow cytometry, compare phenotypic distributions of CD4
and CD8 T cell subsets between HIV-1 infected and exposed uninfected
Kenyan infants during the first year of life.
Examine the correlation between CMV viraemia and cellular activation during
acute and post-acute HIV-1 infection.
HIV-l specific CD8 T cell responses in Kenyan infants
The rapid course of HIV-1 infection in infants suggests HIV-1 specific CD8
responses may be less efficient in containing viraemia compared to adults. The
deficiency in CD8 responses could be due to low frequencies of HIV-1 specific
effector cells or an altered phenotype.
80
Specific aims for Chapter 6:
Using class I HLA-tetramers, quantify HIV-I specific CD8 T cells in HIV-I
infected infants during the first year of life.
Compare frequencies of tetramer + cells with results from IFN-y ELI Spot
assays in the children.
Using multicolour flow cytometry describe the phenotype of HIV -1 specific
CD8 T cells during the course of infection.
Immunophenotyping using multicolour flow cytometry
Multicolour flow cytometry is a powerful method for describing cellular phenotype.
Successful use of this method requires careful optimisation of techniques and
validation of assays. The large volumes of data generated using this method require
well-planned data management systems.
Specific aims for Chapter 7:
Describe the generation of the novel class I HLA-A *2902 tetramer.
Describe optimisation and validation experiments used to design the
phenotypic assays.
Describe the integrated data systems generated for the collection, storage,
management and retrieval of flow cytometry, clinical and other laboratory
data.
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Chapter 2
The Nairobi Mother-Infant Cohort:
The Natural History of Infant HIV-1 Infection
Introduction
The Nairobi mother-infant cohort (CTL cohort) was established in 1999 by the
Universities of Nairobi, Washington and Oxford. At the time of its inception, HIV-1
prevalence in Kenya had peaked at 15% (548) and the Government of Kenya (GoK)
was not yet able to provide antiretrovirals (ARVs). Rates of mother-to-child
transmission of HIV-1 (MTCT) were very high; a landmark study performed in the
same clinics had recently revealed the cumulative risk of HIV-l transmission at 24
months in breastfed infants to be 36.7% (390). Follow-up studies were aimed at
identifying correlates of MTCT. Studies from commercial sex workers and
discordant couples suggested virus specific T cell responses may provide protection
from HIV-l infection in highly exposed individuals (42, 183,208,276,456). It was
proposed that these responses could be protective in other highly exposed groups such
as breastfed infants (299, 300, 457). The CTL cohort was thus established with 2
major goals: 1) to identify immune factors providing protection from HIV-1
acquisition (163-165), and 2) to identify correlates of disease progression(333, 401).
The intensive clinical follow up and specimen collection in this cohort enabled the
construction of a model for HIV-l infection in ARV-naive breastfed infants. This
chapter describes the natural history of HIV-1 infection in infants from the CTL
cohort during the first two years of life. This chapter will not provide a
comprehensive review of the cohort, previously published data is referenced, and data
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presented here will be limited to those facets relevant to the aims of this thesis,
specifically: 1) rates and timing of HIV -1 transmission 2) HIV -1 viral load and CD4
values and 3) mortality in the cohort. These three sections form the setting against
which this thesis aims to understand infant immune development in the setting of
HIV -1 and how the infant immune system responds to HIV -1 viral replication.
Materials & Methods
Enrolment and follow up
The ethics review committees of the Universities of Washington and Nairobi
approved the use of human subjects for this study. Women attending Nairobi City
Council clinics for antenatal care were offered HIV -1 counseling and testing, women
screened before 28 weeks gestation who were HIV -1 seropositive and planned to live
in Nairobi for two years after delivery were invited to enroll in the study (407).
Counseling was provided to support safe infant feeding. Azidothymidine (AZT) was
provided during the final trimester to reduce the risk of HlV -1 transmission (492).
Women delivered their infants at Kenyatta National Hospital (KNH) under the care of
study-trained midwives and neonatal examinations were performed by study
paediatricians. Women and children visited the study clinic monthly for postnatal
care and follow up. During each visit mothers provided information regarding infant
feeding and reported illnesses. Postnatal care for mothers and infants included blood
counts, RNA viral loads, routine infant vaccinations (418), and the provision of
trimethoprim sulphamethoxazole (TMP-SMX) prophylaxis for the prevention of
Pneumocystis jiroveci pneumonia (PCP) (88). All patients were followed for 1 year
after delivery and blood specimens were obtained at birth (cord and venous), months
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1, 3,6,9, and 12. HIV-I infected infants and their mothers were followed up for an
additional year at 3-monthly intervals.
In the case of a maternal or infant mortality, clinic and hospital records were reviewed
to determine a likely cause of death. If a child died outside of hospital, cause of death
was evaluated by verbal autopsy interviews with the next of kin. The limitations of
verbal autopsies in delineating specific causes of death have been described (508) but
difficulties in obtaining consent for postmortems necessitated this method.
HIV-J diagnosis and quantification
During enrolment between 1999 and 2002, the laboratory facilities in Nairobi were
unable to provide adequate diagnostic services for infant HIV-1. Dr. Julie
Overbaugh's laboratory at the Fred Hutchinson Cancer Research Center (FHCRC,
Seattle, Washington) provided HIV-I diagnostics and RNA measurements. Infant
HIV-1 infection was diagnosed by nested PCR amplifying HIV-1 gag DNA from
dried blood spotted on filter paper (131). HIV-l RNA viral loads were measured in
cryopreserved plasma specimens, using the Gen-Probe assay (157). This assay has a
limit of detection of 50 copies/ml. HIV-1 infection in infants was diagnosed as the
detection of either HIV-1 DNA or RNA, followed by a positive specimen at the
subsequent visit. In utero transmission was defined by the detection of HIV-1 DNA
or RNA in the sample obtained on the day of birth. Infants testing negative at birth
. and positive at 1month probably represent a mixed group, comprised of late in utero,
intrapartum, and early breast-milk transmissions.
84
Blood counts
Blood counts were performed by the WHO Collaborative Centre Research and
Training Laboratory in the Department of Medical Microbiology of the University of
Nairobi. CD4+ and CD8+ T cell counts and percentages were determined at each
visit following HIV -1 diagnosis using TriTest CD3FITC/CD8PE/CD45PerCP
antibodies (BD Biosciences, San Jose, California, USA) and FACScan analysis with
CELLQuest Software (BD Biosciences).
Data management and analysis
Clinical and laboratory data were collected and stored in a Microsoft Access Database
(Microsoft Inc., Redmond, Washington, USA) and analysed using Stata SE v.9 (Stata
Corp. College Station, Texas, USA). HIV -1 RNA viral loads were logrs-transformed
for figures and comparison tests. Proportions were compared using Fisher's exact
test, continuous variables were compared using Mann-Whitney U test. Kaplan-Meier
survival analyses and Cox regression were used to describe time to infection, viral
load peak and set-point, and death. Outcome data was censored if a child exited the
study before 24 months and there was no record of death. Lowess curves fitted with
running means were used to describe viral load and CD4 trends over time.
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Results
Enrolment and follow-up
The CTL cohort was recruited from Nairobi City Council clinics between 1999 and
2002. During this time 31,731 pregnant women were screened for HIV-1 infection.
Seroprevalence in the Nairobi antenatal clinics was 14%. A total of 510 women were
enrolled in the study, 476 live singleton births were delivered, and 465 were observed
for at least 1 year post partum.
Rates and timing of HIV- I transmission
There were 90 HIV-l transmission events recorded during study follow-up (19.4%).
Timing of infection was available for 87 infants, for subsequent analyses children
were categorised by: in utero (positive at birth = 30) peri partum (negative at birth
positive at 1month = 41) and late (first positive after 1month = 16) inf~ction.
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Survival analysis was performed to describe the effect of breastfeeding on timing of
HIV-1 infection (Figure 2.1) Timing of HIV-1 infection was estimated by taking the
midpoint between the age at the last negative diagnosis and the first positive
diagnosis. The majority of transmissions occurred by 1 month of age, with a median
time to first HIV-1 infection of 0.49 months (95% Cl = 0.46-0.52). Data for feeding
status was available on 86 of the infants. No significant difference was detected for
timing of HIV-1 infection in the formula (13 infants) vs breastfed (73 infants) groups
(breast group median = 0.49 months Cl = 0.47-0.52, formula group median = 0.46
months Cl = 0.16-0.76, p = 0.52).
Viral loads during the first two years of life
HIV-1 RNA viral loads were retrospectively measured in all cryopreserved plasma
specimens. Overall, there were 384 measurements of infant viral load in the HIV-l
infected infants during the study period, with a median of 4 observations per infant
(range 1-9). Viral load during early infection strongly predicts time to AIDS and
survival in both infants and adults (410, 443, 473, 496). Two variables were created
to summarise the containment of viral load during early infection, "peak" (to
summarise the viral load burst size) and "set-point" (as a surrogate for steady state
viral load). Peak viral load was defined as the maximum viral load measured within 6
months of infection. As an estimation of an infant's steady state viral load, set-point
was defined as the first viral load observation measured at least 6 weeks after the
peak. The pattern of viral load in the cohort differed remarkably from that observed
in adults undergoing primary HIV-1 infection. There was great heterogeneity
between patients with some infants having a net reduction in viral load, and others a
net increase during follow up. Hence "set-point" used here is not completely
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Figure 2.1. Timing ofHIV-l infection in the CTL cohort.
KM analysis is used to estimate timing of HIV -1 infection in 87 infants. Infants were
grouped by mode of feeding, log rank p = 0.52 for comparison of breastfed (red line) vs
non-breastfed (blue line).
analogous to that defined elsewhere in adults. HIV -1 viral loads were persistently
high during primary infection in the infants; longitudinal models fitted to data
demonstrate an overall pattern of a very high peak followed by gradual reduction in
children surviving the first 12 months (Figure 2.2). Overall, viral load peaked at a
median of 1.7 months post infection at 6.8 10glOcopies/ml. Mean HIV -1 set-point
was 6.1 10glO copies/ml (Table 2.1). Peak and set-point HIV-I viral loads were
similar in children with in utero (mean peak 6.7 10gIOHIV -1 RNA copies/ml, set-
point 6.3 10glOHIV -I RNA copies/ml) and peri partum infection (peak 6.9 logIOHlv-
1 RNA copies/ml, set-point 6.2 logIO HIV -1 RNA copies/mI, p = 0.2, P = 0.9,
respectively). Peak viral load in the late infection group was similar to that of the
infants with infection by 1 month (peak 6.7 10gIOHIV -1 RNA copies/ml, p = 0.5), but
there was a trend for lower set-point in the late group (5.7 logIO HIV -1 RNA
copies/ml, p = 0.09), perhaps implying better control over viraemia. Timing of HIV-I
acquisition affected time to peak and set-point viral load. HIV-I viral load peaked
later in the in utero group (3 months) compared to those with peri partum (0.58
months, p = 0.0001) or late (1.6 months, p = 0.04) infection. Children with HIV-l in
utero also had longer time to set-point compared to those with peri partum infection
(6.2 vs 3.0 months, p < 0.0001).
Peak Time to peak· Set-point Time to set-point"
Group Mean±SE Range Median IQR Mean±SE Range Median IQR
ADHIV+ 6.8±0.079 5.0-8.4 1.7 0.58-3.0 6.1 ±0.094 3.4-8.0 5.4 2.6-6.2
1" lltero 6.7±0.15 5.0-8.4 3.0 1.3-6.0 6.3±0.13 5.0-8.0 6.2 6.0-9.0
PolPIl""", 6.9±0.10 5.2-8.1 0.58 0.47-2.6 6.2 +0.13 5.8-8.0 3.0 2.5-5.4
Late 6.7±0.19 5.8- 8.0 1.6 1.0-3.0 5.7±O.31 3.4-6.9 4.8 4.2-6.3
Table 2.1. Summary ofHIV-1 viral load indicators in HIV-I infected infants.
All values are given in months. "in utero vs peri partum p = 0.0001, in utero vs late p
= 0.04, bin utero vs peri partum p < 0.0001.
88
A)
1
I
r-,
E
~
<,
'"Cl> 0a.8\.0<:zer
~"" •I
0
c;,
.9
<T~L
0 3 6 9 12 15 18 21 24
8)
r--
E
<,
."
c:>
Ci
8\.0
<{ 1zer~
?:LJ"J
I
0 •c;,
.9
<T
24
Figure 2.2. PIa rna HI -1 RNA viral load during the first 2 years of life.
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CD4 and immunosuppression
CD4 measurements were available in 68 infants. There were 685 CD4 observations,
with a median of 2 observations per infant (range 0-8). Infants were grouped into
categories based on both CDC(89) and WHO(576) immunologic criteria. CD4 values
at 6 months were available in 34 infants with HIV -1 acquisition before 1 month of age
(Table 2.2). The majority of infants reached CD4 values adequate to classify them as
immunosuppressed during the course of study follow-up using either WHO (32/34,
94%) or CDC (74%) staging criteria. The WHO staging was more appropriate in
distinguishing children at risk of death in this cohort, as there was 50% mortality in
the "moderate" immunosuppression as defined by the CDC classification (9/18
children). Using either staging criterion, deaths were also observed in the group with
no evidence of immunosuppression (2 children-CDC, 1 child- WHO).
CDC Category CDC Criteria
CD4Iml CD4% % Infants (oIN) % Deaths (nIN)
No evidence ~ 1500 & ~25 26% (9/34) 22% (2/9)
Moderate 750 - 1499 or 15 -24 53% (18/34) 50% (9/18)
Severe <750 or < 15 21% (7/34) 71% (5/7)
WHO Criteria .
WHO Category CD4% % Infants (oIN) % Deaths (nIN)
None/insignificant >35 6% (2/34) 50% (1/2)
Mild 30-35 3% (1134) 0%
Advanced 25-29 26% (9/34) 11% (119)
Severe <25 65% (22/34) 64% (14/22)
Table 2.2. Immunologic indicators of immunosuppression in the cohort.
Infants with HIV -I detection by I month were categorised using CD4% and CD4
cells/ml data at 6 months of age based on the 1994 CDC(89) and 2006 WHO(576)
staging criteria.
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Infant mortality
Despite frequent clinical follow-up and TMP-SMX prophylaxis, mortality was very
high in the cohort; 33 (38%) died during the first year of life, cumulative mortality at
2 years was 54% (47 infants). Infant mortality was highest among the children with
in utero HIV-1 infection (20/30, 67%), followed by the peri partum (23/41, 56%) and
late (4/16,25%) infection groups. Mortality in the late group was significantly lower
than the in utero p = 0.01) or peri partum (p = 0.04). Overall, infants with infection
by one month of age had a greater risk of death at 2 years (61%, 43171 infants) than
those with late infection (25%, 4/16, OR = 4.6 Cl = 1.4-16).
A description of the maternal and infant correlates of infant mortality in this cohort
have been published (401). This paper also describes morbidity and causes of death
in the cohort and will not be revisited here in detail. The predictors of infant mortality
emerging in the multivariate model were maternal CD4 count < 200 cells/ml (HR =
2.7, p = 0.03) and delivery complications (HR = 3.4, p = 0.005). Infant CD4
percentage ~ 15% at 6 months was significant in the univariate model (HR = 5.5, P =
0.01). A decline in CD4 percentage of more than 10% was associated with a 3-fold
greater risk of mortality (HR = 3.0, CI= 1.2-7.1).
The above report was published before plasma viral loads had been measured, infant
viral load was thus not included in these models. The impact of viral load on infant
mortality is examined in this section, in combination with CD4 values. In agreement
with the published report, data here are limited to infants who survived at least 6
months of follow up to provide sufficient follow up data for group comparisons (68
infants).
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Survivors had better control of HIV -1 RNA viral load and less precipitous CD4
declines than non-survivors (Figure 2.3). Mean peak and set-point HIV-l viral loads
were higher in the infants who died during follow up (Table 2.3). The mean peak
viral load in the mortality group was 7.0 loglO HIV-l RNA copies/ml and 6.6 logIO
HIV-I RNA copies/ml in the survivors (p = 0.01). The mean set-point viral load was
6.4 10glOHIV-I RNA copies/ml in the mortality group and 5.9 10glOHIV-l RNA
copies/ml in the survivor group (p = 0.002). Time to peak and set-point were similar
between survivors and mortalities (p > 0.05 for each). Median CD4 percent (13% vs
25%) and absolute count (842 vs 1569 cells/ml) at 6 months were lower in the infants
who died.
Mortalities Survivors
Mean or Median Mean or median Comparison (p)
(±SE) or (IQR) (±SE or IQR)
Peak HIV -1 viral load 7.0 ± 0.12 6.6 ± 0.11 0.01
Set-point HIV -1 viral load 6.4 ± 0.14 5.9±0.13 0.002
Time to peak 3.0 (0.74-5.6) 2.4 (0.80-3.0) 0.2
Time to set-point 5.5 (2.7-8.7) 5.6 (2.6-6.2) >0.9
CD4% at 6 months 13 (9.0-21) 25 (19-28) 0.05
CD4 cells/ml at 6months 842 (623-1440) 1569 (1170-2200) 0.007
Table 2.3. Indicators of RIV-1 disease progression in infants dying before, or
surviving 2 years of life.
Cox regression was used to explore factors influencing infant survival time. The
subset of 65 infants provided 1092 person-months of observation, with an overall
incidence rate of 26.5 deaths/WOO person-months. Although there were more deaths
in the group with HIV -1 acquisition before 1 month, mean survival time in the three
groups was similar: in utero group 19 months (16-21), peri partum group 23 months
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Figure 2.3. D4 value and viral loads in children surviving or dying during the
fir t two ear of life.
Scatter plot with lowe cur es fitted to mean A) CD4 percent and B) HIV-l RNA viral
load fr m tim f fir t d t ction to 24 months. Red = survivors to 24 months, black =
death after m nth and before 24 month. Group shown is limited to children with
fir t I fIV-1 dciccti n b) I m nth of age.
(14-20), late group 21 months (17-24), (p > 0.05 for comparisons between each
group). As mentioned above, CD4 percent at 6 months was a strong predictor of
survival in univariate models. Using Cox regression CD4 percent at 6 months was
found to predict time to death (HR = 0.92, Cl = 0.87-0.98). HIV-l peak and set-point
viral load were also examined as predictors of death, for each log increase in peak
viral load, there was a 2-fold increase in risk of death in the HIV-l infected children
(HR = 2.0, Cl = 1.1-3.4). Set-point viral load was the strongest predictor of time to
death (HR = 2.4, Cl = 1.1-4.7). No association was found between time to peak or
set-point and survival time (p = 0.1, p = 0.9, respectively). When CD4 percent and
set-point viral load were combined together in a regression model, only CD4 percent
at 6 months remained significant (p = 0.02 CD4%, p = 0.2 set-point), with a hazard
ratio ofO.9 (0.86-0.99).
Discussion
Despite advances in HIV-1 diagnosis and treatment, HIV-1 remains a major cause of
morbidity and mortality among African children. With universal antenatal screening,
aggressive ARV, and avoidance of breast-feeding, the risk of MTCT can be reduced
to -1% (4). However, in regions where Hlv-I prevalence is high, public and private
resources are so severely limited that only a small percentage of women benefit from
these interventions; the latest UNAIDSIWHO update reports that only 9% of women
globally are able to access these interventions(S49). Consequently, the majority of
pregnant women deliver without any mv-1 support, and the number of infected
children is growing. Paediatric mv -1 prevention, treatment, and vaccination thus
remain a global health priority. An understanding of natural infection is invaluable to
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both treatment and vaccination strategies. This chapter describes the natural history
of HIV-I infection in ARV-naive Kenyan children.
Though antenatal AZT was provided to the mothers, a number of children became
infected during the study. At birth 6.5% of the children in the current study were
found to be infected with HIV-I, which is in range of the figure reported from the
Thai short-course AZT study (4.8% at birth(492». Additional transmissions
intrapartum and through breastfeeding resulted in an overall transmission frequency
of 20%. There were very few transmissions after one month of age and the overall
timing of transmission was similar between breast-fed and formula-fed children. This
observation is consistent with other reports demonstrating that virus levels are highest
in the colostrum and early milk(454) and the risk of transmission through
breastfeeding after 1month is lower but consistent(390).
The natural history of infant mv -1 differs substantially from the typical course of
HIV-l observed in infected adults(410, 411, 453, 496) (Figure 2.4) Several factors
may explain the more aggressive disease course observed in infants with HIV-1.
Infection via the oral or gut mucosa in utero, intrapartum, or via breast milk may
accelerate CD4 depletion of the GALT. Infection in utero may cause damage to T
cell repertoires by death of infected thymocytes(482) or negative selection of antigen-
specific T cells(505). Genetic similarity between mother and infant may result in the
transmission of variants with pre-adapted fitness for the new host (214, 319, 502).
HIV-1 specific responses generated by young infants are less frequent and weaker in
magnitude than in adults, but become stronger over time(78, 467), suggesting a
maturing of cellular immunity with age. Weak CD4 Th1 type responses in neonates,
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Figure 2A. The natural hi tory of HIV-l infection in adults and infants.
N
Figure how HI -1 viremia and CD4 values from HIV -1 infected adults and infants.
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or responses skewed toward a Th2-type response may fail to support CD8 T cell
responses(246, 564, 565). Elevated regulatory T cell frequencies may also inhibit
cellular immune responses in utero (316). Finally, co-infection with other pathogens,
particularly tuberculosis(222) and cytomegalovirus,(93, 149, 284, 293, 396) may
increase mortality in HIV-1 infected infants.
Very high rates of morbidity and mortality are observed during primary HIV-l
infection in young infants, in the current cohort and others(395, 401). This pattern
differs substantially from the course of infection in adults, where the median time to
AIDS or death is 10 years in the absence of therapy(460). Viral load measurements
early in HIV-1 infection predict disease progression and survival in HIV-1 infected
adults and infants(136, 365, 366, 410, 496,521). For many infants in the CTL cohort,
there was no clear peak viral load followed by reduction to a set-point that is
analogous that observed in adult infection; viral loads continued to rise until death or
exit from the study. "Peak" viral loads occurring at 6+ months are more likely a
measure of disease progression than containment of acute infection. Consequently,
peak and set-point definitions were restricted to 6 months post infection. Set-point in
the infants is also not an ideal measurement of steady state viral load, because in
many cases viral load increased after peak. However, the term is useful for
summarising the containment of viraemia achieved by some infants. Later acquisition
of HIV-I was associated with shorter time to peak and set-point viral loads, and this
group had a greater drop from peak to set-point, implying better control over
viraemia. The group with in utero HIV-1 acquisition had a longer time to peak and
set-point viral load. This may be due to the suppressive effect of AZT acquired in
utero. Peak and set-point viral load were strong predictors of time to death in the
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cohort, each 10glOincrease in either peak or set-point was associated with ~2-fold
increased risk of death.
CD4 depletion is the hallmark of HIV-1 disease progression, and is highly predictive
of mortality (162, 365, 431, 444). Though adult CD4 decline sharply during acute
infection, their numbers are partially restored after set-point is reached, after which
they slowly decline during the years of host-viral equilibrium preceding AIDS(167,
411). In the current cohort a consistent decline was observed in both CD4 percent
and absolute counts/ml during study follow-up. By 6 months of age, 94% of infants
met WHO definitions for immunosuppression, and CD4% at 6 months was predictive
of mortality by 2 years of follow-up. Staging by WHO(576) and CDC(89) showed a
very high risk for mortality in children with a broad range of CD4% frequencies.
Opportunistic infections (01) are uncommon at values above 500/ml in adults(378),
but this does not appear to be the case in very young children who may develop 01
and AIDS at relatively high CD4 values(382). Children living in resource-poor
settings may be at an additional risk of co-infections due to increased exposure to
bacterial pathogens, helminth infections, viral co-infections and tuberculosis.
At the time of this study enrolment and follow-up, ARVs were not widely available in
Kenya. In 2004, ARVs became available to the OoK, which began a massive
distribution programme through hospitals, research groups and NGOs. Women and
children of the CTL cohort are now receiving ARVs at a number of treatment centres
in Nairobi. Previous studies have demonstrated that mortality is reduced by the
initiation of ARV early in Iife(169, 561), and the CDC recommends immediate
treatment for all infants less than 12 months 0Id(89), regardless of immunological
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parameters of symptoms. Recent data from South Africa(558) demonstrate ARV
initiated before 12 weeks of age can substantially reduce morbidity and mortality in
young infants. The data presented here suggest that Kenyan infants are at an
extremely high risk for death from IIIV-1 during the first two years of life and must
be included in national strategies for HIV /AIDS treatment.
Summary
This chapter describes viral load, CD4, and mortality trends in the CTL cohort. Early
viral loads and CD4% at 6 months emerged as strong predictors of mortality. The
following chapters explore potential factors that may contribute to the aggressive
course of HIV -1 disease in very young children.
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Chapter 3
Primary CMV infection:
A co-factor for HIV-I disease progression in African infants?
Introduction
Cytomegalovirus (CMV) infection may be an important co-factor for disease
progression in human immunodeficiency virus type 1 (HIV-I) infected children. Co-
infection with CMV has been associated with a 3-fold increased risk of mortality
during the first year of life(93, 149, 284, 293, 396). In adults, CMV viral load is
predictive of HIV-I disease progression and mortality (126, 159, 510). Though it is
clear that CMV co-infection influences HIV-1 disease progression, the mechanism by
which CMV influences HIV-1 progression in infants is unknown, and the quantitative
relationship between levels of HIV-1 RNA and levels of CMV DNA in infants has
not been determined.
If CMV presents a significant risk factor for HIV-1 disease progression, the impact
might be greatest in African children where CMV is commonly acquired in infancy
(40, 372). Infant mortality in HIV-1 infected infants in the absence of treatment is
very high in sub-Saharan Africa (52% at 2 years(401» compared to western cohorts
(-15% at 18 months(249» (395), and co-infections may contribute to excess
mortality. The current study was performed to examine the impact of CMV co-
infection and HIV-1 disease progression in Kenyan infants.
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Materials & Methods
Participants
A subset of 44 HIV-1 infected (HIV+) and 20 HIV-I exposed uninfected (HIVexp-)
infants were selected from the CTL cohort who met the following criteria: survival to
at least 3 months of follow up and a plasma specimen available within l month of
birth. Specimens from 13 healthy HIV-1 uninfected Kenyan women were obtained
from a separate cohort (MIP cohort) with similar characteristics(63).
HIV-l diagnosis and quantification
Infant HIV-! infection was diagnosed by nested PCR amplifying HIV-I gag DNA
from dried blood spotted on filter paper(13 I). HIV-I RNA viral loads were measured
in cryopreserved plasma specimens, using the Gen-Probe assay(IS7). HIV-1 infection
in infants was defined as the detection of either HIV-1 DNA or RNA, followed by a
positive specimen at the subsequent visit.
Infants were grouped according to first HIV-I detection= in utero (sample collected
within 48 hours of birth positive, IS infants) peri partum (negative at birth, positive
by I month, 16 infants) or late (after I month, 13 infants). Peak viral loads were
defined as the highest viral load measured in the first 6 months of life. HIV-I set-
point was defined as the first viral load observation measured at least 6 weeks after
the HIV-I peak.
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CMV diagnosis and quantification
The CMVScan (BD Diagnostics, Sparks, Maryland, USA) system, which detects
CMV IgM & IgG antibodies, was used to estimate CMV seroprevalence in the HIV-l
infected and uninfected women. Thirteen HIV -1 uninfected women and 29 HIV-l
infected women were screened at delivery for the presence of CMV antibodies.
Nucleic acids were extracted from 200 f..llof plasma using the Qiagen UltraS ens virus
extraction kit (Qiagen, Valencia, California, USA). CMV viral loads were obtained by
quantitative PCR detecting the glycoprotein B gene (gB) as previously described(65).
PCRs were performed in triplicate for each individual and the mean was calculated of
the replicates. The lower limit of detection was 1 copy/reaction. Negative and
indeterminate PCR assays were assigned a value equivalent to the midpoint between
the limit of detection and zero. Peak CMV viral load was defined as the highest viral
load observation for each infant.
Statistical analyses
SPSS v.ll (SPSS, Inc. Chicago, Illinois, USA) and Stata SE v.9 (Stata Corp. College
Station, Texas, USA) for Macintosh were used for statistical analyses. Viral loads
were base 10 log-transformed (LoglO) before comparisons. T-tests and Mann-Whitney
U tests were used to compare continuous variables, Chi Square tests were used to
compare proportions. Pearson correlation was used to measure independence between
continuous variables. Kaplan-Meier and the log-rank test were used to compare time
to CMV infection and death between dichotomized variables. Cox regression was
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used to estimate the hazard rate of death. Median smoothing splines fitted with cubic
curves were use to illustrate changes in viral load over time.
Results
Prevalence and transmission of CMV in the Nairobi mother-child cohort
Adult CMV seroprevalence in HIV-I infected pregnant women was 97% (28/29) and
100% (13/13) in the uninfected women. CMV viral loads were measured at delivery
in 13 HIV-1 uninfected and 64 HIV-1 infected women. None of the uninfected
women from the control cohort had detectable CMV viraemia; 11/64 (17%) HIV-l
infected women had detectable plasma CMV viraemia. The mean CMV plasma viral
load in the II viraemic women at delivery was 1.5 IOglOcopies/ml (range 1.5-2.2).
Infants were serially monitored for CMV viraemia during the first two years of life.
Despite an additional year of follow-up in the HIV+ group, the median number of
observations in HIV+ and HIVexp- infant groups were similar due to the high rate of
mortality in the HIV+ group (median of 6 observations/infant in each group).
Overall, CMV viraemia was detected in the plasma of 95% (61/64) of the infants by 2
years of age (Table 3.1). The overall prevalence of CMV infection by 12 months of
age was similarly high in both HIV+ (41144,93%) and HIVexp- (19/20, 95%) infants.
CMV prevalence at 1 year was similar between infants acquiring HIV-1 in utero
(15/15, 10(010),peri partum (14/16,88%), and late (12/13,92%).
CMV was acquired early in life and most of the 42 co-infected infants acquired HIV-
1 first (60%,25/42 infants). Intrauterine acquisition of HIV-I was associated with an
increased detection of CMV viraemia at birth: 27% (4/15) with HIV-1 in utero vs
100
2.0% (1149) of all other infants (p = 0.009). CMV and HIV-I viraemia were detected
concurrently in 9 infants (21%) and 8 infants (19010) acquired CMV first. CMV was
detected earlier in infants with intrauterine acquisition of HIV -1 (median 0.5 months,
95% Cl = 0.0, 1.3) compared to infants with peri partum (median 2.0, Cl 1.7, 2.3, P =
0.002), late (median 2 months Cl = 1.8, 2.2, p = 0.02,) or no HIV -I infection (median
2.0, Cl 1.7,2.3, p = 0.001).
CMV was detected in the blood of five infants at birth (4 HIV+, 1 HIVexp-).
Detection of maternal plasma CMV viraemia at delivery was not associated with
infant CMV detection at birth (p = 0.6). Four aviraemic mothers delivered infants
with detectable CMV, 11 CMV viraemic mothers delivered infants without CMV
detection, and only I mother-child pair was concurrently CMV viraemic at delivery.
Neonatal examinations were performed on all infants; no physical signs of congenital
CMV were observed. The HIVexp- infant (81-249) with CMY viraemia at birth
survived and exited the study at 12 months, three of the four HIV+ infants died, one
had failure to thrive and died with pneumonia at 15 months, one died with sepsis at 6
months, and one died with pneumonia at 7 months.
101
- ~ ~ II) NI ~ 0:> o () .- -~ .- .-S S II)..d
,.-... .s ~ e .i-"...
rIl - .- .- .- rJ:i- ,-., ,-., ,-., t=:' ,.-... ,.-... ,.-... ~ ;> ;>= V) r- V) 00 0 - N ...~ ~ - V) V) V) \0 \0 ~ +-' ~ ~ ~cf?- ~ ~ ~ ~ ~ ~ ~ ~= ~ cf?- cf?- '?J( cf?- cf?- \0 +-'.. 00 - U 00 ~ ~ U- r- \0 o- ~ V) .......- r-- N 00 00 "" "" o. 0 .- II) .-e II) dN 8 § ..c c:Il
0 () 0 ;>
c:Il II) - ~'i:' ci. II) ..c >. 0"0 .- .-Q,I 0 +-'= II) .-.c :s .- ~ ~ c:IlS ,.-... ~ s .- '5:s ,-., ,.-... ,.-... -.. -.. N - ~ ~ C"= ,.-... - N N N N N - os g... M - 0- Q,I ~ - - - - - o£ cS rJ:i- ~ ~ ~ -- -- -- M 0 e -• • 0 ~ '?J( '?J( ~ '?J( '?J( - .... ~ e I._ 0S ....J 0 - ~ ~ ~ :>M 0 --N V) N N N N - -Q,I 00 "" "" "" "" ~ ~ d ::tf N • ~ ~._ Q,I ~ .§ '€ II)~ >. ·El> ~ 0. +-' .- II)
~ E
-.. ! ~ () ..c +-',.-... -.. -.. -.. -.. M .-
~ 1a SU ~ -.
-. N M M ~ V) N
~N
~
~0 ~ - - - - - r-: = .- "0..c:I 2. '-' ~ '-' -- -- '-' \0'?J( 'C ~ - II) .-- cf?- cf?- ~ '?J( cf?- ~ - I +-'._ - ::s :> () .s~ .;:: M 0 0 '-'0 V) - - 00 ~ "0 - ~ .~rIl ~ r- OO 00 00 "" 0 c:Il ::t- N 1: .- ~c:I ~ c:Il -5 c:Il~ ~ - +-'..c:I .~ I ~= ,.-... ~ :>._ M ~ c.,:.;:;.- -.. -. ~ s:: ~.... -. .- V) V) V) -e .- ,.-... ~ ~ - ... .-
~
.-~ ~ 00 - - - - - = c...... ...~ ~ '-' '-' '-' '-' '-' -- '-' 0 ~ 0 -5 ~'?J( '?J( '?J( cf?- V)• ::a '?J( cf?- '?J( - 0 = ... .~M 0 0 0 -- ._ i 8 -... ~ r- M M ~ 0= N V) 0- 0- 0 0 0 V) c:Il 0 rJ:iQ,I - - - cl Q,I 0 ~ cl ~~ ..c:I c:Il... Z II)Q,I ~ "0 ~ V 0C. ,.-... e ..,l = - 0. eQ,I - .- - "0! ~ -. -. t=:' .- 6' .- -. ~ ._ c:Il () ~ -~ M 0- - N .c .- ~ rJ:i- M M ~ ~ ~ e ;> Ji"" ~ £ -~ v-i I• '-' '-' '-' '-' -- '-' ~ N- = cf?- ._ .s rJ:i ~:I '?J( cf?- ~ '?J( '?J( cf?- ~ - • ~ 0 ~e ~ - ~ '-' Z ~ e II)a:.. 0 ~ - M V):I M 00 00 0- 0- 0- ~ Q,I 0 I ~U N ..c:I $' S 0 QO... N 0 ..8.S N ~ ......J() ]-.. • .- ~ -i M e () u-. .- .- -- .- N ._ .--. -. 00 00 00 "" 0- S ~ () e ()... ~ .- '?J( ~.! - '-' - - - - - r-: Q,I ... e e'-' '-' ~ '-' -- -- 0 f ._ V) ~c:I ~ '?J( ~ ~ '?J( '?J( '?J( N - ;> ~ .- "" .-0 0
~ 0 -- ._ ~ ... ;> c:Il._ V) 0 V) V) ~ .sc:I N .... -~ 0- 0- 0- "" ~ i ;> ~ .~ ~N ~U ~ ~U ._U c:Il t;..,". .... ~ U II) ] 0._ ~ II) § ]e Q,I ~ § c:IlQ,I ~ .- () 00e c:I t;.., () II) .- 'CQ,I 0 ..8 ..c a s-._ -~ • II) ~ ....i i t bI) ~ "0 0g ~ ~ ()c:I ...
~
.&> ~ ! c.N ~ U ~ II) ~ ..- ~ \0 0\ - N ~ ~ .S ~ 8 a:....c:I ..c:I ..c:I ..c:I ..c:I ..c:I ... ~ 8- ~ 0 §-
..c:I ... ... ... ... ... ... - Q,I =- ;:s u 0 e1: = c:I c:I c:I c:I = • S ~ ·5 0~ ~ ~ ~ ~ ~ ... ~ rJ:i bI)._ '1 ~ ~ '1 '1 ~ ~ ._ .~ ~ ~ "= ~ ~ ~] 0 0. 0Q,I .... 0 .--- () e -€ Q.c ~ ~• 0~ u .-.- - ..c ._
Impaired containment ofCMV in HIV-J co-infected infants
CMV viral loads were examined during the first two years of life. As a group
HIVexp- were better able to control CMV replication than HIV+ infants (Figure 3.1).
CMV viral loads rapidly decreased in the HIVexp- group during the first year of life
while in the HIV+ group CMV viral loads declined more slowly. Peak CMV viral
load was defined as the highest viral load measured for each infant during the first 6
months of infection (Figure 3.2). Overall, children with early HIV -1 infection (before
I month) had significantly higher peak viral loads (3.1 10gIOcopies/mI, IQR 2.6-3.5)
than children with no HIV -I infection (2.7 10gIOcopies/ml, IQR 2.1-3.3, P = 0.05).
Peak viral loads were similar in the late infection group (2.910gIO copies/ml, IQR 2.5,
3.1) and the HIVexp- children (p = 0.5). Median peak CMV viral load was 3.110glO
copies/ml (IQR 2.6-4.0) in the group with HIV -1 infection in utero, and 3.1 10glO
copies/ml (IQR 2.3-3.5) in the peri partum group.
Primary co-infection with HIV-l and CMV
CMV infection was present in nearly ail HIV+ infants. As discussed in Chapter.2,
very high viral loads were maintained in the majority of infants with HIV -1 infection.
In comparison, CMV viral loads were more efficiently controlled, with a steady
decline to lower levels observed following acute infection (Figure 3.3). The
extraordinary prevalence of CMV in the cohort, and the very early timing of
transmission made comparisons of HIV -1 viral loads between CMV viraemic and
aviraemic infants impractical, as only 2 HIV+ infants did not have detectable CMV
viraemia. Pearson correlation was used to describe quantitatively the relationship
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Figure 3.3. Longitudinal HIV-l and CMV viral loads in co-infected children during
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the fir t two year of life.
HIV -I (black) and (orange) viral loads are shown with fitted median smoothing
spline. hi! r n h \\ n here ur iv d 12 m nth of follow-up and were diagnosed with
HIV -I infecti n ) 1 m nth f age and CMV at 3 months.
between CMV and HIV-I viral load (Figure 3.4). Peak CMV viral load was
positively correlated with HIV-1 peak (p = 0.36, p = 0.02) viral load, but not set-point
viral load (p = 0.1).
Infant mortality during co-infection
High CMV viral load is an important predictor of death in HIV-I infected adults(159,
510) and may also be correlated with survival in infants. Twenty-two infants from the
subset died during the course of the study: 3 HIVexp-, 8 HIV+ in utero, 7 HIV+ peri
partum, and 4 infants with late breast milk HIV-I acquisition. In Cox-regression,
peak CMV viral load predicted time to death among co-infected infants who had
acquired HIV-I in utero (p = 0.03, HR = 2.1, 95CI 1.1-4.3). No effect was found
when all HIV+ children were analysed as a group (p = O. 3). Since HIV-I viral load
has a strong effect on infant mortality (Chapter 2, HIV-I set-point HR = 2.4), the
survival analysis was adjusted for HIV-1 set-point viral load. All 42 children with
CMV had a defined HIV-I set-point viral load. The adjusted HR for peak CMV viral
load was 1.7, and for HIV-l set-point was 2.1, neither were significant (p = 0.1 CMV,
p = 0.074 HIV-l), indicating effects of CMV viral load could not be discriminated
from the strong effect of HIV-I set-point in the current study (Figure 3.5).
The effect of timing of CMV acquisition was also examined. Only 4 children in the
current study were infected with CMV at birth, so children were stratified by CMV
diagnosis by 1 month of age or after Figure 3.5. Without adjusting for HIV-l viral
load, there was a trend for increased mortality in children with early CMV acquisition
among the group of all Hlv+ infants (p = 0.06) and those with HIV-l before 1month
(p = 0.07). To control for HIV-1 viral load, infants were stratified based on HIV-l
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Scatter plot and linear prediction of HIV -1 and CMV viral loads in co-infected infants.
Spearman's p = 0.36, p = 0.02.
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set-point viral load above or below the cohort mean of 6.1 10glOcopies/ml (Table 3.2).
There was no difference in survival between groups of infants with high set-point
viral load and low set-point with early CMV (Table 3.2, groups 1-3). However, none
of the children with low HIV -1 set-point and late CMV acquisition died (group 4).
The results of the survival analysis were similar when excluding children with late
HIV -1 infection.
aMean survivalGroup N Deaths
infants
Group 1) High HIV VL & Early CMV 8 75% (6/8)
Group 2) High HIV VL & Late CMV 17 59% (l0/17)
Group 3) Low HIV VL & Early CMV 6 50% (3/6)
Group 4) Low HIV VL & Late CMV 11 0%(0111)
(months ± SE)
13 ± 2.0
16 ± 2.0
16 ± 3.3
(all censored)"
Table 3.2. Mean survival times of children stratified by time of CMV viraemia
and HIV -1 set-point.
Early CMV = CMV acquisition prior to 1 month, Late CMV = after 1 month. High
and low HIV -1 set-point was defined as above or below the cohort mean of 6.1 10glO
copies/ml. "Mean survival times are restricted to the follow-up of 24 months, children
not dying before 24 months are censored, so true mean is underestimated. ~o
children with low HIV -1 set-point and late CMV acquisition died, all data are
censored so no mean survival time can be estimated.
Since children in groups 1-3 were similar in survival time and mortality, a Kaplan-
Meier survival analysis was performed comparing group 4 to the combined groups 1-
3. Having high viral load or early CMV acquisition greatly increased risk of death
among all the children with HIV-I (p = 0.0013), and those with early HIV-l
acquisition (p = 0.0087). It was not possible to calculate a hazard ratio because none
of the infants in group 4 died (Table 3.3).
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Time of HIV-l Comparison groups N amen survival Log-rank p
infection infants (months ± SE)
All infections Group 4 children vs 11 (all censored)"
others 31 15 ± 1.4
p = 0.0013
Before 1 month Group 4 children vs 7 (all censored) b
others 23 15 ± 1.6
P = 0.0087
Table 3.3. Children with low HIV -1 set-point and late CMV acquisition have the
best prognosis during the first two years of life.
Group 4 = children with HIV-I set-point viral load below the mean and CMV
acquisition after 1 month others = children with high set-point viral load or early
CMV acquisition (Groups 1, 2, and 3 from the previous table). "mean survival times
are restricted to the follow-up of 24 months, children not dying before 24 months are
censored, so true mean is underestimated. b No children with low HIV-I set-point and
late CMV acquisition died, all data are censored so no mean survival time can be
estimated.
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Discussion
Although the burden of CMV disease has been substantially relieved by the advent of
HAART in 1996(182,255,408), CMV retinitis and end organ disease continue to be
major causes of morbidity in HIV-I patients(39, 125, 126, 570, 571, 584). CMV is
not quiescent in patients on HAART with good HIV-1 suppression and even low
levels of CMV viraemia have been associated with increased disease progression and
mortality( 126, 159). CMV has been associated with increased mortality among HIV+
infants, though the mechanism by which CMV accelerates HIV-1 disease is unknown.
In this Kenyan paediatric study of HIV-1 infected and uninfected infants, CMV
prevalence was extremely high during early infancy. Infants with HIV-1 contained
CMV less effectively than HIV-I uninfected infants and HIV-1 and CMV levels were
correlated. The timing of CMV acquisition was found to have a significant effect on
survival during the first year of life in co-infected infants.
Because this study was conducted retrospectively and only cryopreserved plasma
specimens were available for diagnosis and quantification of CMV, these data must
be interpreted with the following limitations in mind. Firstly, levels ofCMV DNA in
plasma are lower than in cells and the figures reported here likely underestimated true
levels of viraemia. However, since comparisons of HIV-I infected and uninfected
infants were made using identical methods the differences between groups could be
discerned despite some decreased sensitivity in the assays. In addition, since >95% of
the infants in the study had detectable viraemia at some point during follow-up, it is
unlikely that false-negatives contributed significantly to overall prevalence estimates,
though they may slightly modify estimates of timing of CMV infection and point-
prevalence. A second limitation of the study was that the cohort was not primarily
lO7
established to study CMV and was not designed to identify clinical signs of CMV
infection. No CMV symptoms were detected in the congenitally infected infants in
this study, which is consistent with previous reports showing children born to
chronically infected women are often asymptomatic(519). CMV rarely causes clinical
symptoms when viral loads are low, and the levels of CMV viraemia detected in the
current study suggest that CMV is unlikely to be the direct cause of death in the
infants(306) (553). However, paediatric CMV and HIV-I can contribute to several
non-specific symptoms such as failure to thrive, sepsis, and gastrointestinal disease;
these were morbidities that significantly contributed to mortality in the study
cohort( 401) and it is possible CMV disease played a role in some of these deaths.
Finally, HIVexp- provided a control group for the CMV studies. These infants are not
ideal controls as "healthy infants", as they have an increased rate of mortality during
the first year of life and altered immune function compared to infants born to HIV-I
negative mothers(104, 205).
CMV incidence was very high during the first year of life; more than 80% of infants
were infected by 3 months of age, independent of HIV -1 infection status. This figure
is higher than has been reported in The Gambia (50-60% CMV prevalence at 6
months and -85% at 12 months of life) (40) (553). CMV is acquired vertically (in
utero or via breast milk) and horizontally (from other children, relatives)(l40, 227,
517), and the very high prevalence in this cohort is likely due to a combination of
mixed modes of transmission.
Congenital CMV occurred in a high proportion of infants who became infected with
HIV -I in utero. This suggests similar maternal-infant factors may influence
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susceptibility to HIV-I and CMV infection in utero. Increased risk of congenital
CMV infection has been previously noted in HIV-I infected children(149). Women
with cervical shedding of HIV-I are more likely to be shedding CMV and this may
contribute to an increased risk of intra-partum transmission (380). Breast milk viral
load is correlated with transmission in both CMV (227) and HIV-I (454). No
correlation was found between maternal CMV viraemia and congenital CMV
transmission in this cohort. There are other reports of discordance between maternal
viraemia and congenital CMV transmission, and anti-IgG avidity tests are more
predictive of transmission(311, 441). Congenital CMV typically results from primary
infection during pregnancy(518) but it is unlikely that the 5 women who transmitted
CMV in utero were acutely infected, as they were CMV seropositive at delivery and
had low CMV viral loads. Discordance between maternal viraemia and congenital
transmission may indicate that CMV replication at localized sites during chronic
infection is sufficient for transmission despite a lack of systemic reactivation.
CMV viral load was examined during the first year of life in infants with and without
HIV-I co-infection. CMV levels were highest among children with early acquisition
of HIV-I, suggesting acute co-infection with mv-1 compromised containment of
CMV. CMV levels were similar among children with late HIV-1 acquisition and
those who remained uninfected. Longitudinal comparisons of viral load over time
showed more rapid decline of CMV viral load in HfVexp- infants than in the HIV+
group. HIV-1 facilitates CMV replication via systemic immunosuppression, and this
is likely to explain the differences in kinetics of CMV replication in HIV-1 infected
and exposed uninfected infants(151, 175,254).
lOO
A previous study by Boriskin et al. reported higher levels of CMV viral load in
.infants < 2 years of age with advanced disease progression, but found no correlation
between cellular CMV load and HIV-I viral load (60). The suppressive effect of
ARVs in the Boriskin study is likely explain the differences in findings. Several
mechanisms may explain the link between HIV -I and CMV viral replication. First,
CMV is an opportunistic pathogen that replicates more easily in immunosuppressed
individuals( 151, 175, 254); high HIV -1 viral load and immunosuppression is likely to
translate to impaired control of CMV replication. Second, HIV -I and CMV may
interact directly at the single cell level, either through transactivation of HIV -1 via its
promoter or by altering HIV-I tropism(218, 308). Though the co-factor effect has
been demonstrated in vitro, there is yet no evidence this occurs naturally during
infection, and since HIV -1 and CMV establish their reservoirs in different cell types,
an indirect mechanism seems more likely. Finally, CMV may augment HIV-l
replication via widespread cellular activation. HN -1 requires cellular activation for
efficient infection of T cells( 146). Monocytes are productively infected by
CMV,(234) and through production ofIL-12 and their role as antigen presenting cells,
have the potential to activate CD4 T cells.
CMV viral load has previously been reported to predict survival in adults with HIV-l
infection (126, 159, 510). Peak CMV viral load was only predictive of death in the
children with in utero acquisition of mv-1. After adjusting for HIV -1 set-point, no
independent effect of CMV viral load was detected. The strong correlation between
HIV -1 and CMV viral load further confounds the analysis, and if the level of CMV
viraemia contributes independently to mortality, a larger study would be necessary to
see an effect of CMV viral load over that of mv-1 viral load.
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Others have reported poor prognosis for HIV-1 infected children born with congenital
CMV (149). In the current study, 3 of the 4 children with HIV-I and CMV co-
infection at birth died. Though the frequency of congenital CMV transmissions was
high in the current study, the numbers were not large enough to perform a similar
analysis examining congenital co-infection and disease progression. However, it is
likely that the true number of congenital infections was underestimated in the current
study, as discussed above, the sensitivity of plasma viraemia has not been evaluated in
infants as a diagnostic method. All infections before 1 month were thus grouped
together to examine the effect of early CMV acquisition on mortality. Among all
children with co-infection, early CMV was associated with a trend in increased
mortality at 24 months. No mortality was observed in the group with low HIV-1 set-
point and CMV acquisition after 1 month, suggesting that delaying CMV acquisition
may benefit survival in children with low HIV-I viral load. Timing of CMV
acquisition had no effect on mortality in children with high set-point HIV-I.
CMV remains the most common viral cause of congenital disease globally(477, 478)
and even among healthy children presents significant morbidity and developmental
defects. CMV diagnostics among asymptomatic newborns is not standard practice for
the care of healthy or HIV-1 infected infants, and the value of treating sub-clinical
CMV viraemia to support HIV-I treatment has not been investigated in neonates.
CMV treatment is invasive, toxic and expensive(47), and may not be practicable
considering the current scale of the HIV-I epidemic. However, screening for CMV by
PCR or antigenaemia may identify HIV-I infected children at especially high risk for
mortality. Several studies have shown CMV prophylaxis with oral ganciclovir or
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valaciclovir to reduce morbidity and mortality in immunosuppressed patients (125,
511) (159). The importance of a CMV vaccine, and better therapeutic agents for the
treatment of CMV should be re-assessed in context of the paediatric HIV -1 pandemic.
Though HAART will undoubtedly change the epidemiology of CMV infection in
paediatric populations, the global community may be years away from the WHO's
target of universal access to ARV treatment. Until that goal is realized, a CMV
vaccine may have great benefit for children with undiagnosed HIV -1 infection.
Summary
CMV prevalence is high among Kenyan children exposed to HIV -1 infection. HIV-l
infection impaired containment of CMV replication. CMV infection contributes to
HIV -1 disease progression co-infected children, particularly those with concurrent
acute infection.
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CHAPTER4
Lymphocyte distributions in healthy and HIV -1 exposed
Kenyan infants
Introduction
The understanding of viral infections in young infants may be confounded by the
complexity of factors influencing the development of immunity in early life. Age-
related changes in T cell subsets, first exposure to environmental pathogens, and
vaccination may result in the diversification of lymphocyte populations. In Chapter 3
CMV incidence was shown to be very high during the first months of life in Kenyan
infants born to HIV-1 infected mothers. CMV infection in particular has been shown
to elicit dramatic changes in the CD8 cell subset that can persist throughout life (372,
417, 572, 578). CMV may play an important role in the shaping of lymphocyte
populations in Kenyan children.
The aim of this chapter is to establish age-normal values for cellular phenotype in
Kenyan children who are at high risk for CMV infection. Two groups of infants are
studied, drawn from a cohort of HIV-1 negative women and children (MIP cohort-
children unexposed to HIV-1) and HIV-1 positive mothers (CTL cohort-infants
exposed to HIV-1). The second aim of this chapter is to assess CMV-induced
changes in lymphocyte phenotype, and assess the relationship between cellular
activation and CMV viral load.
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Materials & Methods
Subjects & sampling
The CTL cohort was described in Chapter 2. CMV and HIV-1 diagnostics were
described in Chapter 3. Ten HIV-l exposed uninfected children (HIVexp-) were
originally selected based on survival to 12 months and availability of specimens, but
specimens from 3 children did not arrive from Kenya, so in total 7 HIVexp- children
were followed up longitudinally. One additional child with a single specimen stored
at Oxford was screened at 6 months (CTL-'BI-087).
Infants from a separate cohort of healthy HIV-1 negative women and their infants
were also screened as HIV-1 unexposed controls. The MIP cohort was recruited in
Nairobi in the same clinics as the CTL cohort. Following birth, infant HIV-I status
was further confirmed by PCR. MIP infants were not screened longitudinally, infants
had blood collected at birth and one other time point post partum, at either 1, 3, or 6
month of age. Ten MIP infants were randomly selected for immunophenotyping
studies.
In total, 18 HIV uninfected children were studied. MIP and CTL infants had different
study follow-up. Children from the CTL group (born to HIV-1 infected mothers)
were screened serially during the first year of life (birth, followed by 1, 3, 6, 9, 12
months) according to sample availability. CMV viral loads were performed on MIP
infants as described in Chapter 3. However, because of larger gaps in sampling it was
not possible to estimate the timing of CMV acquisition as precisely in the MIP infants
as it was in the HIVexp- infants.
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Specimen collection
Venous and cord blood was collected into EDTA tubes. Approximately 0.2 - 3 ml of
blood were collected from each infant. Two 7-ml tubes of cord blood were collected
immediately after delivery. Whole blood was centrifuged for 10minutes at 1500 rpm
to separate plasma, which was divided into aliquots and stored at -80°C. The
remaining blood was then diluted with equal volume of RPM! medium, separated by
density gradient centrifugation, and washed with RPM! cell media supplemented with
10% FCS (RIO). Cells not used in fresh immunological assays were cryopreserved in
FCS supplemented with 10% DMSO freezing media and stored in liquid nitrogen.
Between 2 and 10million PBMC were frozen in each vial.
Multicolour flow cytometry
Cryopreserved PBMC were thawed at 37 °C and placed into 5 ml of sterile filtered
FCS then washed twice with RPMI + IO%FCS (RIO) before staining. Staining with
Trypan blue indicated excellent viability (typically >90%) though in most vials less
than 100% of stored cells were recovered. Between 2-8 million cells were recovered
per vial, and these were divided equally between wells for staining.
The phenotype of T cells was determined by the expression of cellular antigens using
multicolour flow cytometry. Antibodies used in the study are shown in Table 4.1, and
the mixed panels used in each stain are shown in Table 4.2. The antibody titrations,
optimisations, and validation experiments involved in establishing the multicolour
flow assays are described in detail in Chapter 8. To minimise intra-patient variability
all cells from a single infant were stained in the same experiment. Cells were spun
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down and supernatant removed leaving a minimal volume (approximately 20 !AI)of
media. To minimise intra-assay variability antibody master-mixes were made in each
experiment and the aliquots were added to cells using a multi-channel pipette. Since
small cell numbers were expected from some of the cryopreserved specimens,
staining was performed in 96-well V-bottom tissue culture plates to maximise cell
adherence during washing steps. This method also reduced pipetting steps and the
volume of reagents used. Cells were incubated with antibody for 20 minutes in the
dark at room temperature, washed twice with PBE (PBS plus 0.5% BSA; 0.5 mM
EDTA) and resuspended in CellFix solution (BD Pharmingen, Oxford, UK). The
volume of CellFix diluent was determined by the approximate number of cells in each
tube, this was typically 170-200 !-ll.
For Panels B and D, the above protocol was followed for surface staining. Instead of
the final fixing step, cells were permeabilised by adding 300 ~l of CytoPermlCytoFix
permeabilisation solution (Pharmingen) and incubating for 20'minutes in the dark at 4
QC. Cells were washed twice with Perm buffer, which uses saponin to permabilise the
cells. Since saponin permeabilisation is reversible, the remaining wash and
incubation steps were done in the Perm buffer. Cells were stained with intracellular
antibodies in a volume of 100 !-llfor 30 minutes in the dark at 4°C, washed twice and
resuspended in 170-200 ul of buffer.
Excluded assays
Due to procedural errors, some infants had incomplete antibody panels: MIP-Bl-ll0
and MIP-Bl-122 do not have Bcl-2 or perforin staining (panels B&D). Upon
thawing, the majority of cells from MIP-Bl-173 and MIP-Bl-167 were dead; these
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assays are excluded from the analysis. The perforin-PE staining was not consistent in
staining patterns, and did not match previous reports, and is excluded from analysis
here.
Analysis and gating
Cells were acquired on a Cyan ADP or LX instrument using Summit software (Dako
Cytomation, Angel Drove, UK). As many cells as possible were acquired in each
tube. Cells were acquired at 1500 to 3000 events/second. This was achieved by
diluting the cells with PBS and adjusting the flow stream. Flow stream adjustments
were kept to the minimal level to prevent the frequency of "doublets" (E.g., more than
one cell) passing through the laser at once. FCS files were analysed with FlowJo
software (Treestar, Inc., Olten Switzerland). Data were re-compensated during
analysis using single stain controls and FlowJo's automated compensation platform.
Cells stained with isotype controls were used to establish cut-off channels for positive
and negative staining. A single donor's cryopreserved cells provided all
compensation and isotype controls for the experiments so antibody stability and
instrument variability could be monitored over time.
The major T cell subsets were defined as shown in Figure 4.1. First, granulated cells,
dead cells and debris were excluded by size and granularity. Gating of lymphocytes
was extended to high forward scatter to include larger, activated cells. Next, CD3
expression was used to exclude monocytes and NK cells. The expression of high
levels of CD4 or CD8 was used to distinguish the major T cell subsets. In neonates, a
large number of CD4+CD8+ T cells were observed. These cells are likely to be a mix
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Figure 4.1. Gating to elect CD4+ and CD8+ T cell subsets.
A) Exclu ion of debri , dead cells and granulated cells. B) Selection of T cells by CD3+
expression. ) election of pure single positive CD8bright and CD4+ cells.
of recent thymic emigrants, activated CD4 and CD8 cells. These cells were excluded
for the current analysis to maximize purity of CD4 and CD8 single-positive T cell
subsets. The phenotype of T cells was defined based on singular expression of a
particular cellular antigen, or a combination of antigens. A description of the cellular
antigens examined in the study is provided in Table 4.3.
Fluorochrome Antibody Clone Manufacturer
AC7 CD4 RPA-T4 BD Pharmingen
AC7 COl6 3G8 BD Pharmingen
APC CD95 DX2 BD Pharmingen
APC CD27 0323 eBioscience, San Diego, CA
FITC CD69 FN50 Dakocytomation
FITC CD71 Ber-T9 Dakocytomation
FITC CD28 C028.1 Dakocytomation
FITC BcI-2 124 Dakocytomation
FITC CD45RA OX-33 BD Pharmingen
PB CD3 UCHTI Dakocytomation
PCS COS6 N901 (NKH-l) Beckman Coulter, High Wycombe UK
PC7 C08 RPA-T8 BD Pharmingen
PE C038 AT13/5 Serotec, Oxford, UK
PE CD27 M-T27 I Oakocytomation
PE C02S ACT-l Oakocytomation
APC CD71 M-A7l2 BD Pharmingen
PCS CDlS2 BNI3 BD Pharmingen
PE CCR7 FAB197 R&D Systems, Minneapolis, MN
APC CD45RA HIlOO BD Pharmingen
APC HLA-OR TU36 BD Pharmingen
PE perforin 27-35 BD Pharmingen
FITC CD57 TBOl Serotec.Table 4.1. Antibodies used in IDImunophenotyping studies.
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C
A B 0 E F
ProlifnatioD
F1uorotbromt Co-stimulatioD Apoptosis Cytotoxicity ActivatioD Treg
HomiDg& StDeSttDct
FITC CD2S BcI-2 CDS7 CD28 CD69 CD7l
PE CD27 CD38 CCR7 Perf orin CD38 CD2S
PE-Cy5 CD56 CD56 CD56 CD56 CD56 CDl52
PE-Cy7 CDS CDS CDS CDS CDS CDS
Pacific Blat CD3 CD3 CD3 COl CDl CDl
APe CD45RA COOS CD7l CD27 HLA-DR CD4SRA
APC-Cy7 CIM Co.. CD4 CD4 CD4 CD4
Table 4.2. Antibody panels used to describe cell phenotype.
Fluorochromes are shown in the left most column. Labels at the top of each column
describe the main phenotype described by each mixture of antibodies. Primary subset
markers are shown in bold.
Data management
Flow cytometry data was exported from FlowJo as text files, modified with a program
and uploaded into a customised database. Queries were used to extract flow
cytometry data, viral loads, and infant mortality data. Though several hundreds of
different analysis possibilities (cell phenotypes) were imported into the database, only
a small fraction of these were extracted for analysis here.
Statistical methods
Clinical and laboratory data were collected and stored in a Microsoft Access Database
(Microsoft Inc., Redmond, Washington, USA) and analysed using Stata SE v.9 (Stata
Corp. College Station, Texas, USA). Cell frequencies and viral loads were loglO-
tranfonned before comparisons. Mann-Whitney rank-sum tests were used to compare
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median celJ frequencies between MIP and HIVexp- groups of infants. Comparisons
of frequencies between visits were pair-wise with matched values for each infant.
Correlations were tested using Spearman's rank test. Models of cell frequencies and
viral load over time were generated using cubic smoothing splines of time-point
medians.
Antigen
CD3+
CD4+
CDSbrighl
CD25+
CD27/CD28
CD45RA+/-
CD152+
CD57+
CCR7+
CD71+
CD38bright
CD69+
HLA-DR+
CD95+
Bcl_2bright
Perforin
Phenotype defined
Tcell
CD4 subset
CD8 subset
/L-2R: utilisation ofIL-2, activation, Treg (high on CD4+)
Early (CD27+CD28+) and late (C27-CD28-) effector phenotype of
CD4 or CD8. Intermediate CD4 (CD27-CD28+), intermediate CD8
(CD27+CD28-)
Memory phenotype, transient expressionfrom CD45RA+ 7 CD45RA-
7CD45RA+
CTLA-4: negative regulatory signalling
Senescence
Homing to lymphatics, antigenic naivety
Transferrin receptor: iron utilization, proliferation
Constitutive expression on neonatal T cel/s, activation with co-
expression of HLA-DR
Early lymphocyte activation
Class II MHC: activated T cells
FasR: vulnerability to apoptosis via Fas pathway, on Bc/_2"im cells
highly vulnerable to apoptosis
Protection from apoptosis
Component of granule-mediated cytotoxicity
Table 4.3. Lympboeyte subsets examined in the study.
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Infant MonthCMV Follow-up
detected
"IV -unexposed
MIP-BI-I04 aviraemic M6
MIP-BI-110 birth CBMC&M6
MIP-BI-lll 6 CBMC&M6
MIP-BI-119 aviraermc CBMC&M6
MIP-BI-122 aviraemic CBMC&M6
MIP-Bl-134 aviraemic CBMC&Ml
MIP-BI-137 aviraemic CBMC&MI
MIP-BI-146 aviraemic CBMC&Ml
MIP-BI-167 3 CBMC&M3
MIP-BI-173 aviraemic M3
"IV -1 exposed uninfected
CTL-BI-059 3 Ml-12
CTL- BI-081 3 CBMC-MI2
CTL- BI-087 NT M6
CTL- BI-I03 aviraermc CBMC&Ml
CTL- BI-122 3 CBMC-M12
CTL- BI-180 3 MI-12
CTL- BI-272 3 CBMC-M15
CTL- BI-461 3 CBMC-M15
Table 4.4. Summary or foUow-up and CMV detection in HIV-uninfected
children.
MIP children were born to HIY -1 negative mothers. CTL children were born to HIV-
I positive mothers, but remained HIY-l negative by DNA and RNA assays for the
duration for study follow up. NT = not tested. CBMC = cord blood mononuclear
cells, M=month of study follow-up.
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Results
Lymphocyte distribution in healthy Kenyan infants from the MIP cohort
Table 4 summarises the follow-up and CMV testing in the children. Frequencies of
cells with selected phenotypes are shown for HIV-I uninfected MIP infants in Table 5
(CD4+) and Table 6 (CD8+). Though there were specimens examined at 1 and 3
months, this was a very small number of infants (4 children) so only data from birth
and 6 months are shown. At birth, both CD4 and CD8 subsets consisted of primarily
resting, non-activated, naive cells. In cord blood, the majority of CD4 and CD8 T
cells were CD27+CD28+, CD45RA+, CCR7+, indicating a naive phenotype. The
frequency of cells expressing CD152 (CTLA-4) was also low in both CD4 and CD8
subsets. Overall, frequencies of activated cells were low, as measured by the
expression of CD69+, HLA-DR+, or CD38brightHLA-DR+ in both the CD4 and CD8
subsets. The majority of cells expressed CD38 at high levels, consistent with other
reports in newborns. In the cord blood low frequencies of cells expressed markers
indicating vulnerability to apoptosis, CD95+ frequencies were low and >99% of cells
expressed high levels of Bcl-Z. CD71 expression was used to estimate the frequency
of proliferating cells. It was expressed on approximately 1% of cord blood CD4 and
CD8. Very low frequencies of senescent (CD57+) cells were observed in the cord
blood, <2% in both CD4 and CD8 subsets. Approximately 4% of CD4 T cells
expressed high levels of CD25+ consistent with a regulatory T cell phenotype.
Only 3 infants provided matched data at birth and 6 months, so pair-wise comparisons
were underpowered and could be misleading. It is not possible here to measure with
precision differences between the 6 month and cord blood frequencies, but the data is
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presented here for reference, and for later (non pair-wise) comparison with HIVexp-
infants. Though a small number of infants were examined at 6 months of age, there
was evidence of antigenic stimulation in CD4 and CD8 T cells, particularly in the
CD8 subset. At 6 months, approximately 40% of CD4 and 50% of CD8 had lost
expression of CCR7. Evidence of antigenic stimulation was also detected by
diversification of CD27CD28 subsets from CD27+CD28+ into double single, and
double negative populations in the CD4 and CDS. CD45RA + and CD45RO-
subpopulations were diverse in CD27CD2S expression, indicating the outgrowth of
effector cells. CD71 +, CD152+ and Treg frequencies remained low at 6 months.
Overall, frequencies of activated T cells were low at 6 months in both CD4 and CD8
subsets «10% were CD69+, HLA-DR+, or CD3SbrightHLA-DR+), though the range
of expression in these markers was wide; some infants had high frequencies of
activated cells (up to 13% CD4+CD3SbrightHLA-DR+, and 26% CDS+CD38brightHLA_
DR+). At 6 months cells highly vulnerable to apoptosis (Bcl-2dimCD95+) had
appeared (median 4% of CD4, 10% of CD8), though the majority of cells continued
,
to express the highly protected (Bcl_2brightCD95_)phenotype (median 62% of CD4,
63% of CDS). CD57+ cells began to appear at high frequencies in the CDS subset
(median 20% in CDS) but remained a very small population in the CD4 subset
(median 1.3%). Overall, the phenotype of cells at 6 months is representative of a
diversifying population of T cells, though it is not possible to know from the current
data if this is due to age, infection, vaccination, or some other unmeasured
environmental influence.
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cord blood 6 months
(n=8) (n=4)
Co-stimulation
Early (CD27+CD28+) 89.9 (64.1-94.3) 71.4 (28.5-93.5)
Intermediate (CD27-CD28+) 3.81 (0.62-28.3) 18.2 (l.92-30)
Late (CD27-CD28-) 1.96 (1.13-9.19) 5.11 (0.74-49.4)
CD45RA+ 72.7 (25.7-81.9) 50.8 (31.4-69.7)
·CD45RA+/Early 92.5 (77.0-94.4) 81.4 (38.4-94.6)
CD45 RA+Ilntermediate 2.41 (0.58-17.9) 13.3 (1.04-19.9)
CD45RA+/Late 1.91 (0.83-7.1) 4.34 (0.61-39.6)
·CD45RA-lEarly 84.3 (60.2-94) 63.6 (24.2-92.5)
CD45RA-llntermediate 7.00 (0.79-33.5) 21.7 (3.24-39.4)
CD45RA-lLate 2.24 (0.68-17.4) 5.98 (0.92-52.8)
C0152+ 1.76 (0.68-3.72) 1.19 (0.82-8.1)
Vulnerability to apoptosis
Bcl-2OO'-
C095+
Bcl-2OOPCD95-
Bcl_2diJIICD95+
99.2 (93.9-99.7)
14.2 (2.24-35.4)
77.0 (64.2-93.9)
0.72 (0.13-3.11)
Homing & proliferation
CCR7+
C057+
C071+
84. t (80.2-89)
1.21 (0.79-1.26)
0.965 (0.7-1.29)
87.2 (79.7-94.7)
30.0 (15.2-44.7)
62.0 (53.5-70.4)
3.73 (2.81-4.65)
6 t.2 (41.5-80.8)
1.26 (1.23-1.29)
0.89 (0.86-0.92)
,---------------------------------------------------------------Activation
CD69+
HLA-DR+
bCD38brip•
CD3Sbri'-HLA-OR+
1.51 (0.3-29.5) 0.995 (0.36-3.37)
2.94 (1.84-11.3) 5.66 (2.31-17.4)
94.6 (84.8-98.8) 85.8 (79-96.1)
3.065 (1.75-10.8) 5.28 (2.22-13.2)
-i~;"----- ----- ---------------------.i.ii (i.49-8~35-)- - - - 2.90 -(O~57:j.4i)-
Table 4.5. CD4 Iympboqte distribution in healthy children born to HIV-
negative women.
Median cell frequencies (min-max) are shown as percent of CD4 cells, except
8percent of CD45RA+ or RA- cells. bCD38bright cells are not all activated, CD38 is
constitutively expressed on neonatal cells.
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Cord blood 6 months
(0=8) (0=4)
Co-stimulation
Early (CD27+CD28+) 63.8 (35.2-75) 31.4 (9.13-65.3)
Intermediate (CD27+CD28-) 29.4 (23.2-54.8) 36.2 (30.5-48.7)
Late (C027-C028-) 1.14 (0.1-19.6) 28.5 (0.36-52.6)
CD45RA+ 85.5 (46.6-92.2) 61.4 (42.3-79.4)
·CD45RA +/Early 68 (32.6-76.8) 42.5 (9.39-69.8)
CD45RA +lIntermediate 28.5 (2 I .3-50) 32.9 (24.6-47.2)
CD45RA +lLate 1.06 (0.032-37.3) 21.2 (0.11-54.8)
·CD45RA-lEarly 49.4 (21.7-78.6) 21.0 (8.18-44.3)
CD45RA-lIntennediate 49.65 (19.1-78.3) 49.2 (37.5-54.4)
CD45RA-lLate 0.44 (0-3.73) 34.1 (1.3-44.6)
CD152+ 2.05 (0.95-7.26) 2.03 (1.01-6.72)
Vulnerability to apoptosis
Bcl-2brighl
CD95+
Bcl-2brighlC095-
BcI-2dimCD95+
99.3 (97.9-100)
5.98 (0.88-12.7)
89.7 (72.6-98.3)
0.179 (0-0.72)
Homing" proliferation
CCR7+
COS7+
CD7I+
80.5 (75.5-87.2)
1.17 (1.07-1.88)
1.085 (0.88-2.07)
Activation
CD69+
HLA-DR+
bCD38bript
CD38brilhlHLA-DR+
2.09 (0.43-19.6)
3.32 (1.23-18.2)
90.5 (65.1-94.6)
2.15 (1.18-18.7)
77.0 (59.5-94.4)
25.4 (20.2-30.6)
63.3 (49.1-77.4)
10.1 (1.48-18.8)
50.75 (32.4-69.1)
19.8 (4.4-35.2)
0.665 (0.42-0.91)
2.07 (0.53-4.27)
7.26 (5.1-20.2)
78.7 (52.4-92.9)
6.48 (4.82-25.8)
Table 4.6. CD8 lymphocyte distribution in healthy children born to HIV-
negativewomen.
Median cell frequencies (min-max) are shown as percent of CD8 cells, except
'percent of CD45RA+ or RA- cells. bCD38bright cells are not all activated, CD38 is
constitutively expressed on neonatal cells.
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Lymphocyte distribution in HIV-l negative children born to HIV-l infected women
Phenotype and CMV viral load data were available for 8 HIV-1 exposed uninfected
(HIVexp-) children. Lymphocyte distributions for selected cellular antigens are
shown in Tables 4.7 and 4.8. Comparisons were made between MIP and HIVexp-
phenotype distributions in cord blood and at 6 months. In cord blood, the HIVexp-
infants were less diverse in CD4+ C027C028 subpopulations than the unexposed
(MIP) infants. In cord blood, the unexposed MIP infants had higher frequencies of
CD4+CD27-CD28- compared to the HIVexp- group (2% vs 0.5%, p=0.03). The
HIVexp- infants had lower frequencies of Bcl_2brightcells (median 83% vs 99010, p =
0.03) than the unexposed infants. Frequencies of regulatory T cells were higher
among the HIVexp- group than the unexposed MIP cord blood (9.6% vs 4.2%, p =
0.02).
In the C08 subset, the unexposed MIP infants were also more diverse in CD27CD28
expression at baseline, with lower cord blood frequencies of CD27+CD28+ than the
HIVexp- infants (64% vs 84%, p = 0.007) cells. Higher frequencies of CD8+Bcl-
2brightcells were present in the cord blood of unexposed infants compared to HIVexp-
infants (99% vs 86%, p = 0.01). In the CD45RA+ subpopulation of CD8+, MIP
children had more cells in the intermediate and late phenotypes compared to HIVexp-
infants (intermediate 28.5% vs 13.7, p = 0.007, late 1.06% vs 0.061%, p = 0.05). In
the CD45RA- subset, MIP children had lower frequencies of early cells compared to
HlVexp- (49.4% vs 76.2%, = 0.05).
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At 6 months, no differences in CD4 subpopulations were detected between the MIP
and HIVexp- children. Higher frequencies of apoptotic-vulnerable CD8 cells were
detected in the HIVexp- infants. CD8+CD95+ (37% vs 25%, p = 0.05) and
CD8+Bcl-2dimCD9S+ (29% vs 10%, P = 0.05) cell frequencies were higher in the
HIVexp- group.
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CMV initiates changes in lymphocyte distributions from HIVexp- children
In the present cohort, CMV was highly prevalent among the HIV -1 uninfected
children, 95% were viraemic by 12 months. To clearly delineate CMV- induced
effects from age- induced effects on the immune system, a subgroup of 6 HIVexp-
children were studied who had first become detectably CMV viraemic at 3 months of
age. Pair-wise comparisons were made between frequencies at 1 month (pre-CMV)
and 3 months (acute infection) and between 1 month and 12 months (chronic
infection) for selected phenotypic markers.
Costimulator:y phenotype
The expansion of late CD27-CD28- CD8 T cells has been described in healthy adults
and children with CMV. Figure 4.2 shows an example of lymphocyte distributions
during acute CMV infection in an HIVexp- infant. CTL-BI-081 became CMV
viraemic at 3 months, with a baseline plasma viral load of 5021 CMV copies/ml. The
first detection of CMV coincided with an increase in intermediate (CD27+CD28-)
and late (CD27-CD28-) CD8 T cells, which by 12 months had become the
predominant phenotype (62% ofCD8). This pattern was observed in all of the infants
with CMV viraemia (Figure 4.2 C&D). In the CD4 subset the increase in late
phenotype cells was smaller in magnitude, but also significant (p = 0.05) during acute
CMV. Late phenotype cells persisted during the period of study follow-up, with
increased frequencies of late CD4 and CD8 at 12 months compared to pre-CMV
levels at 1 month (p = 0.04 for CD4 subset, p = 0.04 for CD8 subset).
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Figure 4.2. CMV infection initiate change in co-stimulatory phenotype.
Dot plots how c J I from HI exp- infant CTL- B 1-081 during the first year of life. Cells
were stained with antib d pan I . 5000 e ents are shown for A) CD4+ and B) CD8 T
cell subsets. The pati nt b arne viraemic for CMV at 3 months of age with a viral load
of 5021 copie rnl. D) hov change in late phenotype cell frequencies during the
first year of life D r all HI exp- children with first CMV detection at 3 months. Coloured
lines show data for indi idual patient, black dashed line is a median spline curve
summarising all fII exp- infant with first CMV at 3 months. P values indicate
compari ons of month I \ , and m nth 1 vs 12.
Homing and senescence
CCR7 and CD57 were used to identify lymphoid homing and senescent T cells.
Figure 4.3 shows changes in CCR7 and CD57 frequencies during CMV infection in
CTL-BI-081. CCR7+ cell frequencies declined rapidly in both CD4 and CD8 subsets
concurrent to the detection of CMV viraemia, with the exception of one infant who
maintained high frequencies of CCR7+ cells in both subsets. Large populations of
CD57+ cells appeared in the CD8 subset at 3 months (p = 0.002) and persisted to at
least 12 months of age (p = 0.0003). In the CD4 subset CD57+ cells also appeared,
with elevated frequencies at 12 months compared to pre-CMV levels (p = 0.05).
CD71 was used to measure proliferating cells. CD71+ cells remained low throughout
the study period and did not change significantly with time or in response to CMV
detection (data not shown).
Cellular activation
Activated T cells were studied by their expression of CD38, CD69, and HLA-DR
CD69 was expressed at low levels on CD4 and CD8 T cells and was not detectably
altered by CMV infection (data not shown). Though low levels of activated cells
were detected in the cord blood of many infants, CD38 and HLA-DR expression
changed dramatically following CMV detection. Figure 4.4 shows CD38 and HLA-
DR staining in HEPS infant CTL-BI-081. A dramatic increase in CD38brightHLA_
DR+ cells is observed in the CD8+ subset at 3 months. Changes were more subtle in
the CD4 subset, the frequency of activated CD4 T cells slowly increased in this child.
Overall, activation peaked at 3 months then declined in the CD8 subset. At 12
months, frequencies of CD38brightHLA-DR+cells remained elevated compared to
baseline levels in the CD8 subset (p = 0.04). In the C04 subset, no significant
133
A) CD4
13)CD8
1 month
022 Oll
,er'
>0'
'0'
,,,.
III
".
'0'
~~
~lo"
8
'0'
10' 103
<FL2> CCR7 PE
,0' ,<>,
<Fl_2)o CCR7 PE
,0' ,<>,
<H2> CCR7 PE
C) CD4+ R7+
8 ..
~
iil
+0,,"
!'lo
';!'"
'S~~80-~
0
#~
0
N
~
0
0
• •
•
p - 0.3
10 1 12
E) CD4+ CD57+
8
~
s P = 0.07
:;z
s
~
~
~
:;;
~
0
0
p 00
015
07>
3 months 12 m
09'55
10'
102 103
<FL2> CCR7 PE
102 103
<FL2> CCR7 PE
D) CD8+ CCR7+
----------=-~~--==~~~~-.-.- p = 0.07
o
T ~
5 6 7
Age 111 months
T • -,.
9 10 11 12o
F) CD8+ CD57+
8
g
s
,0
""8f6
~~.,
S~
'0#:;:
:;;
;>
0 f
0
p = 0.0003
5 6 7
Age In months
10 11 12
Figure 4.3. CMV infection results in decreased CCR7+ and increased CD57+ frequencies.
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and median pline (da h d black line). P value indicate comparisons of month 1 vs 3, and
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Figure 4.4. CMV infection re ults in cellular activation of CD4 and CD8 T cells.
Dot plots show CTL-B 1-081 cell, stained with panel E antibodies and analysed as described. A)
C04+ and B) D8 Tell ubset. &D) show C038bnghtHLA-OR+ cell frequencies during the
first year of life for indi idual children. Coloured lines show individual children. Dashed black
line is a median pline. P alue indicate comparisons of month 1 vs 3, and month I vs 12.
changes in CD38brightHLA_DR+were detected from pre-CMV and acute (p = 0.1) or
chronic infection (p = 0.3).
Spearman correlation was used to examine the relationship between cellular
activation and CMV viral load during acute (3 months) and chronic (12 months)
infection. CD38brightHLA_DR+was used to describe activated cells. At 3 months,
there was a positive correlation between activated CD8+ T cells and CMV viral load
Figure 4.5 (p = 0.88, p = 0.02). No correlation was detected between activated CD8
and viral load at 12months (p = 0.2), or between CD4 and viral load at 3 (p = 0.6) or
12 (p = 0.3) months.
Vulnerability to aPQptosis
Bcl-2 and CD95 expression were used to characterise vulnerability of T cells to
apoptosis. Cell subsets were identified based on the expression of these two markers;
highly protected cells were defined by Bc1_2brightCD95_,and highly vulnerable cells
Bcl-2dimCD95+. Staining for these markers is shown for CTL-BI-081 in Figure 4.6.
Prior to infection, frequencies of vulnerable cells were low. The detection of CMV
infection results in the redistribution of cells from protected to vulnerable phenotype.
The accumulation of Bcl_2brightCD95+cells was observed primarily in the CD8
subset. In the CD4 subset, many cells expressed CD95, but Bc1-2was retained during
acute CMV infection in the majority of cells. Longitudinal assessment of all the
infants showed an increase in vulnerable CD8+ cells during acute infection (p = 0.002
for 1 vs 3 months) that persisted for at least 9 months post infection (p = 0.001 for
comparisons at 1 vs 12 months). In the CD4 subset, changes from pre-CMV
frequencies were not significant at 3 (p = 0.4) or 12months (p = 0.06).
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Discussion
Large volumes of data have been generated describing phenotypic changes to
lymphocyte populations in HIV-1 infection. The expression of several cell surface
molecules are modified with HIV-1 infection, and have been associated with the risk
of HIV-I disease progression (68, 121, 241, 327, 358, 429, 430). However, little is
known about the baseline lymphocyte populations in healthy infants and uninfected
infants with HIV-I exposure. In addition to age-related effects(l30, 381), differences
in exposure to environmental pathogens may translate to different underlying
lymphocyte distributions in healthy individuals (156, 369, 432, 587). The study of
healthy subjects is necessary to discriminate virus-induced effects on the immune
system from growth, exposure to other pathogens, and childhood vaccination. In the
present cohort, at least 30% of children born to HIV-negative women, and 95% of
children born to HIV-1 infected women were infected with CMV at 1year. Studies in
healthy Gambian children have shown CMV to initiate rapid and widespread changes
in the whole CD8 T cell subset(372). It is not yet known if these changes have an
adverse effect on child health, or the ability to mount an immune response against
other pathogens. Additionally, the study of HIV-I infected children in this cohort
must also take into account the background CMV prevalence and CMV-associated
changes as a likely confounder to interpretation of the HIV-I data. This chapter
documents changes in lymphocyte distributions during the first year of life in healthy
and mv-1 exposed uninfected infants, and describes the effect of CMV on T cell
subsets.
In the MIP children with no HIV-1 exposure, cord blood cells were primarily naive,
early maturation, apoptosis-protected phenotype. Cellular activation was observed at
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low levels, and low frequencies of proliferating cells were detected. At 6 months,
both CD4 and CD8 subsets became more heterogeneous, with evidence of increasing
antigen experience, increased populations of apoptotic-vulnerable cells, and increased
cellular activation. The appearance of phenotypically differentiating CD8 cells in the
MIP infants may be attributable to age, vaccination, or infection. Though at least 3 of
these children were infected by CMV 6 months of age it is not possible to say these
changes occurred in response to CMV.
A study in the US measured lymphocyte frequencies in a large cohort of infants and
adolescents, their markers included CD28, CD45RA, CD38, HLA-DR and
CD95( 497). The two studies were quite different in their follow-up, the current study
was longitudinal and the US study was cross-sectional and grouped infants into
intervals of 3 months; so the two studies must be compared with some caution.
American and Kenyan children were similarly antigen naive at birth. However, by 6
months changes in CD4+CD45RA+, CD8+CD45RA+, CD8+CD38+, and
CD8+CD95+ cells were observed in the MIP children whilst little difference was seen
between the 0-3 and 3-6 month groups in the US study. A longitudinal study by De
Vries (123) in the Netherlands also demonstrated similarly naive cells in cord blood
with gradual diversification with age. Studies in Ethiopian children have shown
similar phenotypic distributions of memory and activation phenotypes at birth but the
development of higher frequencies of activated and memory cells with age (544). In
Ethiopia this may be related to persistent helminth infections which activate T cells
(269, 273, 274). These studies suggest that environmental factors may have a great
impact on lymphocyte subsets during the first few months of life.
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There were notable differences between the HIVexp- and unexposed infants,
including higher baseline frequencies of Treg (CD4+CD25bright)and apoptotic-
vulnerable cells in the HIVexp-. The unexposed infants also had more diverse
CD27CD28 subsets at baseline. From this small study it cannot be determined
whether these differences are a result of mv -1 exposure. Though the demographics
of the MIP and CTL cohorts are similar, HIV-1 infection in the CTL cohort is likely
to mean higher rates of maternal infections from other environmental pathogens
(including CMV reactivation, rotavirus, heminths, and tuberculosis), and subsequent
infant exposures. It is also not possible to ascertain from this study whether these
differences are immunologically significant to the infants, or if there are long-term
effects of HIV-1 exposure on cellular immunity. Others have reported differences in
CD4 phenotype and function of HIV-I exposed uninfected children(103), with
exposed children having lower naive cell frequencies and higher frequencies of
activated and memory cells. An alternative hypothesis is that exposure to HIV-I from
the mother results in the generation of an adaptive immune response. This is
somewhat supported by evidence of HIV-1 specific T cell responses in HIV-l
exposed uninfected infants (299, 300, 316, 506).
Serial measurements of CMV viral load and phenotype in the HfVexp- group enabled
the construction of a model of CMV infection involving both the virus and changes in
lymphocyte populations. Unfortunately CMV is so prevalent during infancy in Kenya
that it was not possible to study CMV-uninfected infants as a control group, and
comparisons can only be made with data from other studies. Since the majority of
infants became CMV viraemic at 3 months of age, it was possible to standardise the
stage of CMV infection relative to the age of the children. Figure 4.7 depicts a
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Figure 4.7. Lymphocyte redi tributions during CMV infection.
Cubic median splines summarise data for HIVexp- infants to 12 months. All infants
became CMV viremic at 3 months. A) CD4 B) CDS. Dashed black = log10 CMV
viral load, yellow = CD38bnghl,gray = CD45RA+, brown = naive (CCR7+), blue =
apoptotic vulnerable (Bcl-2dllnCD95+), orange = senescent (CD57+), green = late
(CD27-CD28-), red = acti ated (CD3SbnghIHLA-DR+), pink = proliferating (CD71+)
summary of viraemia and lymphocyte changes during primary CMV infection in
HIVexp- children. During acute CMV infection, CCR7+ cells declined from baseline
values in both CD4 and CD8 subsets, indicating encounter with antigen and loss of
homing to lymphoid tissues. Populations of late (CD27-CD28-) (26) phenotype and
senescent CD57+ (39, 161) CD8 T cells increased as is consistent with other reports
from CMV cohorts. Large increases were observed in activated and apoptosis-
vulnerable CD8 T cells concurrent with CMV infection. These cells subsequently
plataued or declined over time. There was a positive correlation between
CD8+CD38brightHLA-DR+ cells and CMV viral load during acute infection at 3
months, but not at 12 months. No correlation between activation and viral load was
observed in the CD4 subset. A steady age-related decrease in CD38+ cells was also
observed in both CD4 and CD8 subsets.
Overall, changes in the CD4 subset were of a much smaller magnitude than those
observed in the CD8. The current study is underpowered to draw conclusions about
the effect of CMV in this subset, and a large study would be able to examine more
subtle effects in the majority of markers. However, changes in co-stimulatory
molecules (CD27/CD28) and CD57 persisted for at least 9 months post infection,
suggesting CMV did induce changes in the CD4 subset. Very low levels of activation
were detected in the CD4, and only small populations of apoptosis-vulnerable cells
were observed. The smaller scale of CD4 changes may suggest tighter homeostatic
control over activation in this subset. CD4 responses in neonates may be biased
toward development of Th2 phenotype(434, 564) and the presence of very high
levels of activated cells, especially Th2 cells, could result in levels inflammation
dangerous to the host.
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Many changes were observed concurrent to the appearance of CMV viraemia in the
infants. Though this evidence suggests the changes observed may be CMV-induced,
it is not possible to determine from this study what proportion of these changes occur
in CMV -specific T cells. The recent paper by Miles and colleagues (372) have
demonstrated that changes in the whole CD8 subset largely mirrored what was
happening in the CMV -specific CD8 population. A recent study using overlapping
peptides to study CD4 and CD8 responses to the entire CMV genome found that
CMV -specific cells comprised a very large proportion of memory CD4 and CD8 cells
in latently infected (seropositive) people, a median of 9.1% of CD4 and 10.2% of
CD8 (526). The size of virus-specific cells during primary infection is likely to be
even higher(8I, 302, 346, 372, 583). However some of the changes observed here
may also be attributed to coincidental infection with other pathogens, for example,
Epstein-Barr virus, rotavirus, and helminths are common infections in Kenyan infants.
Summary
Dramatic changes were observed during the first months of life in infants undergoing
acute infection with CMV. At birth, CD4 and CD8 T cell subsets were shown to be
primarily naive and to contain low frequencies of activated cells. During acute CMV
infection, rapid changes were observed in the CD8 subset that suggested
diversification in response to antigenic stimulation, including the appearance of cells
with late, activated, apoptotic-vulnerable, and senescent phenotypes. Frequencies of
activated CD8 T cells correlated with CMV viral load during acute infection.
Changes in the CD4 subset were subtle relative to the CD8 compartment. At 9
months post CMV infection, frequencies of CD4+CD27-CD28-, CD4+CD57+,
139
CD8+CD27-CD28-, CD8+CD57+, CD8+CD38brightHLA-DR+, and CD8+Bcl-
2dirnCD95+ cells remained elevated compared to pre-CMV levels.
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CHAPTER5
Lymphocyte redistributions during HIV -1 infection
in Kenyan infants
Introduction
Chapter 4 described widespread changes in the distribution of T cell phenotypes in
HIV-l exposed uninfected infants (HIVexp-) during infection with CMV. Many of
these same phenotypes are also altered during HIV-1 infection. These include
markers of activation (CD38. HLA-DR, CD69, CD95), co-stimulation (CD27 and
CD28), proliferation (Ki67. CD71). senescence (CD57), lymphoid homing (CCR7
and CD62L), memory (CD45RA and CD45RO), and apoptosis (Bcl-2 and CD95).
Several of these markers have been correlated with increased HIV-1 viral load and
disease progression, and it is now widely accepted that persistent immune activation
plays an important role in HIV-I pathogenesis (54, 219, 422).
The study of subjects undergoing acute HIV-I infection offers insight into the
immune-pathogenesis of infant HIV-I infection. The current chapter describes
changes in lymphocyte phenotype during acute and post-acute HIV-I infection in
infants from the CTL cohort undergoing co-infection with CMV.
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Materials and methods
Subjects and sampling
A subset of HIV-I infected (HIV+) children were selected from the CTL cohort based
on survival through 3 months of age and specimen availability. Children were chosen
if they were HIV-I RNA or DNA positive by 1 month of age, survived 3 months of
follow-up, and had cryopreserved PBMC available for experiments. The HfVexp-
children described in Chapter 4 serve as a comparison group of CMV-infected infants
for this chapter.
Diagnostic and Virologic assays
mv -1 diagnosis and viral loads were performed as described in Chapter 2. CMV
diagnostics were performed on all infants as described in Chapter 3.
Flow cytometry methods and excluded assays
Cryopreserved PBMC were thawed and stained with antibody panels A-F, and
analysis and gating were performed as described in Chapter 4. Due to procedural
errors, some infants had incomplete antibody panels: CTL-BI-103 does not have
intracellular staining (panels B&D). Upon thawing, the majority of cells from CTL-
B1-411 were dead. PBMC from subject CTL-B1-116 were dead at month 9 and
PBMC from CTL-B1-161were dead at month 3 and are excluded from analysis.
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Statistical methods
Clinical and laboratory data were collected and stored in a Microsoft Access Database
(Microsoft Inc., Redmond, Washington, USA) and analysed using Stata SE v.9 (Stata
Corp. College Station, Texas, USA). Cell frequencies and viral loads were 10glO-
tranfonned before comparisons. Mann-Whitney rank-sum tests were used to compare
median cell frequencies between HIV + and HIVexp- groups of infants. Correlations
were tested using Spearman's rank test. Models of cell frequencies and viral load
over time were generated using cubic smoothing splines of time-point medians.
Results
HIV-J infected children in the study
A summary of follow-up, CD4, viral load, and CMV diagnostic data from the HIV-I
infected (HIV+) children is provided in Table 5.1. As observed in the greater cohort,
HIV-I viral loads were very high and most infants (15/19) were immunosuppressed
with CD4%s < 25%. There were 11 deaths among the 19 children (58%) during the
two-year observation period, the majority of these were attributed to pneumonia and
diarrhoeal illnesses. Two infants were septic at the time of death, one infant had
meningitis, and one had tuberculosis.
Phenotype frequencies in HIV-l infected children
Tables 5.2 and 5.3 show frequencies of selected T cell phenotypes for all HIV+
infants at each study time-point. As observed in the HIVexp- and MlP children, both
CD4 and CD8 cells were primarily naive, protected from apoptosis and resting. Great
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changes, marked by increased antigen experience and heterogeneity were observed
during the following 24 months in the HIV+ children. These figures are presented for
comparison with previous studies measuring lymphocyte subpopulations in paediatric
HIV-1 infection. However, by examining all the children together as a group, one
cannot know if these effects are induced by HIV-lor CMV infection.
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HIV-J induced changes in lymphocyte distributions of infants co-infected with CMV
Longitudinal comparisons were made between HIVexp- and HIV + groups during the
first year of life. CMV infection was detected in 17 of the 18 (94%) HIV -1 infected
children with phenotype data. In order to control for timing of CMV infection,
comparisons are only made between children with first CMV detection at 3 months of
age (8 HIV+ and 6 HIVexp- children). The HIV+ children were analysed as a group
because all had HIV -1 infection by 1 month of age. Differences between groups in
cord blood and 1 month of age can thus be attributed to HIV -1. The effects of acute
CMV infection at 3 months of age were evident in both the CMV+HIVexp- and the
co-infected children, and additional changes were observed in the HIV + group. In
general, HIV -1 co-infection resulted in changes remarkably similar to those elicited
by CMV, but the magnitude and duration of the lymphocyte redistributions were
enhanced by HIV -1.
Co-stimulatory molecules
Changes in CD27 and CD28 expression were observed during acute HIV -1 and CMV
infection. Figure 5.1 shows data from several infants with or without HIV-l or CMV
infection. Little change was observed in the CD4 subset in response to either CMV or
HIV-l infection (Figures 5.IA-E). However, both CMV (Figure S.lG & H) and HIV-
1 (Figure 5.1J) infection were accompanied by the redistribution of CD8 T cells from
early into more differentiated subpopulations. The infant co-infected at birth had very
high frequencies of cells in both the intermediate and late CD8 subpopulations in cord
blood (Figure 5.11).
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Patient CTL-BI-IS9 (Figures S.IE and J), who was first HIV-I RNA positive at
month I and first CMV positive at month 20 is used in the following sections as an
example of changes induced by HIV -I. Because HIV -1 and CMV infection were
separated by 9 months, this infant's data are especially valuable for visualising the
independent effects of the virus on cellular phenotype. Though HIV -1 infection was
first detected at I month, intermediate CD8 cells were not observed until 3 months,
and little change was seen in the intermediate CD4 subset. Though intermediate CD8
T cells increased, only a small percentage of late CD27-CD28- cells were observed
until after the arrival of CMV at 20 months. In the CD4 subset, most cells continued
to maintain an early phenotype, but small populations of intermediate and late cells
were also observed.
To identify HIV-l induced effects on the cohort lymphocyte frequencies were
compared in HIV+ and HIVexp- children. To control for timing of CMV infection
and duration of follow-up, comparisons were restricted to children with first CMV
detection at 3 months (8 HIV+ and 6 HIVexp- children). Comparisons were made
between HIV+ and HIVexp- cell frequencies up to 12 months of age. Figure S.2
shows summary data for CD27/CD28 subset distributions. In cord blood, early,
intermediate and late phenotype cells were similar in frequency between HIVexp- and
HIV+ infants (p>O.OS for both CD4 and CD8). At 1 month, the median frequency of
early phenotype CD4 cells was higher in the HIV+ group (p = 0.05). With the
incidence of CMV infection at 3 months, early phenotype cells declined rapidly in the
CD8 subset but were maintained in the CD4 cells for both HIV + and HIVexp- infants.
Increases in late phenotype cells were observed in both the CD4 and the CD8 subsets
but changes were more dramatic in the CD8. The HIV+ infants had lower
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Figure 5.2. Early, intermediate and late phenotype frequencies for HIVexp-CMV+
and HIV+CMV+ infant.
Box plots show Irequ ncie of A) earl , B) intermediate and C) late phenotype cells for
CD4 (left column) and D8 (right column) T cells. Red = HIV+ infants, blue = HlVexp-
infants. Data h wn i r tricted to children with CMV by 3 months of age. Box plot
shows median line, upp r and lower box hinges stretch to zs", and 75th percentiles,
whiskers show upper and lower adjacent alues, outliers shown as closed circles.
frequencies of early CD8 cells at 6 months (p = 0.05) and higher frequencies of late
CD4 cells at 9 months (p = 0.05). Frequencies of CD4 and CD8 cells with
intermediate phenotype were similar between HIV+ and HIVexp- at all time points (p
> 0.05). The accumulation of late phenotype cells was similar between groups in the
CDS subset (p > 0.05 for all time points). CDlS2+ was also measured on T cell
subsets. Few CD4 and CD8 cells expressed detectable levels of this antigen (Tables
5.2-3) and this marker was not detectably changed by age or HIV-I infection (p >
0.05 for comparisons between HIV+ and HIVexp- at each time-point).
Homing, antigen experience and senescence.
Cells were stained with CCR7 and CDS7 to estimate lymphoid-homing and senescent
cell frequencies. Patient CTL-B1-159 is used to illustrate the effect of HIV-l
infection on distributions of these cells (Figure 5.3). There was a decrease in CCR7+
cells during primary HIV-1 infection in both the CD4 and CD8 subsets. By 3 months
populations of CDS7+ cells have appeared in the CD8, but these do not reach high
frequencies until CMV infection is detected. By 24 months, 22% of the infant's CD8
were COS7+.
Figure 5.4 shows group summaries for HIVexp- and HIV+ children. In cord blood,
frequencies of CCR7+, COS7+ and CD45RA+ cells were similar between HIV+ and
HIVexp- infants. CCR7+ cells decreased in both the C04 and COS subsets.
However in the C04 subset, HIVexp- infants had lower frequencies of CCR7+ cells
compared to HIV+ at 1 month (p = 0.05). CCR7+ cells declined more rapidly in the
COS subset, and in this subset HIV+ infants had a lower frequency of CCR7+ cells at
1 month (p = 0.05). The accumulation of senescent (CD57+) cells was observed
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Figure 5.4. R7+, DS7+ and CD4SRA+ frequencies for HIVexp-CMV+ and
HIV+CMV+ infant.
Box plot how frequenci of ) CCR7+ and B) CD57+ and C)CD45RA+ cells for CD4
(left column) and
CMV by 3 m nth
D (right column) T cells. Data shown is restricted to children with
rage. Red = HI + infants, blue = HIVexp- infants.
primarily in the CD8 subset and was not detectably increased in the children co-
infected with HIV-I (p > 0.05 for each time-point). C04+C057+ frequencies were
higher in the HIV+ group at 9 months of age (p = 0.01).
CD45RA+ cell frequencies were similar between HIV+ and HIVexp- infants at all
time points in the CD4 subset, but were substantially reduced throughout infection in
the C08+ cells. C045RA+I- cells were further subdivided by the expression of C027
and C028. No differences were detected between distributions of C027C028
subpopulations within CD45RA+ and CD45RA- gates between HIV+ and HIVexp- (p
> 0.05 for each comparison of early/intennediatellate between HIV+ and HIVexp-)
(Figure 5.5). Throughout infection. the C04+ T cells maintained a predominantly
early phenotype in both the CD45RA and CD45RA- subpopulations, suggesting these
cells are mostly naive or early effector phenotype. Small populations intermediate
and late phenotype cells appeared in the CD4+CD45RA- subset at 3 months. The
C08 subset showed dramatic changes over time. Intermediate phenotype cells
accumulated within both subpopulations but were predominant in the CD45RA-.
- Late phenotype cells were found in both subpopulations and became predominant in
the CD45RA+. suggesting these cells had fully differentiated and had begun to re-
express CD45RA+.
Transferrin receptor CD71 was used as a surrogate marker to quantify proliferating
cells. Though dynamic changes were observed in CCR7 and C045RA during HIV-l
infection. they were not accompanied by increases in proliferation as measured by
CD71. CD71 remained constant during the period of observation, and was not
significantly different between groups of HIV+ and HIVexp- infants (Figure 5.6). No
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Figure 5.5. Di tribution of pbenotypic subsets within CD4SRA+I- subpopulancns in
HIV -1 infected infant .
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cells in HIV-J infected infant grouped b CD4SRA expression. A) CD4+CD4SRA+ B)
CD4+CD4SRA- ) D8+ D4SRA+ D) CD8+CD4SRA-. Blue = early, red =
intermediate, green = late phenotyp cells.
8 8
~ 0'"
:;J :;J
)2 R. +
§g -0b'"u
g5l 85:
-0 -00" 0.-
'# '#
g :;;
;;: 0N
9 9
0 .... 0 g .- ID. """CZI ...
0 12 1~ 0 12 24
Figure 5.6. CD71+ cells in HIVexp-CMV+ and HIV+CMV+ infants.
Box plots show frequencies of CD71 + cells as a percentage of CD4 and CD8 T cells.
Data shown is re tricted to children \ ith CMV by 3 months of age. Red= HIV+ infants,
blue = HIVexp- infants.
differences were detected in frequencies of Treg (CD4+CD25bright) cells between the
HIV+ and HIVexp- infants at any point during observation (p > 0.05) and did not
detectably change during the period of observation (Table 5.2).
Cellular activation
Cellular activation during viral infection was studied using a combination of cellular
antigens. Early activated cells were measured by expression of CD69, but these did
not change detectably during infection. Activated T cells were also identified as
CD38brigh'HLA-DR+. Figure 5.7 shows cellular activation in CTL-BI-159. Cellular
activation was observed by expansion of CD38brigh'HLA-DR+ cells in the CD8 subset
at 1 month, these cells persisted through follow-up in the infant. Activated CD4 were
present from birth in the infant (16%) and their numbers declined by 1 month (5.6%).
At 3 months activated CD4 increased to 21%, but then frequencies declined and
remained at a lower level even following CMV infection at 20 months (6.8%)
Comparison of HlVexp- and HIV+ infants revealed higher frequencies of
CD38brigh'HLA-DR+ CD8+ cells in HIV+ infants at 1 and 3 months of age (p = 0.02,
P = 0.04, respectively, Figure 5.8. Low levels of cellular activation were observed in
the CD4 subset, but no difference was detected between the HIVexp- and HIV +
groups. CD69 expression was expressed at low levels in HIV + and HIVexp- infants
and no significant expansions were observed concurrent HIV -l or CMV infection.
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Figure 5.8. Lymphocyte activation in HIVexp-CMV+ and HIV+CMV+ infants.
Box plots show frequencies of A) CD38brightHLA-DR+ and B) CD69+ cells for CD4 (left
column) and CD8 (right column) T cells. Data shown is restricted to children with CMV
by 3 months of age. Red = HIV+ infants, blue = HlVexp- infants.
Vulnerability to apoptosis
CD95 and 8cl-2 were used to categorise cells by vulnerability to apoptosis. Bcl-2 and
CD95 staining in CTL-B1-159 (Figure 5.9) illustrates the large frequencies of
vulnerable Bcl_2dimCD95+ cells that appeared following acute viral infection with
HIV-1. Large populations of apoptotic vulnerable cells were maintained in the infant
through the first year of life. and comprised 50% of CD8 at 24 months. Changes in
the CD4 subset were also dramatic, but different to those observed in the CD8.
CD95+ expression was high on CD4 at birth and increased such that -85% of cells
were CD95+ at 3 months. By 9 months CD95 frequencies had declined. Though
some cells had reduced Bcl-2 expression, no discrete populations of Bc1_2dim cells
were easily identified in this infant.
In comparisons between HIV+ and HIVexp- children Bcl-2, CD95 and cells co-
expressing both markers were examined. In comparisons between HIV+ and
HIVexp- children an increase in vulnerable cell frequencies was observed in both
CD4 and CD8 subsets with increasing age (Figure 5.10). In the CD4 subset, HIV+
infants had higher frequencies of vulnerable cells at 3 (p = 0.04) and 9 (p = 0.03)
months of age. Changes in the CD8 were more pronounced, HIV+ children had
higher frequencies of vulnerable cells at 1 (p = 0.01) and 3 (p = 0.05) months of age.
In the CD8 subset, HIV+ infants had higher frequencies of CD95+ cells in cord blood
(p = 0.03) and at 1 (p = 0.01), 3 (p = 0.03), 6 (p = 0.01), 9 (p = 0.03), and 12 (p =
0.04) months. CD8+Bcl_2brightcells were lower in HIV+ children compared to the
HIVexp- at 1 month (p = 0.01).
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Figure 5.10. Vulnerability to apoptosis in HIVexp-CMV+ and HIV+CMV+ infants.
Box plots show frequencies of A) Bc1-2d,mCD95+ B) CD95+ and C) Bcl_2bright cells for
CD4 (left column) and CD8 (right column) T cells. Data shown is restricted to children
with CMV by 3 months of age. Red = HIV+ blue = HIVexp- infants.
Lymphocyte frequencies and viraemia during HIV-l infection
The relationship between HIV -1 viral load and cellular activation was examined
during acute and chronic HIV -1 infection. Spearman correlations were performed
using CD38brightHLA-OR+ frequency and HIV-l viral load. To eliminate CMV viral
load as a confounder, infants were examined at birth (6 infants with in utero infection)
and 1 month (5 infants with first HIV -1 detected at 1 month) before becoming CMV
viraemic. No correlations were significant in the CD4 subset at birth (p = 0.5) or 1
month (p = 0.2). Frequencies of activated CD8+CD38brightHLA-DR+ cells were
negatively correlated with viral load in cord blood (p = -0.89, p = 0.02) but not at 1
month (p = 0.6) (Figure 5. J 1 A).
At 12 months, all surviving infants with viral load measurements were examined for
correlations with viral load (8 infants). A positive correlation was detected between
frequencies of CD4+CD38brightHLA-DR+ and HIV-l viral load (p = 0.74, p = 0.03),
and no correlation was detected for the C08 subset (p = 0.5)(Figure 5.11 B).
Lymphocyte activation and co-infection with CMV
It was reported in Chapter 3 that early acquisition of CMV infection (by 1 month of
age) was associated with increased risk of death in the cohort. To investigate whether
co-infection with CMV may increase activation during early HIV -1 infection,
frequencies of activated cells were compared between infants at 1 month who had
acquired CMV (HIV+CMV+, 6 infants) or had not yet acquired CMV (HIV+CMV-, 8
infants, Figure 5.12). HIV+CMV+ infants had significantly higher frequencies of
CD4+CD38brigh'HLA-OR+ cells at 1 month compared to HIV+CMV- infants (median
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Figure 5.11. Activated cell are correlated with HIV-l viral load during acute and
chronic infection.
A) Frequencie of D8+ D38bnghlHLA_DR+ cells are negatively correlated at birth in
infants with in utero acqui ition of HIV-I (who are CMV aviraemic), r = 0.-89, p = 0.02.
B) At 12 month, frequencies of CD4+CD38bnghlHLA-DR+ cells are positively correlated
with HIV -1 viral load in infants with HIV -1 infection by 1 month of age (not adjusted for
duration of MV infection) p = 0.74, P = 0.04.
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Figure 5.12. CMV co-infection and T cell activation at 1 month of age.
HIV -1 infected infants were analysed at 1 month of age before becoming CMV viraemic.
Frequencies of activated ) CD4 T cells are higher at 1 month of age in HIV-l infected
infants with CMV co-infection, p = 0.05. B) There is no significant difference between
frequencies of acti ated CD8 between the groups of infants, p = 0.5. C) HIV-l viral load
is similar between infants with and without CMV at this time-point p = 0.4. Box plot
shows median line, upper and lo er box hinges stretch to zs", and 75th percentiles,
whiskers show upper and lower adjacent values, outliers shown as closed circles.
3.27%, range 1.8-23.5% vs 1.98% range 1.3-5.69%, p = 0.05). There was no
significant difference between frequencies of activated CD8 cells in HIV +CMV + and
HIV+CMV- infants at month 1 (median 35.0% range 5.22-52.8% vs median 22.6%
range 4.15-58.6%, p = 0.5). No significant difference was found between HIV-I viral
load in the HIV+CMV+ (6.1 ioglO HIV-l RNA copies/mI, range 1.76-7.6) and
HIV+CMV- (6.6 ioglO HIV-l RNA copies/ml, range 4.72-7.64, p = 0.4) groups at 1
month of age.
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Discussion
Dynamic changes were observed in the T cell subsets of the infants undergoing HIV-l
infection. Previous studies examining cellular phenotype in HIV-1 infected infants
have been cross-sectional and included children with varying durations of infection.
Studies of healthy children have revealed age-related redistributions in lymphocyte
populations (156 , 497, 544 ), so phenotypic data collected from older children may
not be comparable to infants. This is also the first report to evaluate CMV as a
possible confounder to HIV-1 studies. CMV has been found to have a dramatic effect
on T cell phenotype (372), and the very high incidence of CMV in African infants
may further confound HIV-1 studies. Ideal controls for these studies would include
HIV+CMV- infants and HIV-CMV- infants with similar longitudinal follow-up, but
these were not available for the current study. However, by focusing on infants with a
constrained timing of HIV-I and CMV infection, it was possible to somewhat reduce
the confounding effect of two infections occurring in a very short space of time.
Overall, lymphocyte redistribution in the HIV-1 infected children was very similar to
the pattern that was observed during acute CMV infection of HIVexp- infants.
Changes were most dramatic in the CD8 though CD4 cells also showed increased
heterogeneity suggestive of antigenic stimulation. In the CD8 subset, HIV-I resulted
in increased activation, vulnerability to apoptosis, and the development of memory
cells.
A model describing HIV-1 viral load and phenotypes was created analogous to the
model ofCMV infection (Figure 5.13 and Figure 4.7). HIV-I introduces considerable
chaos into the distribution of CD8 phenotypes during co-infection with CMV. CMV
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Figure 5.13. Lymphocyte redi tributions during HIV-l and CMV co-infection.
Cubic median pline umman data for HIV+ infants to 12 months. All infants became
CMV viraemic at 3 months and acquired HIV -1 by 1 month of age. A) CD4 B) CD8.
Dashed black = log 10 MY viral load, black solid = log 10 HIV -1 viral load, yellow =
CD38bngh\ gra = 04 RA+. brown = narve (CCR7+), blue = apoptotic vulnerable (Bel-
2dimCD95 ). range = ene ent (CD57+), green = late (CD27-CD28-), red = activated
(CD38bnghtH - R ). pink = prolif rating (CD71+).
and HIV-1 initiated very similar changes in the CD4, with the notable exception of
increased frequencies of apoptotic vulnerable cells at 3 and 9 months.
CD38 has been studied extensively in the context of HIV-1 infection. Elevated
frequencies of activated cells have been reported in both adults and infants
undergoing HIV-I infection (260 , 428 , 430, 591 ), and these have been correlated
with HIV-I viral load. disease stage, and risk of mortality (55,190,207 ,321,332,
499 ). The initiation of HAART results in normalised CD38 expression. In infants,
CD38 is expressed on the majority of T cells, so the marker cannot be used alone to
identify activated cells. In infants, activated T cells can be distinguished by high
levels of CD38 and HLA-DR co-expression (430). In the current study, increased
frequencies of activated CD8 T cells were observed at 1 month of age (before CMV
infection) and at 3 months (concurrent to acute infection with CMV). Remarkably
little activation was observed in the CD4 subset during acute co-infection and
frequencies between HIV+ and HIVexp- infants were similar at all time points.
Increased CD38 and HLA-DR expression on CD4 T cells has been reported during
HIV-1 infection in adults and infants(279, 430). In agreement with the current
cohort, these studies also reported Jess activation in the CD4 subset relative to CD8
(-10%) (442).
Interestingly, the frequency of activated CD8 T cells was negatively correlated with
HIV-I viral load at birth in infants with in utero HIV-l infection. However, no
correlation was observed during acute infection in the infants with first HIV-l
detection of HIV-I at 1 month. Longer duration of HIV-I infection may explain why
an association was observed at birth and not at 1 month. AZT crosses the placenta
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and the suppressive effects of AZT on viral load in the infants infected in utero may
also contribute to the different trend observed in this group (328). Women in labour
were given AZT in accordance with study protocols and this could reduce viraemia in
the infants without any participation from the infant immune system (492).
Conversely, at 12 months. there was a positive correlation between the frequency
activated C04 cells and viral load. and this is consistent with other reports during
chronic infection(279. 430 ).
C095 is upregulated on activated T cells, and its expression is associated with
increased susceptibility to apoptosis via FasL engagement (17, 73, 133, 267). C09S
and Bcl-Z expression were closely associated in the C08 subset, with Bcl-2 down-
. regulation accompanying C09S expression, and this has been demonstrated to
correlate with a high vulnerability to apoptosis (251,592). However, C095 and Bcl-2
are indicative of vulnerability to apoptosis, but are not themselves measurements of
apoptosing cells. Higher levels of vulnerable (Bcl_2dimC095+) C08+ cells were
found in the HIV-I infected children throughout infection, and this is consistent with
other reports in adults and children that report increase C095 or decreased Bcl-2
expression during HIV -J (30, 64, 358, 420). In the C04 subset, many cells
expressing C095 continued to express high levels of Bcl-2, suggesting that these cells
are not as likely to undergo apoptosis as the C08 subset. A report by Boudet and
colleagues has also shown that C095 expression on C04 does not correlate with the
down-regulation of Bcl-2( 64), though other reports have cited significant decreases in
Bcl-2 expression on CD4 from HIV -J patients (141). The low frequencies of
activated and apoptosis vulnerable CD4 cells detected in the blood may be poorly
reflective of the true scale of CD4 apoptosis, which primarily occurs in the tissues.
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The majority of CD4 depletion has been shown to occur in the gut-associated-
lymphoid tissue (GALT). and though peripheral CD4 counts recover following acute
infection or ART in adults, the depletion in the GALT persists(69, 220, 325, 362).
CCR7 is lost upon acquisition of effector phenotype, enabling cells to move to the
periphery and home to areas of inflammation. CCR7+ and early phenotype
(CD27+CD28+) cells were persistently high in the CD4 subset during infection. In
the CD4 subset, substantial frequencies of CD45RA- cells were detected, although
these were not significantly different from the HIVexp- group. This is in contrast to
the CD8 subset, which had markedly reduced frequencies of CCR7+ and early
phenotype cells over time. Changes in CD45RA cell frequencies were also more
dramatic in the CD8 subset, and these changes were amplified by the presence of
HIV-1. HIV- 1 infection did not significantly alter the distribution of early,
intermediate, and late phenotypes within the CD45RA+/- subpopulations. In the
CD4+CD45RA+ subpopulation cells were predominantly CD27+CD28+, suggesting
a naive phenotype(26, 28). In the CD4+CD45RA- subset, more differentiation was
observed into intermediate and late effector cells, but the subpopulation still consisted
of primarily early (CD45RA-CD27+CD28+) phenotype cells at the end of follow-up.
CD8+CD45RA+ cells were a heterogeneous mix of naive, intermediate, and late
differentiated cells with the naive population steadily declining over time. After 3
months the CD8+CD45RA- subset was primarily late and intermediate phenotype.
Though these changes suggest differentiation in response to antigen, from these data it
is not possible to know what percentage of these changes are occurring in HIV-
specific cells. Considering the presence of CMV co-infection, it is likely that
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significant populations ofCMV-specific CD8 also comprise the CD27-CD28- subsets
(26,39).
Frequencies of senescent CD8+CD57+(68) cells have been reported to increase
during HIV-I infection (313, 409, 436). CD57+ phenotype cells increased
dramatically in the CD8 subset of both HIV+ and HIVexp- infants, and an additional
HIV-1 induced effect was not observed in this population. A transiently higher
frequency of CD4+CD57+ cells was detected in the HIV+ children at 9 months.
Though others have reported altered CD69 (121) CD71 (428) and Treg (377, 545)
frequencies, no differences were detected between the groups of HIV+ and HIVexp-
infants in the current study.
Early infection with CMV was shown in Chapter 3 to be associated with mortality in
the HIV-1 infected children. The excess mortality in the children with low HIV-1 set-
point viral loads suggests that the effect of CMV may augment HIV-1 disease
progression in children that might otherwise have better prognosis. The phenotypic
studies have demonstrated increased frequencies of activated CD4 cells during acute
HIV-1 in infants with CMV co-infection. The size of the current cohort is too small
to study the effect of activation while controlling for viral load, but no difference in
HIV-lor CMV viral load were detected between infants with early and late CMV
infection. Together these data suggest that acquisition of CMV during acute HIV-l
infection could potentially affect disease progression by increasing the level of
cellular activation.
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Summary
Dramatic changes were observed in the CD8 subset in response to HIV -1 infection in
the infants. These changes were very similar to those observed during acute CMV
infection, but co-infected infants had greater and more sustained frequencies of
activated, vulnerable, and differentiating cells. Alternately, changes in CCR7 and
CD57 appeared to be primarily attributable to CMV. Changes in the CD4 subset were
very small in comparison to the CD8, and this is surprising considering these cells are
the primary hosts of HIV -1 infection. Activation of CD4 during acute Hlv-I
infection was increased by the presence of CMV co-infection, and this may contribute
to the mechanism by which CMV alters survival in HIV -1 infected infants.
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Chapter 6
HIV -Specific Immune Responses During Primary
HIV -1 Infection
Introduction
The poor control of HIV -1 infection exhibited by most infants suggests that neonatal
T cells are ineffective in limiting viral replication. Much data supports the ability of
infants to mount cellular immune responses to viral infection, however responses to
different viral infections appear to be quantitatively and qualitatively different. For
CMV, the majority of children are able to generate a CMV specific CDS response to
one or more peptides ex vivo during early infection (94, 372, 546). Age does not
appear to be an impediment to generating strong CMV -specific responses, fully
functional effector cells have been detected in during the first weeks of life, and in a
foetus at 2S weeks gestation (346). CDS T cell responses in children with CMV are
similar in frequency and effector functions to those described in adults (346) (546)
(94). CMV -specific CD8 appear to have diverse effector function, including the
production of IFN-y, MIP-lf3 and TNF-a and the capacity for cytotoxicity. The
frequency of these cells by tetramer staining also appears to be stable over time,
responses measured during early infection are detected many months later at a similar
magnitude.
Conversely, the detection of HIV-1 specific CD8 T cells is less frequent in infants and
of a smaller magnitude than those observed during early HIV -1 infection in adults
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when measured by IFN-y, IL-2 or cytotoxicity assays (298, 333, 337-339, 359, 487,
489, 506). However, CTL escape mutations are generated by infants suggesting in
some cases responses are sufficient to exert selection pressure on virus to mutate(l70,
425). Recent studies using overlapping peptides to screen the entire HIV-1 genome
have revealed more frequent CD8 responses in infants (534). Infants who survive the
first year of life are able to generate stronger responses with increasing age (78, 333,
467). Whether this is due to a survivor effect or a true maturing of the immune
response is not known. It has been suggested that high frequencies of regulatory T
cells may also limit responsiveness of neonates compared to older children (316,
371).
The mechanisms underlying poorly functional CD8 responses in infant HIV-l
infection are not understood. Sub-optimal priming of T cells or a lack of proper CD4
help may result in the development of antigen-specific CD8 functionally different
from adults. HIV-1 specific CD8 T cells from Kenyan infants were examined using
tetramer staining and multicolour flow cytometry to determine whether the frequency
or phenotype of virus-specific cells was different from adults undergoing acute HIV-l
infection.
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Methods
HLA Typing and peptides
DNA was extracted from peripheral blood mononuclear cells with the Puregene DNA
Isolation Kit (Puregene, Minneapolis, Minnesota, USA) and used in amplification
refractory mutation system-PCR (75) to determine infant HLA types. Peptides were
synthesised by Dr. Kati DiGleria using F-MOC chemistry at Weatherall Institute of
Molecular Medicine.
EL/Spot Assay
ELISpot assays were performed on all infant specimens from the CTL study cohort at
1, 3, 6, 9 and 12 months of age (333). A subset had retrospective ELISpot assays on
frozen cord blood specimens after HLA types had been obtained. Peptides were
selected on the basis of HLA type from a panel of optimized CTL epitopes previously
used for studies of CTL responses in Kenyan sex workers (275) (Table 1). Clade A
and 0 peptide variants were used, as these are the most common subtypes identified
in Kenya (393). Since HIV-l subtyping was not performed as part of this study,
epitopes that vary in subtypes A&D were mixed in equal amounts for the ELISpot.
Assays were performed on freshly isolated cells obtained from EDTA anticoagulated
blood. PBMC were isolated by density gradient centrifugation and resuspended in
RPMI medium supplemented with 10% heat inactivated fetal bovine serum (RIO).
The ELISpot assay was performed as previously described (305) with modifications
described in (275). Briefly, 96-well Millipore plates (Millipore Corp, Bedford, UK)
were coated with I-DIK Mab at 15 ug/ml (Mabtech, Nacka, Sweden) and incubated
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at 37 -C for 2 h. Plates were washed six times with sterile RPMI then blocked for 30
minutes with RIO. PBMC from HIV-l infected or exposed uninfected subjects were
added to the plates in duplicate at 2x1051well and stimulated with either PHA at 20
ug/ml (positive control, Murex Biotech, Dartford, UK), RIO media alone (peptide
control), or 20 flM peptide. The plated cells were incubated at 37 -C and 5.0% CO2
overnight. Following incubation, plates were washed six times with PBS plus 0.05%
Tween-20 (Sigma Chemicals Co., St. Louis Missouri, USA) and coated with
biotinylated anti-IFN-y-Mab 7-B6-I at 1 ug/ml (Mabtech) for 3 h at room
temperature. Plates were washed six times with PBS-Tween, followed by the addition
of streptavidin-conjugated alkaline phosphatase (l:1000, Mabtech) for 1.5 h at room
temperature. Plates were washed again and developed with an alkaline phosphatase-
conjugate substrate kit (Bio-Rad Laboratories, Hercules, California, USA) for 10 min
or until blue spots were clearly visible in the PHA control wells with the naked eye.
The reaction was stopped by washing with tap water. Spots were counted with the
AID ELISpot reader and software (Autoimmun Diagnostika, Straperg, Germany).
Spot forming units (SFU) was defined as the average number of spots in duplicate
wells. and HIV-l-specific SFU (HIVSFU) was defined as SFU minus the average
~
number of spot forming cells in the negative control wells. A positive response was
defined by an assay meeting the following criteria: (1) strong response in the PHA-
stimulated positive control wells, (2) HIVSFU at least 50 HIVSFU/l06 PBMC after
subtraction of no peptide control and (3) SFU at least twice the value of the negative
control.
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HLA Protein Sequence HLA Protein Sequence
AI PI7 GSEELRSLY B8 Nef FLKEKGGL
AI Rev ISERILSTY B8 p24 DIYKR WIIIEIYKRWII
A2 RT ILKEPVHGV IILKDPVHGV B8 RT GPKVKQWPL
A2 Nef ALKHRAYEL B8 gpl60 YLKDQQLLIYLRDQQLL
A2 PI7 SLFNTV ATLiSL YNTV ATL B8 pl7 GGKKKYRL/GGKKKYKL
A2 P24 TLNA WVKVIITLNA WVKVV BI4/Cw8 p24 DRFFKTLRAIDRFYKTLRA
A2 RT VIYQYMDDL BI4/Cw8 p24 DLNTMLNTV IDLNMMLNIV
A2 Nef VLEWRFDSRL BI4/Cw8 p24 RAEQASQEVIRAEQATQEV
A2 Nef PLTFGWCYKL BI4 gpl60 ERYLKDQQL
A3 PI7 KIRLRPGGK BI51Cw4 gpl60 SFNCGGEFF
A3 Nef QVPLRPMTYK BI8/49 p24 FRDYVDRFYK~RDYVDRFFK
A3 Gpl60 TVYYGVPVWK BI8/49 Nef YPL TFGWCY IYPL TFGWCF
A3/11/33 RT AIFQSSMTKlSIFQSSMTK B27 p24 KRWIILGLNKIKRWIIMGLNK
A3/31 Gpl60 RLRDLLLIVTR B35 p24 PPIPVGDIY
A3/11/31/33 RT DLEIGQHRTK B35 Nef VPLRPMTY
A3 Nef DLSHFLKEK B35 RT HPDIVIYQY INPDIVIYQY
A24 Gpl60 YLRDQQLLIYLKDQQLL B35 gpl60 TA VPWNASW ITNVPWNSSW
A241B44 P24 RDYVDRFYKTLlRDYVDRFFKTL B35 RT EPIVGAETFY
A24 Nef DSRLAFHHM B37m Nef YFPDWQNYT
A25 P24 DTINEEAAEWI ETINEEAAEW B42 p24 GPGHKARVL
A261B70n2 P24 YVDRFFKTL B42 Nef TPQVPLRPM
A29 Gpl60 FNCGGEFFY B45 RT GAETFYVDGA
A30 RT KLNWASQIY B51 Pol EPIVGAETFY
A30 PI7 RSL YNTV ATL Y B53 p24 ASQEVKNWMlATQEVKNWM
A30 Gpl60 IVNRVRQGY B53 p24 TPQDLNMMLITPQDLNTML
A30 RT KQNPDIVIYQY B53 p24 DTINEEAAEW
A30 Gp41 KYCWNLLQY B53 p24 QATQEVKNW
A6802 Protease DVTLEDINL B53 p24 VKNWMTETLL
A6802 Int ETAYFILKL B57/5801 p24 TSTLQEQIGWITSTLQEQIA W
A6802n4 RT ETFYVDGAAN B57/5801 p24 KAFSPEVIPMF
A6802n4 Protease ITLWQRPLV B57/5801 RT IVLPEKDSW
A6802 Protease DTVLEEMNL B57 p24 ISPRTLNAWILSPRTLNAW
B7/8101/42 Nef TPGPGVRYPLlTPGPGIRYPL B57 Pol KITTESIVIW
B7 Gpl60 IPRRIRQGL B70/72 RT DVKQL TEVV IDVKQLAEA V
B7 P24 SPRTLNAWV Cw4 p24 QASQEVKNW
87 P24 GPGHKARVL Cw4 pl7 KYRLKHLVW
B7/8101 P24 ATPQDLNTM Cw8 RT VTDSQYALGI
B7 Nef FPVTPQVPLR Cw8 Gpl60 NCSFNISTSI
Cw8 Nef KAAVDLSMFL
. .Table 1. Peptades used ID IFN-g ELISpot assays•
168
Study subjects and selection of specimen subset for tetramer staining
Infants from the CTL study are described in Chapter 2. A subset of infant specimens
was evaluated with both ELISpot and tetramer staining. Tetrarner staining was not
performed on all infants because tetramers are not available for all of the HLA types
and epitopes used in this study. Also, experience in the laboratory has shown that
tetrarner positive cells are rarely identified from specimens with < 400 HIVSFU/I06
PBMC in ELISpot assays. Since the production of tetramers is expensive and
laborious, only specimens that were previously defined as positive by ELISpot were
stained with tetramers. The panel of tetrarners available for screening included those
previously identified as highly immunodominant in African cohorts that were
produced in the Human Immunology Unit: HLA-A03, B08, and B57. Responses to
HLA-A29 gp120 were frequently detected in the infants and were very high in
magnitude compared to other epitopes. Possession of the HLA-A29 allele was also
associated with increased risk of early HIV-I acquisition in the CTL cohort (RR =
2.0)(164).
The algorithm for choosing infants for tetramer staining was: I) Choose the first
specimen with >300 HIVSFU/I06 PBMC 2) Choose all available PBMC specimens at
study visits prior to and after a specimen meeting criteria (1). Seven infants had
ELI Spot assay results of sufficient magnitude, and had cryopreserved PBMC
available for tetramer staining.
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Tetramer staining
In all staining experiments, 3 million cells were resuspended in approximately 200 ,.d
of RIO media, and tetramer added. The cells were incubated at 5% CO2, 37°C for 15
minutes. The cells were split into three parts for staining with Panel X, Y, and Z
antibodies. Antibodies used in combination with tetramer staining are shown in
Tables 2 and 3. Cells not used for tetramers were stained with Panels A-G as
described in Chapter 4. Master mixes of antibodies to surface antigens were added to
the cells in v-bottorn plates and incubated at room temperature in the dark for 20
minutes. The cells were washed twice and fixed with CytoFix (BD Pharmingen,
Oxford, UK). Before acquisition, cells were refrigerated at 4°C at least one hour for
the inactivation of HIV-l.
For perforin staining, the above protocol was followed for tetramer and surface
staining. Instead of the final fixing step, cells were permeabilised by adding 300 !J.Iof
CytoPermlCytoFix permeabilisation solution (BD Pharmingen) and incubating for 20
minutes in the dark at 4°C. Cells were washed twice with Perm buffer. Saponin is
used in this kit to permeabilise the cells, and since this process is reversible if saponin
is removed, cells were kept in the saponin buffer for the remainder of wash and
incubation steps. Cells were stained with intracellular antibodies in a volume of 100
ul for 30 minutes in the dark at 4°C. Cells were washed twice with Perm buffer and
resuspended in 170-200 j..llof Perm buffer.
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Fluorochrome Panel x Panely Panel z
Pacific Blue CD3 CD3 CD3
PE Tetramer Tetramer Tetramer
PE-Cy5 CD38 HLA-DR CD38
FITC CD28 CD57 Perforin
APC CD27 CD4SRA CD9S
APC-Cy7 CD8 CD8 CD8
Table 2. Antibody mixes used in the description of tetramer-stained cells.
Fluorochrome Antibody Clone Manufacturer
PB CD3 UCHTI Dako
AC7 CD8 RPA-T8 Pharmingen
APC CD27 0323 eBioscience
FITC CD28 CD28.1 Dako
PCS CD38 HIT2 Pharmingen
APC CD4SRA HIIOO Pharmingen
APC CD95 DX2 Pharmingen
PC5 HLA-DR 045-6 Pharmingen
FITC PERFORIN d09 Pharmingen
Table 3. Antibody clones and suppliers.
Analysis and gating
Cells were acquired on a Cyan ADP or LX instrument using Summit software (Dako
Cytomation, Angel Drove, UK) as described in Chapter 4. FCS files were analysed
with FlowJo software (Treestar, Inc., Olten Switzerland). Data were re-compensated
during analysis using single stain controls and FlowJo's automated compensation
platform. Cells were first gated by size and granularity, then selected for CD3+ and
CD8bright expression. A specimen was classified as "tetramer positive" by the
presence of a discrete population of tetramer-stained cells in the CD3+ gated
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population what was positive in the CD8hi region, but not the CD8- region. Gates
were then placed such that <1% of cells were staining positive in the CD8- quadrant,
and then applied to CD3+CD8+ gated cells to provide tetramer percentages as a
proportion of CD8 T cells. Data were exported from FlowJo and uploaded into the
FACS LIMS as described in Chapter 4. HIV-I negative donor cells were used to
confirm an absence of staining for each tetramer.
Statistical Analysis
Clinical and laboratory data were collected and stored in a Microsoft Access Database
(Microsoft Inc., Redmond, Washington, USA) and analysed using Stata SE v.9 (Stata
Corp. College Station, Texas, USA). Cell frequencies and viral loads were logJO-
tranformed before comparisons. Mann-Whitney rank-sum tests were used to compare
median cell frequencies between groups of infants. Correlations were tested using
Spearman's rank test.
Results
Frequencies oj tetramer-stained cells during HIV-J injection in infants
Data describing overall T cell responses in the CTL study cohort have been published
and will not be repeated in detail here (333) (506). ELISpot data were screened for
specimens with responses> 300 HIVSFU/I06• Responses from this subset were
selected if they were directed toward epitopes matching available tetramers. Seven
infants met these criteria and had PBMC specimens available for further experiments
(Table 4). Four of the infants responded to A29 Env, and 3 infants responded to A3
Nef. B8 Nef or 857 p24.
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An example of tetramer staining in and HIV -I infected infant is shown in Figure 6.1.
Very high frequencies were often found during acute infection, HIV -I specific cell
frequencies ranged from 0.14-3.82% of CD8+ T cells. Table 4 summarises
frequencies of tetramer+ cells detected in the 7 infants. Correlation analysis revealed
a decline in tetramer+ cell frequencies over time (Figure 6.2, p = 0.03, P = -0.48).
However, analysis of the whole cohort showed an increase in the magnitude of
ELISpot responses over time (333). Tetramer-positive cells were consistently found
in specimens that were ELISpot positive above 300 HIVSFU/I06. The one exception
was CTL-B 1-170, at 6 months there was a positive ELI Spot response of 685
HIVSFU/I06 but no tetramer-positive cells were detected. In some cases tetramer+
cells were detected when IFN-y responses were measured below 300 HIVSFU/I06
(CTL-BI-045 month 6 and CTL-BI-291 month 6). Infant CTL-BI-159 had a
negative ELISpot result at 6 months (30 HIVSFU/I06 with negative control staining
of 25 SFU/I06), but a very large population of tetramer-stained cells (2.21%).
Otherwise there was good concordance between positive ELI Spot responses and the
detection of tetramer-positive cells.
Figure 6.3 shows tetramer, ELISpot and HIV-I viral load data for each infant during
two years of observation. Analysis of the entire cohort has previously revealed no
relationship between the presence of ELISpot responses or the magnitude of those
responses and HIV-l viral load (333). The relationship between frequencies of HIV-I
specific cells and levels of viraemia may vary depending on the stage of infection
(acute or chronic), and the current study is underpowered to rigorously examine the
relationship between the two. The most observations were available at 9 months (5
infants) of age, and no significant correlation between HIV -I viral load and tetramer+
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Figure 6.2. Tetrarner raining cell frequencies decrease over time.
Linear predicti n line how decrea e in tetrarner-staining cells over time. Tetramer
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Figure 6.3. HIV-l specific immune
responses and viral load in infants.
ELISpot assays were performed on all
available specimens up to one year, viral loads
were performed on all available plasma
specimens during follow-up. Tetramer
stairung was performed on available
specimens following the algorithm described
in the methods. Subjects 159, 291, and 334
died at 24, 17, and 11 months, respectively .•
viral load • ELISpot +Tetramer
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o
frequency was detected (p = 0.1). Despite the generation of high frequencies of
tetramer+ and IFN-y-producing cells, subjects CTL-BI-159, CTL-BI-291, and CTL-
BI-334 experienced persistently high viraemia and died during follow-up (at 24, 17,
and 11 months, respectively).
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Subject HIV+ Class I HLA Peptide ELI Spot Tetramer
alleles (HIVSFU/I06)
CTL- In utero AI.A3. A3 nef- MI:ND MI:ND
BI-045 BI5.B57. QVPLRPMTYK M3: negative M3:ND
Bw4.Bw6. M6: 248 M6: 0.66%
Cw4,Cw7 M9: 1170 M9: 1.58%
M12: 385 M12: 0.99%
M24:ND M24: 0.32%
CTL- In utero A29.A74. A29 gp120- Cord: negative Cord: 0%
BI-093 BI4.BI503. FNCGGEFFY MI: negative MI:O%
Bw6. M3: 373 M3: 3.82%
Cw2 M6:585 M6: 0.91%
MIO:358 MIO :ND
M12:993 M12: 1.36%
MI5:ND MI5: 0.88%
M24:ND M24:0.14%
CTL- Peri partum A29,A30, A29 gp120- MI: 58 MI:ND
BI-159 84501, FNCGGEFFY M3: 425 M3: 1.79%
Bw6, Cw6 M6: negative M6: 2.21%
M9: 723 M9: 1.94%
MI2:ND MI2:ND
M24:ND M24: 0.45%
CTL- In utero A30,A3402, B57 p24- Ml:ND MI:ND
BI-170 B42,B57. KAFSPEVIPMF M3: negative M3:ND
Bw4.Bw6, M6: 685 M6:0%
Cw7,Cw17 M9:ND M9:ND
M12:1432 MI2:0.96%
CTL- Peri partum A29,A74, A29 gp120- Cord:ND Cord: 0%
BI-291 8420,BI5, FNCGGEFFY MI:ND MI:ND
Bw6, M3: 120 M3:ND
Cw2,Cw17 M6: 238 M6: 0.55%
M9:ND M9: 0.24%
M12: 685 M12: 0.62%
MI5:ND MI5: 0.88%
CTL- Peripartum A29,A26, A29 gp120- Ml:ND MI:ND
BI-334 B13,BI5, FNCGGEFFY M3: negative M3:ND
Bw4,Bw6, M6: negative M6:ND
Cw2,Cw6 M9: 2040 M9:0.67%
M12: ND M12: ND
CTL- Peri partum A2,A31, B8 nef- M I: negative Ml:ND
B]-454 B8,B]S, FLKEKGGL M3:90 M3:ND
Bw6, M6: 135 M6:ND
Cw7,Cw8 M9: 303 M9:0.59%
M12: 450 M12: ND
Table 4. ELlS pot and tetramer staining in HIV+ infants of the CTL cohort.
M = age of infant in months. ND = not tested at time-point (infant missed clinic visit
or no PBMC specimen available). ELISpot results are shown as HIVSFU/l06 PBMC,
b ight For a full description of ELISpot responses in the cohorttetramer as % of CD8 n . ,
please refer to (333).
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Phenotype of tetramer positive cells
The phenotype of tetramer positive cells was described by staining with antibody
panels X, Y, and Z. Phenotype data was not available for infant CTL-BI-454, or
infant CTL-BI-29I at months 12 and 15. CTL-BI-170 did not have perf orin staining
performed, Due to the small sample size of this study, it was not practical to make
comparisons between phenotypes for T cells directed against different HIV -1
epitopes, so all HIV -1 tetramer data was analysed as one group. HIV -I specific cells
had a phenotype distinct from the general CD8 population (Figure 6.4). The
percentages of HIV -1 specific cells distributed among the major phenotypes at
different ages are shown in Table 5.
As previously described in adults, the majority of HIV -1 specific cells in all infants
were of the intermediate (CD27+CD28-) co-stimulatory phenotype, however a
significant proportion of the tetramer+ cells were also early (CD27+CD28+) and late
(CD27-CD28-). The tetramer positive fraction remained predominantly intermediate,
> 40% of cells were intermediate in each infant throughout infection (Figure 6.5).
HIV-I specific cells were highly activated (CD38bright,HLA-DR+, CD95+). Serial
observations in four infants showed the majority of tetramer+ cells expressed
activation markers on the cell surface throughout infection, though the density of
HLA-DR+ and CD38brightexpression on cells declined over time (Figure 6.6)
In the majority of infants, HIV -1 specific cells were predominantly CD45RA-
throughout the observation period, suggesting an effector or memory phenotype.
CTL-BI-045 was an exception, whose A3 cells were predominantly CD45RA+,
suggesting a terminally differentiated memory phenotype (Figure 6.7). CD57+
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Figure 6.4. HIV -1 specific
CD8 T cells have a phenotype
distinct from the greater CD8
subset.
Representative staining from
infant CTL-B1-093 at 3 and 12
months of age. HIV -1 specific
cells lymphocytes(gated:
S 37
/CD3+CDSbngh'/ tetrarner+) are
shown in red, overlaid on the
whole CD8 subset (gated:
Iymphocytes/
shown in grey. HIV -I specific
CDS were predominantly115
10'
intermediate in phenotype
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(CD27+CD28-(A)). Most HIV-
I specific cells were CD4SRA-,
and CD57+ cells accumulated
with time (B). Compared to the
whole CDS subset, HIV-I
specific CDS were highly
\0'
activated, bothexpressing
HLA-DR (C) and CD3Sbright
(D). HIV-I specific cells
expressed CD9S (D). Perforin
was found in the majority of
HIV-I specific cells during
acute infection, but levels
decreased over time (E).
100
(J) • • •
Cl) 75o
+"-
Cl)
E 50
"'"-...
Cl)... 25-0
~0
0
3 6 9 12 24
Age in months
Figure 6.5. Summary of co-stimulatory molecule expression in infants with HIV-l
infection.
Percent of early (orange, CD27+CD28+) intermediate (blue, CD27+CD28-) and late
(lime, CD27-CD28-) phenotype cells are shown as percent of tetramer-gated cells. Data
at month 15 is omitted because only one infant had phenotype data at this age.
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Figure 6.6. Expression of activation markers on DIV -1 specific CD8 T cells.
A) Line plots show frequencies for A) CD38bright, B) HLA-DR+ and C) CD95+ cells
during follow-up. Cells were gated lymphocytes/CD3+CD8bright/tetramer+. Expression of
activation markers CD38 and HLA-DR decreased over time. Expression of CD95 remained
high. D) Channel number is shown on x-axis, relative frequency on y-axis. Histograms are
shown running from front to back with time. Red = month 3, blue = 6, orange = 9, green =
12, purple = 15, light blue = 24.
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replicating antigen-specific cells. C057+ cells accumulated within C045RA positive
and negative cells in both the tetramer+ and whole C08 subset.
The frequency of tetramer+ cells expressing perforin was widely variable among
infants, but the overall trend was for decreasing frequencies from baseline
measurements. Relative perforin content was described by median fluorescent
intensity (MFI). Perforin MFI decreased in two of the infants (CTL-BI-045 and
CTL-BI-093), and was persistently low in two others (CTL-BI-159 and CTL-Bl-
291, Figure 6-8).
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Discussion
HIV-1 follows an aggressive course in infants characterised by persistently high levels of
viraemia, rapid CD4 decline and a high risk of death. In adults, the reduction of HIV-1 viral
load and subsequent control during clinical latency are controlled by CTL (481) (261) (421).
HIV-1 specific CD8 responses are detected less frequently in infants and reduced effector
function is proposed to explain their poor control of viral load. The generation of fully
functional CD8 T cells in combination with CD4 T cell help has been strongly associated
with long term survival in HIV-1 infected adults and children. A subset of children with
strong IFN-y ELISpot responses were examined with tetramer staining to determine if T cell
frequency and phenotype were comparable to what has been reported in adults undergoing
acute HIV-1 infection.
High frequencies of tetramer-stained cells were detected in infants with strong IFN-y ELISpot
responses. The frequency of HIV-1 specific CD8 T cells identified by tetramer staining is in
the range of other reports in infants and young children (79, 231, 357, 488) and is the range
observed in adults during acute and post-acute infection (22, 402, 412). The decrease
observed over time cannot be attributed to clearance of viraemia as all of the infants
maintained very high viral loads -1 million copies/rnl. Conversely, the decrease in tetramer-
stained cells may be due to increased apoptosis following persistent viral stimulation. Virus
has not yet been sequenced from the children, so it is not possible to comment on CTL escape
as factor in declining frequencies of tetramer-stained cells.
179
Overall, there was good concordance between the presence of a positive ELISpot and a
population of tetramer-stained cells. Previous studies have demonstrated that not all
tetramer+ cells have the ability to produce IFN-y upon re-stimulation (79, 489). The
observation that ELiSpot responses in the CTL cohort became stronger with time (333), and
tetramer+ cells decreased suggests that a greater proportion of HIV-1 specific T cells are able
to make IFN-y with age, even if their overall numbers are reduced. Unfortunately, limited
specimen availability did not enable the simultaneous evaluation of tetramer staining and
intracellular cytokine staining for IFN-y. Tetramer and ELlSpot performed here are not
directly comparable for a number of reasons. First, ELISpots were performed on freshly
isolated PBMC and reflect frequencies of cells expressed as a proportion of PBMC. Ratios
of CD4, C08 and NK cells in blood change rapidly during early life (130), so the
proportional numbers of CDS input into ELISpot assays may change. Secondly, tetramer
staining was performed on cryopreserved cells gated to eliminate dead cell debris and NK
cells. Thus the parent population from which the tetramer+ cells derive is thus different from
that in the ELISpot. Finally, epitopes selected for tetramer evaluation were chosen based on
strong IFN-y responses, so by default high frequency responses are selected. However some
insights can be gained from group comparisons of the methods. High levels of persistent
viraemia did not result in the maintenance of high frequencies of HIV-1 specific C08. The
high activation status of these cells and expression of C095 suggests they were likely to be
highly vulnerable to apoptosis, and this probably accounts for the decrease in frequency
observed with age.
Persistently high HIV-I viral loads were observed in these children, despite relatively strong
IFN-y responses and high frequencies of tetramer cells. Studies in adults have shown high
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frequencies of tetramer+ cells during acute infection (481) (583) followed by a negative
correlation between tetramer+ cells and HIV-1 RNA viral load (402). The quality of the T
cell response in terms of mature effector function (defined by cytokine production and
cytotoxicity) (45) (291) (79) (514) and sustained CD4 help (90,450) is more closely linked
with control of disease and survival than the frequency of HIV-1 specific cells alone.
The phenotype of tetramer+ cells changed over time in the infants. As demonstrated in
Chapters 4 and 5. CD38 is constitutively expressed at higher levels in infants, and declines
with age. At the first point of detection, cells were CD27+CD28-, highly activated
(CD38brightHLA-DR+CD95+),CD45RA- and contained high levels of perforin. In
subsequent months, CD27+CD28-, CD45RA-, and CD95+ cells continued to predominate
the HIV-1 specific population. Expression of activation markers declined, though they
continued to be maintained on the majority of cells during the period of observation. Cells
became increasingly CD57+ and low in perforin, suggesting a transition to a senescent
phenotype but not necessarily loss of cytotoxicity or IFN-y (68, 313). These changes are very
similar to what has been observed during acute infection of adults (26, 412) 46. The infants in
the study were only followed for 24 months, and the persistently high viral loads (-1 million
copies/ml) maintained during that time make comparisons with chronically infected adults
difficult to interpret. Adults and older children with chronic HIV-1 infection have tetramer
positive cells exhibiting a more "resting" (lower CD38, HLA-DR, CD95+, perforin'l'")
phenotype and are similarly CD27+CD28- and senescent (28, 90, 412). However, the
downward trend in activation markers and perforin, and increase in CD57+ observed in the
current cohort suggests a similar move toward more resting phenotype similar to those
detected in adult and older children. From the limited number of markers examined here, it is
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not possible to conclude that infant HIV-I specific CD8 T cells develop a co-stimulatory,
activated, or senescent phenotype during acute infection that is different from adults. The
current study suggests that IFN-y production in the cells could be impaired in very young
infants, as these responses improved after 1month of age.
Summary
In summary, the current study of infants during acute and early HIV-1 infection show a
similar frequency and pattern of phenotypic changes that are similar to that observed in adults
undergoing acute and early HIV-1 infection. T cell phenotype as ascertained by cell surface
markers does not explain the failure of infant CTL to control HIV-1 replication.
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Chapter 7 New methods
Section I: Synthesis of the novel HLA-A *2902 tetramer
&
Section 2: Optimisation and validations for multicolour flow
cytometry
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Section 1. Synthesis of the novel HLA-A*2902 tetramer
Introduction
Tetramer technology was developed in the 1990s as a method to study antigen-
specific C08 T cells directly ex vivo (22). Before the advent of tetramer technology,
limiting dilution analysis (LOA) was the gold standard used to quantify antigen-
specific C08 cells. In LOA cells are stimulated with antigen, serially diluted,
expanded in culture for two weeks and then assessed for lytic activity with a
chromium release assay. Precursor cell frequency is then estimated by extrapolation
from the lytic assay and dilution. This method underestimated CTL frequencies
because it required cells to survive and repeatedly divide in culture for an extended
period of time, and assumed that all the dividing cells maintained cytolytic function.
Fresh lytic assays performed on cells from patients with HIV-1 infection suggested
that antigen specific C08 frequencies were much higher than estimates from LOA
(84, 211). This suggested that only a subset of the antigen-specific CD8 survived the
in vivo expansion. Similarly, functional assays measuring cytokine release ex vivo
from patients recovered from influenza virus suggested very high effector memory
cell frequencies (305). Direct comparison of LDA, tetramer and intracellular cytokine
staining confirmed that the expansion of antigen-specific CD8 during acute viral
infection and memory responses were higher than revealed by LDA (385).
Tetramer technology works by exploiting the high specificity of the TCR for its
MHC-peptide partner. Tetramers contain four class I heavy chain HLA monomers
with recombinant biotinylation tails, each refolded with a viral peptide of 9-11 amino
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acids long. The addition of streptavidin or extravidin, both of which have 4 biotin
binding sites, allows for the joining of the monomers into "tetramers". In vivo, HLA
molecules expressed on the cell membrane have a very fast dissociation rate from
TCRs, but "tetramerisation' increases the binding affinity of class I HLA for its TCR
ligand, stabilising the interaction. The use of extravidinlstreptavidin bound dyes
(such as PE or APC) allow tetramers to be identified by fluorescence. In addition to
the quantification of epitope-specific cells, multicolour flow cytometry further
expands the applications of tetramer staining to enable descriptions of cell surface
phenotype, function, and TCR expression (29, 403).
Class I tetramers have revolutionised the study of host immune responses, allowing
the direct visualisation of T cells targeting single epitopes. Despite their utility,
tetramer technology has limitations. Because the construction of tetramers requires a
priori knowledge of HLA type, epitope sequences, and immunogenicity, their
application is restricted to the study of pre-identified HLA types and epitopes. For
example, a large number of HIV-1 epitopes have been described, but most of these
are derived from subtype B responses and are recognised by a limited set of HLA
alleles common in Caucasian cohorts. By comparison, African class I HLA alleles
and immunodominance patterns against HIV-1 subtypes A and D are less well
defined. Construction of tetramers is expensive and laborious, and the end product is
not always stable in storage. Consequently, although many HIV-I epitopes have been
defined, a limited number of tetramers are currently available for the study of HIV-1-
specific immune responses.
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HLA types were determined for all infants and mothers in the CTL cohort, and
subjects were screened with ELISpot assays using individual epitopes matched for
their class I HLA types. HLA-A *2092 was common in the cohort, 57 of the 451
HLA-typed children carried at least one A*2902 allele (12.6%), and the gp120-
FNCGGEFFY epitope (582) elicited strong IFN-y responses in 5 of the 8 HIV+
A *2902 children who were screened with. ELISpot assays. This epitope has been
reported to elicit strong CTL responses in some HIV -positive donors, but variants are
common and changes to the glycine at position 4 have been shown to greatly decrease
CTL recognition (582). The possession of HLA-A *2902 has also been associated
with increased risk of vertical HIV-I acquisition (164) and rapid disease progression
(236). This section describes the synthesis of a novel HLA-A *2902 tetramer for the
study of FNCGGEFFY specific CD8 responses in the CTL cohort.
Methods and results
Generation of the recombinant HLA-A *2902 heavy chain clone
RNA was extracted from aB cell line from a Kenyan patient with the HLA-A*2902
allele using the nucleospin kit (Clontech Laboratories Inc., Mountain View California,
USA). cDNA was reverse transcribed using AMY reverse transcriptase (Invitrogen
Corp., Carlsbad, California, USA). Primers were a gift from Dr. Tao Dong. The
beginning of the first class I HLA exon is G-C rich and forms loops that can inhibit
translation. The sense primer was designed to prevent secondary structure formation
and improve translation. A restriction enzyme sequence for Neal was added to the 5'
start of the 5' sense pnmer (5' -
ATATATCCATGGGGCTCCCACTCCATGAGGTATTTCAC-3 ') and a BamHI
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sequence was added to the 3' end of the antisense pnmer (5'-
ATA TATGGA TCCCCCA TCTCAGGGTGAGGGGCTTGGGCAG-5') to enable
cloning. Piu DNA polymerase (Stratagene, LaJolla California) was used 10 maximise
PCR fidelity. The patient's two HLA alleles A*0201 and A*2901 are very similar in
sequence at the 5' sense primer site. In order to ensure preferential amplification of
the A ·2902 allele, the sense primer was designed such that the 3' terminus of the
primer was specific for A*2902 and not A ·020 I, and a high stringency PCR program
was used to amplify the gene:
96°C-60s
(96°C-25s, 70°C-45s,72vC-120s) x 5 cycles
(96°C-25s, 65°C-50s,72°C-120s) x 21 cycles
(96°C-25s, 55°C-60s,72°C-120s) x 4 cycles
72°C-120s
The PCR product was excised from a 1.5% agarose gel and purified using the Qiagen
Gel Purification Kit (Qiagen Ltd., Crawley, UK). Approximately 250 ng of purified
DNA was cut with 2 units of BamHI and Ncol in a double digest (Fermentas
International Inc., Burlington, Canada) with BamHI buffer and supplemented with
BSA) for 4 hours at 37°C. The buffer was exchanged by passing the reaction mixture
through a Qiagen Gel Purification kit column and resuspending in water.
A pET23 expression vector was used for the cloning. A previously constructed vector
containing a different HLA heavy chain (HLA-A*2401) was used for the cloning
because this construct contains the same restriction enzyme recognition sequences
and a biotinylation sequence (GGT GGT GGT CTG AAC GAT ATT TTT) that
enables construction of the tetramer. The heavy chain insert Was removed using
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The clones were sequenced to confirm HLA identity and to ensure the biotinylation
signal sequence was intact. DNA sequencing reactions were performed in the MRC
DNA sequencing facility with primers recognising the vector (sense primer T7 and
antisense rT7). The cloned sequences were confirmed as HLA-A *290201 by running
a BLAST search against the EMBL-EBI IMGTIHLA Database
(http://www.ebi.ac.ukJimgtlhlal. Figure 7.2).
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Figure 7.2. lignment of clone 3 with HLA-A *290201 sequence reference
equence HL 000 6.
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Mini-expression 10 compare protein expression in clones
Three A*2902-PET clones were screened for protein expression. BL21pLysS cells
(Invitrogen) were transformed with the A*2902-PET constructs and grown overnight
on LB-agar plates supplemented with 50 ug/ml ampicillin. The next day, one colony
from each was grown in 2 ml of low salt LB medium (supplemented with 50 ug/ml
ampicillin) shaking at 37°C until the OD at 600 nm was 0.3. Protein production was
induced by the addition of 0.5 mM IPTG. and cultures were grown for an additional 4
•hours. The bacteria were pelleted by centrifugation at 13,000 rpm for 3 minutes and ~
stored at -20°(' overnight. The thawed pellets were resuspended in 50 III of PBS and
25 ul of 3x reducing buffer (50 mM Tr~s-CI pH 6.8, 100 mM OTT, 2% SOS, 0.1%
bromophenol blue. 10% glycerol) and heated for 10 minutes at 95°C. The bacterial
lysates were run on a 12% SOS-PAGE gel at 30 rnA. The gel was stained with
Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories, Hercules, CA, USA) for 4
hours and de-stained over night (10% glacial acetic acid, 50% methanol). A*2902
heavy chain protein (46kD) was induced at similar levels in all clones, clone 3 was
chosen for large-scale production of A*2902 protein (Figure 7.3).
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Protein expression and purification
One colony from the selected A*2902-PET construct was grown overnight, standing,
in 1 litre of low salt LB supplemented with 50 ug/ml ampicillin. Six flasks of the
same medium were inoculated with 100 ml of the start culture, and grown for 3.5
hours shaking at 37°e. The cultures were induced with 0.5 mM IPTG and grown for
another 4 hours. spun down at 4°C at 4000 rpm for 20 minutes, resuspended in 2ml of
cold PBS. and frozen at -80°C overnight.
The pellets were thawed on ice and PBS was added to a total volume of 40 ml. The
PBSlbacteria mixture was sonicated in 6 bursts until the mixture flowed easily. The
lysate was centrifuged for 20 minutes at 15.000 rpm. Remaining bacterial material
was removed from the pellet by scraping with a culture loop, and washing with
distilled water. The pellet was resuspended in 20 ml of Triton wash (0.5% Triton-X-
100. 50 mM Tris pH 8.0. lOO mM NaCI, 0.1% NaN3, 1 mM EDT A, 1 mM DTT)
hornogenised, and pelleted by spinning for 15 minutes at 15,000 rpm. The pellet was
washed twice more with Triton wash and once with 10 ml resuspension buffer (50
mM Trish pH 8.0. 100 mM NaCl. 1 mM EDTA, 1 mM DTT). The pellet was then
resuspended in 40 ml of urea solution (8M urea, 1M Mes pH 6.5, 0.1 mM EDTA, 0.1
mM DTT). rolled at 4°C for 30 minutes, and centrifuged for 15 minutes at 15,000 rpm
to remove precipitate. The Pearce Protein Assay (Bio-Rad Laboratories) was used to
estimate the whole protein content of the preparation. Overall, 128 mg of protein was
recovered. and stored at 3.2 mg/rnl at -80°C.
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Refolding (?OILA-A •]c)()} heavy chain with f32microg/obulin and gp120 peptide
f32microglobulin (132,..)protein had been previously prepared using the same method
described above. The peptide was synthesised in our laboratory by Dr. Kati DiGleria
using F-MOC chemistry. The peptide chosen for refolding is derived from the gp120
region of HIV-J (HXB2 location: 376-374. sequence: FNCGGEFFY). Refolding
buffer (100 mM Tris pH 8.0. 400 mM L arginine, 2 mM EDT A, 5 mM reduced
glutathione. 0.5 mM oxidized glutathione. 0.1 mM PMSF) was prepared immediately
before use and chilled to 4°C. While stirring, approximately 20 mg of peptide
(resuspended in PBS at 10 mg/ml) and 10 mg of 132,..protein were added directly and
rapidly to the refolding buffer. Approximately 34 mg of HLA-A ·2902 heavy chain
protein was added slowly to the mixture. which was left to stir for approximately 24
hours at 4°C. The refolding mixture was spun down at 3000 rpm for 30 minutes at
4°C to remove precipitate. The mixture was concentrated using a stir cell to
approximately 50 mi. then to 5 ml using Amicon centriprep centrifugation devices
(Millipore Corp.. Billerica. Massachusetts, USA). PD-I0 desalting columns
(Amersham Biosciences. Piscataway, New Jersey, USA) were used to exchange the
buffer to (7 ml) 10 mM Tris pH 8.0. The protein was biotinylated at room
temperature overnight using a BirA biotinylation kit (Avidity, Denver, Colorado,
USA). Leupeptin and pepstatin (I ug/ml each) were added to inhibit protease
activity.
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Purification ofprotein monomer
The refolded complex was purified using FPLC (Figure 7.4) and eluted into tris-
buffered saline (20 mM Tris pH 8.0. 0.6% w/v NaCl). Refolded A29 heavy
chainlfJ2~peptide monomer eluted at approximately 150 ml. Free fJ2f.A. protein eluted
at approximately 120 ml and was discarded. Refolded monomer was collected and
concentrated to 2 ml. The concentration of the protein was estimated using the Pearce
Protein Assay. approximately 4.4 mg total protein was recovered at 2.2 mg/ml. To
the final monomer. I mM EDTA and 1 ug/ml each of leupeptin and pepstatin were
added. The monomer was stored in 22 III aliquots at -80cC.
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Figure 7.6. FPL of refolded monomer.
The ref lded hain, ~2microglobulin, peptide complex was purified using
FPL (Figure 7.4) and eluted into tri -buffered saline (20 mM Tris pH 8.0, 0.6% w/v
a I).
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Confirmation ofbiotinylation
Enhanced chemiluminescence (ECl) was used to confirm that the monomer was
biotinylated. One rnicrolitre of monomer was blotted onto a Hybond (GE Healthcare,
Waukesha. Wisconsin. USA) membrane and allowed to dry. Biotinylated 7-B6-1
antibody (Mabtech, Inc .. Cincinnati. Ohio. USA) was used as a positive control. The
membrane was submerged in 4% milk (prepared from powdered milk) and rotated for
10 minutes at room temperature. The membrane was washed for 5 minutes with PBS
supplemented with 0.05% Tween-20; this was done three times. Horseradish
peroxidase-Streptavidin was diluted 1115.000 and added to the membrane, and rotated
at room temperature for 20 minutes. The membrane was washed 3 times with
PBSffween. as described above. The membrane was developed for I minutes with
the Western Blot reagents (Amersham) and visualised using Kodak film (Rochester,
New York. USA: Figure 7.5).
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Figure 7.5. E L to check biotinylation oftetramers.
A&C) Po iti e contr 1 bi tin lated antibody 7-B6-1. B) Biotinylated HLA-A *2902
monomer with no e. travidin or streptavidin added. HLA-A *2902 tetramer
conjugated with D) trepta idin- PC and E) extravidin-PE.
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Generation oftetramers
Tetramerisation of refolded monomeric complexes was achieved by the addition of
streptavidin or extravidin bound to the fluorochromes phycoerythrin (PE, Sigma
Aldrich. St. Louis. Missouri. USA). allophycocyanin (APC, Molecular Probes, Inc.,
Eugene. Oregon). PE-Cy5 (BD Biosciences Pharmingen, San Diego, California,
USA) and Pacific Blue (Molecular Probes). The amount of streptavidin or extravidin
stock added was calculated based on the number of moles of monomer and the
molecular weight of the streptavidin/extravidin-stock. Streptavidin and extravidin
each have 4 biotin binding sites, so a 4: 1 molar ratio of streptavidinlextravidin-stock
to monomer was added. Stocks were added in small aliquots and ECL was performed
at intervals to monitor the amount of unbound biotin remaining. Figure 7.5 shows an
example of a tetramer in which the optimal amount of stock has been added (PE
labelled); unbound biotin is just barely visible as a faint grey spot. In this figure the
APC-biotin sites are not saturated, so the spot is more visible. In most cases, the
amount of extravidinlstreptavidin needed for biotin saturation was less than the
amount calculated based on molarity of the heavy chain. This is probably due to the
overestimation of our monomer concentration. A BioRad Pearce assay was used to
estimate overall protein concentration, but is likely that small amounts of impurities
and misfolded monomer will result in error in concentration measurements. The
different labels were tested on different tetramers (previously synthesised in our
laboratory) and tested on CTL clones specific for their epitope (CMV -NLV and HIV-
B8NEF) to determine which gave the brightest and most specific staining.
Extravidin-Pf (Sigma) and Streptavidin-APC (Pharmingen) were the only
fluorochromes that stained cells brightly and with low background (defined as
minimal staining in CD8 negative celis).
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Optimisation of A29 tetramer staining
Cryopreserved PBMC isolated from an individual lacking the HLA-A*2902 allele
were used as negative controls in the experiments. Control experiments to optimise
tetramer staining were performed on cryopreserved PBMC from an HLA-A*2902
infant previously confirmed to have a response to A29 FNC peptide in ELISpot
assays. An A29-FNC CTL line was generated from these cells in order to have
adequate numbers of cells for control experiments. Cryopreserved cells were thawed
in 5ml of FCS and washed twice with RPM! supplemented with 10% human serum
(HIO) and counted using Trypan Blue to define dead cells. The cells were split and
resuspended at a concentration of 0.5 million live cells/ml. One quarter of the cells
were stimulated for 1 hour with 10 ug/ml A29 FNC peptide at 37°C. The cells were
combined with the unstimulated fraction and suspended in HIO supplemented with 25
ng/ml recombinant IL-7 at a concentration of 2 million cells/ml. Cell lines were
cultured at 5% C02, 37°C. At 3 days in culture, the media was replaced with HlO
supplemented with HI 0 at 200 Vlml. The cells were checked daily and the media
was changed when it became yellow. The cells were split on day 10 when they had
become "crowded" in appearance. On day 0 and 14 cells were stained with A29
tetramer.
In all staining experiments, cells were resuspended in approximately 20 f..llof RIO
media, and tetramer added. The cells were incubated at 5% CO2, 37°C for 15
minutes. Surface antibodies were added and cells were incubated at room
temperature in the dark for 20 minutes. The cells were washed twice and fixed with
Cytofix (BD Biosciences Pharmingen). Before acquisition, cells were refrigerated at
4°C at least one hour for the inactivation of HIV-I.
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A dilution series was performed to determine the optimal concentration of tetramer to
be used in staining. Since cell numbers were limiting even with a CTL line, only two
dilutions were performed and HIV -1 negative donor cells were used as a negative
control. Previous experience in the laboratory has demonstrated that approximately
0.5 ug is sufficient to stain as many as 1 million PBMC. Cells were stained with
tetramer at 25 ug/ml, and 50 ug/ml. There appeared to be no increase in staining with
higher concentration of tetrarner, so staining with 0.5 ug of tetramer (25 ug/ml) was
determined to be of sufficient concentration for high levels of staining of CD8
positive cells with low staining of CD8 negative cells. High populations of tetramer-
stained cells were found in HIV+ A *2902 subjects, and no stained cells were found in
A*2902 negative subjects (Figure 7.6).
201
A)
403 0.074 B 0.51
103 7r.~if··~ 103j " ~t..
r-
" -.·m;s)'·
r-
c-, '.;~~::I. c-,
0 0
W ..'~. W
CL 102 ,.°f" CL 102
1\ 1\
CJ) CJ)
0 0
-' -'
LI) , LI)
Li 101 1- Li 101v v
,.
o 101 102 103
<FL 2 Log> A29 PE
o
Cl.«
12.5
100~~~~~~~ .... ~~~~0~.3~4
1041
FL 2 Loo' A29 PE
Figure 7.6. HLA-A*2902 tetramer staining.
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PBMC from an A) HLA-A *2902 negative patient and an B) HLA-A *2902 positive
patient with HIV -1 infection were stained with A29-PE tetramer. C) A CTL line
(from the same A*2902 po itive patient) shows expansion oftetramer-staining cells at
day 14.
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Fluorochrome labels
Tetramer staining was performed in conjunction with a number of CD8 antibodies
conjugated to different fluorochromes (PE-Cy7, APC-Cy7) and tetramers labelled
with different fluorochromes (PE, APC). The aim was to use a CD8 antibody
conjugated to either AC7 or PC7, because at the time these studies were begun, very
few commercial antibodies were available directly conjugated to these. This would
free up the other channels (FITC, PC5, and APC) for phenotypic antibodies. The best
combination for separating small populations of cells was tetramer-PE and CD8-
APC-Cy7, which gave the brightest staining with tetramer and the best separation
from the tetramer-negative population (Figure 7.7).
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Summary
The HLA-A*2902 tetramer specifically stains CD8 T cells specific for the HIV-I
HLA-A *2902 FNC epitope. The best staining was obtained with extravidin-PE
labelled antibodies. Labelling the CD8 antibody with fluorochromes distant in
emission spectra from PE made the clearest demarcation between tetramer positive
and negative cells.
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Section 2: Optimisation and "aJidations for multicolour flow cytometry
General Introduction
Flow cytometry has been used widely in immunology to describe the phenotype of
cells based on their expression of particular antigens. New instruments with the
ability to measure more than 4 colours have become common in academic
laboratories. Each additional colour utilised increases one's ability to describe
lymphocyte populations as more antibodies/stains can be added to an experiment.
However. each additional colour aJso increases the complexity of experimental design
and data analysis. Our laboratory had no experience with 9-colour flow cytometry at
the inception of this study. so numerous vaJidation experiments were performed prior
to the collection of the real study data. This chapter describes the process of
validation and optimisation of the flow cytometry experiments.
The main aims of these control experiments were:
Optimisation of experimental protocols
Reduction and monitoring of experimental error
Precision. consistency and objectivity in gating of lymphocyte populations
Development of management and analysis systems for large volumes of flow
cytometry data
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Are data collected on two different instruments comparable?
All experiments described in this thesis were performed on Dako Cytomation CyAn
instruments (Dako Cytomation. Angel Drove, UK). Two CyAn models were used in
the study. the ADP and the LX. Both models have the same configuration base
configuration and optics. the LX has an improved red filter and lower red laser output.
The CyAn is fitted with 3 lasers: 405 nm Solid-State Violet Diode, 488 OPSL
Sapphire. and 635 nm Red Diode. This configuration enables an l l-parameter system
of detection: FSC. sse. and detectors FL I thorough FL9.
At the beginning of this study, the WIMM was in possession of a Dako Cytomation
CyAn ADP. Approximately a year into the study this instrument was replaced with
Dako's CyAn LX. and it was necessary to perform the remaining experiments with
the updated model. In order to use data from experiments acquired on the CyAn ADP
and LX, it was necessary to determine whether there were differences in the
measurements produced by the two instruments. Experiments were run concurrently
on both instruments to estimate variation between the measurements.
Methods
Cells from a healthy laboratory donor (Healthy Donor = HD) were stained with
antibody panels A-F, and simultaneously acquired on both machines. Both
instruments were independently configured to optimal photomultiplier tube (PMT)
voltage settings and compensation values. Following acquisition, FCS files were
transferred to a single analysis computer, and analysed independently in separate
FlowJo workspace groups. FCS files were auto-compensated with FlowJo's software
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using single stain controls. For each panel. cells were gated for lymphocytes on
SSC/FCS. (,D3+ cells were gated against SSC. then CD4+ and CD8hi single positive
cells were selected as sub-gates of CD3+. A separate gating path was made for CD3-
C056+ cells on the SSC IFSC lymphocyte gate. These gates applied to each panel of
antibodies so the base subsets (CD3. CD4, CD8, NK) would be the same;
permeabilised cells were gated as their own group separately because their
autofluorescence changes after permeabilisation. CD4+ and CD8hi cells were sub-
gated for further analysis with guidance from isotype controls. Within the subset
gates, cells in each panel were gated for PE+ APC+ and FITC+ staining. Panel G was
excluded from this part of the analysis because it is largely redundant to the other
panels.
Results
Comparison of LX and ADP frequency estimates
Cells stained with panels A-F were gated: Lymphocyte/CD3+ICD4+ and
Lymphocyte/CD3+/C08hi and analysed for FITC, PE, and APC positive staining.
Data collected from the ADP and LX instruments fit a near perfect linear model with
a slope of I (Figure 7.8. slope = 1.00, R square = 0.96, P < 0.0001).
FITC, PE. and APC measurements were also considered as separate groups using
linear regression. These models also showed very good linear correlation: FITC
model: R square = 0.97, slope = 0.90, P < 0.0001 PE: R square = 0.95, slope = 1.1 p <
0.0001 APC: R square = 0.99. slope = 0.99, P < 0.0001.
208
Figure 7.8.
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Antibody Mean (SE) ADP Mean (SE) LX P
frequency estimate frequency
estimate
CD3-PB 61.5 (0.94) 61.2 (2.2) 0.83
CD4-APC-Cy7 47.7 (0.91) 47.4 (0.70) 0.82
CD8-PE-Cy7 39.5 (0.85) 39.3 (0.90) 0.91
aCD56-PE-Cy5 30.2 (1.0) 28.9 (0.73) 0.49
Table 7.1. Pair-wise comparison of ADP and LX estimates of subset frequencies.
apE-Cy5 is excluded from the analysis in Panel F because it is conjugated to CD152.
Comparison between LX and ADP estimates of fluorescence intensity
Channel statistics (mean, median, standard deviation) are often used in flow
cytometry to evaluate relative density of the target antigen's expression on a cell.
Mean fluorescence intensity (MFI) of a fluorochrome is the most commonly used
statistic, it refers to the mean channel number of signals received on the 1024
channels of a flow cytometer. However MFI must be used with caution because it is
extremely vulnerable to experimental error; undersaturation of epitopes, excess
antibody, adjustments in PMT voltage between experiments, and autofluorescence
can modify MFI. By comparison, frequency estimates are more robust. Moving from
the ADP to the LX instrument was a potential source of experimental error for the
current study. MFls were examined to determine whether this measurement error was
consistent and could be used to adjust for differences between machines.
Although the LX and ADP flow cytometers returned similar frequency estimates, the
MFls were different. An example of cells acquired on the LX and ADP generated
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FCS files is shown in Figure 7.9. These dot plots show cells stained with Panel D,
CD27-APC is shown along the y-axis, CD4-APC-Cy7 is shown along the x-axis.
Though the frequency of CD27+ cells gated was similar, the MFI of APC was
significantly higher when measured on the ADP compared to the LX. This difference
may be due to the improved red-filters of the LX. Photomultiplier tubes (PMTs)
logarithmically amplify incoming signals so they can be visualised by the user as dot
plots. PMT voltages are adjusted by the user such that stained cells can be resolved
into positive and negative populations. A higher PMT voltage was applied to resolve
APC-stained cells acquired on the ADP instrument.
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MFls collected from HO cells on the LX and ADP were compared using linear
regression. Lymphocytes were gated, and MFls were estimated for FITC, PE, PE-
Cy5, PE-Cy7, Pacific Blue, APC, and APC-Cy7 in Panels A-F.
With the exception of Pacific Blue, MFI estimates for fluorochromes were higher on
the ADP compared to the LX. Regression showed near perfect linear relationships for
MFI estimates between machines (Figure 7.10). The model fit to the data was: LX =
ADP(slope) + constant. The correlation coefficients (slope) in each model were
significant, but none of the constants were significant; the equation can thus be
simplified to LX = ADP(slope). The correction for FITC was 0.47, PE 0.59, APe
a Ultimately, I decided not to use MFI in comparisons between infants because it is so
vulnerable to experimental error. I used MFI to show differences between different
samples run on the same day (eg, B 1-00x specimens from birth, month 1, etc.).
However, even these should be interpreted with caution as differences in cell numbers
of different specimens may mean different antibody saturation between staining wells.
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Figure 7.10. Linear models for MFIs estimated on the LX and ADP instruments.
There was a near-perfect linear correlation between MFI estimates from the ADP and
LX instruments. For all fluorochromes, the slopes in these models were significant (p
< 0.0001) but the constants were not (p > 0.05) and were thus excluded in the model.
The transformation [ADP x slope] can be used to transform ADP estimates before
compari on with LX data. Linear fits: FITC: R square = 0.99, p < 0.0001, PE: R
square = 0.99, p < O.OOOLAPC R square = 0.92, P = 0.0004.
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Adjustments were not necessary for CD3-Pacific Blue, CD56-PE-Cy5, CD8-PE-Cy7
or CD4-APC-Cy7 because MFI was not used in the analysis of these markers. Pair-
wise comparisons of MFI made between the two instruments demonstrate that ADP
estimates were higher for PE-Cy5, PE-Cy7 and APC-Cy7 compared to LX estimates
(Table 7.2). Pacific Blue estimates were higher on the LX than the ADP.
Antibody Mean (SE) ADP MFI Mean (SE) LX MFI P
estimate estimate
62.0 (0.95) 90.9 (2.0) < 0.0001
63.9 (2.6) 11.6 (0.36) < 0.0001
250 (4.5) 89.1 (2.3) < 0.0001
47.5 (3.1) 20.8 (1.2) 0.0001
CD3-PB
aCD4-APC-Cy7
CD8-PE-Cy7
bCD56-PE-Cy5
Table 7.2. Pair-wise comparison of ADP and LX estimates ofMFls.
Cells were gated on lymphocytes before generating channel statistics.
aAPC-Cy7 is excluded in this analysis from Panel G because its conjugated to CD 16.
bpE-Cy5 analysis is excluded form Panel F because it is conjugated to CD152.
Discussion
Direct comparison of data collected from two different Cyan models revealed
differences between the two instruments. Frequency estimates of cell populations
were similar between the two instruments for all of the fluorochromes tested, but MFI
estimates were not. This is an important observation, particularly for long-running
studies that may utilise multiple instruments, or upgrade to a newer model, as was the
case with the current study.
Simple modelling with linear regression revealed that the equation LX = ADP (slope)
can be used to transform data for comparison between the two instruments used in
this study. A simple linear equation may not be appropriate in all cases, and
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comparisons should be made on the basis of individual instruments to determine the
appropriate model. Alternately, single stain controls or fluorescently labelled beads
can also be used to monitor differences between instruments or changes due to
upgrades or maintenance work. This monitoring should be considered prospectively
before beginning a study.
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Titration of antibodies
Antibodies were titrated in order to optimise resolution of discrete cell populations.
The goals of titration were to achieve antibody saturation of antigen and to maximise
signal-to-noise ratio (SNR). Cryopreserved cells from BD were thawed and stained
with single antibodies. Approximately 300K cells were used per stain. Single
antibody was added to cells at varying volumes: 1, 3, and 5!-li. If saturation was not
reached by 5 !AI,the experiment was repeated with 1, 3, 5, 7, 9 and 10 !AI.
Each antibody used in the study was titrated using single stains of PBMC. Neat
volumes of antibody added were varied, rather than concentration, because in the
laboratory's experience the best staining is achieved with the most concentrated
antibody/cell mixtures. Figure 7.11 shows an example of the titration process. Small
lymphocytes were selected according to FSC/SSC. MFI was plotted for positive and
negative populations. The goal was to achieve saturation of positive staining cells,
but to avoid adding excess antibody, which may result in non-specific adherence to
negative cells. Graphically, over-saturation can be visualised when the cells gated
positive begin to decrease and the cells gated negative begin to increase in MFI
(Figure 7.11C); cells from the negative gate begin to move into the lower range of the
positive gate, causing the overall MFI of the positive gate to decrease. Optimal
antibody volume was identified as the volume before the MFI of negative populations
began to increase significantly and positive MFI levelled off or began to decrease.
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Figure 7.11. Titration for CCR7-PE antibody.
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Controlling and monitoring of experimental error
In order to meet the specific aims of this study, comparisons were made between
individuals (between groups of infants) and within individuals (over time). In order to
maximise the power of these experiments to resolve differences within and between
subjects while reducing experimental error, controls were set up to minimise and
monitor assay variability.
Since this is a longitudinal study, we aimed to reduce variability between different
specimen time-points by running all specimens from an individual in one experiment.
For example, cells obtained from infant BI-OOX at delivery, I, 3,6, 9, and 12 months
would be stained in one experiment. Master mixes of antibodies were prepared prior
to each staining experiment and these were aliquotted in the appropriate amount to
each well during the staining. This minimised intra-assay variation between
longitudinal samples (eg, birth, month I, month 3 etc) specimens stained on the same
day.
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Reduction and monitoring of inter-experiment and inter-patient variability
This study is examining a large number of specimens, so it was impossible to run all
of the specimens in the same experiment. In order to minimize inter-experiment
variation. PMT voltage settings were not altered between experiments (which would
affect MFI). Compensation was checked and modified for each experiment;
adjustments were rarely needed. FlowJo software was used to re-compensate after
each acquisition; FlowJo uses a fixed compensation algorithm so this was chosen as
the most consistent and unbiased method available.
Controls were put in place so that time-dependent changes in instruments (Eg.,
temperature of optics, laser wandering, instrument maintenance) could be monitored.
At a single time point, 100 million cells were isolated from a healthy lab donor (HD),
and split into many separate vials and stored in liquid nitrogen. These cells were used
as controls in all the phenotyping experiments. For each experiment, HD were
stained with single antibodies labelled with FITC, PE, PE-Cy5, PE-Cy7, PB, APC
and APC-Cy7. HO cells were also used for unstained and isotype negative controls.
Since the same source sample was used in each experiment, it was possible to monitor
variation in antibodies and the instrument over time.
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Quality control
The tandem conjugate antibodies were unstable and degraded over a period of weeks
when frequently used. Aliquotting of these into separate dark vials at the time of
receipt somewhat extended the lifespan of these antibodies, presumably by reducing
the amount of light exposure (which causes fluorochrome degradation) and
evaporation (which causes changes in pH). PE-Cy5 antibodies were comparatively
the most stable (> 6 months). APC-Cy7 and PE-Cy7 were much less stable, with a
lifespan of approximately 3 months once opened. FITCIPE and APC antibodies were
very stable by comparison and showed no evidence of declining quality within 6
months to a year of opening.
Tandem conjugates were tested in single stains on a weekly basis before staining CTL
study samples. Full antibody panels were tested on HO cells approximately every 6
months. This process allowed antibody degradation to be detected in time to prevent
inclusion in an experiment.
An example of antibody degradation is shown in Figure 7.12. As the bond is broken
between the PE and Cy7 molecules, one is left with what is essentially a PE-antibody,
and doubly positive (PE+ and PE-Cy7+) cells appear in dot plots. The antibody
shown represents an unusual case as the PE-Cy7 degraded very quickly (over days,
rather than months, and was quickly and apologetically replaced by the vendor) but it
is an excellent example for this discussion. At time day 0, when the antibody was
first opened, it had been aJiquotted into separate dark vials and stored at 4°C. On day
2 and 8, the cells were stained again with the antibody (both from the same aliquot).
On day 8, cells were additionally stained with antibody from an unopened aliquot
221
from day o. By day 2. a separate population of PE-stained cells becomes visible. By
day 8, the antibody has degraded to the point where the majority of stained cells are
doubly positive for PE and PE-Cy7. The unopened aliquot from day 0 also showed
some degradation.
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Isotype controls
Isotype controls were used to determine positive/negative cut-offs for PE, APC, and
FITC. Isotype antibodies were not used to match CD4-APC-Cy7 and CD8-PE-Cy7,
or CD56-PE-Cy5 on cells because these were easily defined as discrete positive or
negative populations. Because of limited patient cell numbers, infant samples were
not stained with isotype antibodies (this would mean an additional 2 tubes/specimen,
or 12 tubes/experiment for infants with 6 visits). Instead, HD control cells were
stained with isotype antibodies, plus CD4 and CD8 antibodies (CD8-PE-Cy7 and
CD4-APC-Cy7). Two panels of isotype antibodies were created, IsoI: CD4-APC-
Cy7, CD8-PE-Cy7, IgGI-FITC, IgGI-PE, IgGI-APC and IsoIl: CD4-APC-Cy7,
CD8-PE-Cy7, IgM-FITC, IgG2b-PE, IgG2b-APC.
HD isotype controls were used to determine positive/negative cut-off channels for
each experiment. Isotype cut-offs were influenced by the use of tandem conjugate
antibodies. Tandem conjugate antibodies such as PE-Cy7 have two emission spectra:
one for the primary conjugate (PE) and one for the tandem (Cy7, which is amplified
by energy from the excited PE-molecule). This is illustrated in the histogram in
Figure 7.13, which compares detection in FL2 (PE) of cells stained with nothing, PE-
Cy5, PE-Cy7 or PE. This "extra peak" must be considered in setting cut-offs to
distinguish positive and negative cell populations. Setting the cut-off correctly
becomes especially important when measuring molecules such as CD69 or CD71,
which are expressed at low density on the cell surface. Mixing the isotype antibodies
with the CD4/CD8 tandem conjugates allows one to set a threshold that takes into
account the PE and APC emission within PE-Cy7 and APC-Cy7. The PE peak is
larger for PE-Cy7 than PE-Cy5, and so the PE cut-off channel was determined by the
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PE peak of PE-Cy7 rather than that of PE-Cy5. Practically, this meant that different
channels sometimes marked the positive/negative cut-offs for the same isotype on
C04 and C08 cells. An example of this is shown in Figure 7.13. Cells were gated by
C04+ or CD8hi expression. The CD4 and CD8hi subsets were then examined for PE,
APC. and FITC staining. The positive/negative cut-off was set as the channel number
where stained cells constituted < I% of the gated population. Cells gated on C04-
APC -Cy7 require a higher cut-off channel to distinguish positive/negative stains for
APC <channel 24.4) compared to cells gated on C08hi-PE-Cy7 (channel 10.1).
Alternately. cells gated on CD8hi-PE-Cy7 (channel 20.3) require a higher cut-off for
PE compared to cells gated on CD4-APC-Cy7 (channel 3.9).
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High throughput method:..
High throughput methods were implemented to reduce experimental error involved in
repeat pipetting. and to increase the number of specimens that could be processed in
one experiment. V-bottorn tissue culture plates (96-well) were used for the staining.
This allowed multichannel pipetting in wash steps, reduced the opening/closing of
caps. and reduced the amount of reagents (PBS, FCS, media, ICS reagents) and
plastics (tubes and caps) that were used in the experiments. The preparation of master
mixes further expedited staining protocols.
Gating strategy
Consistent and precise placement of gates is the primary challenge in the
interpretation of flow cytornetry data. Gate placement becomes especially
problematic in multicolour studies where sequential gating means errors may be
propagated and compounded. Unfortunately. automatic gating algorithms are still in
their infancy - they require a dense number of cells to be well separated from other
populations. and are unable to resolve negative, low frequency or difTuse cell
populations.
The aim of the current study was to make comparisons between individuals and
within individuals over time. The following algorithm was used in gating of the data:
I) Set baseline of isotype control (set negative cut-off of <I% positive staining with
isotype) as in Figure 7.13. Do this separately for CD4 and CD8. 2) Apply gates to
stained cells. copy to all visits so they are the same 3) Check gates, shift to higher
channels if gates bisect relevant populations.
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Figure 7.14 illustrates an example of the gating process. For the majority of samples,
isotype gates appropriately defined populations without further modification. In this
example. isotype samples are used to set cut-offs for positive and negative staining of
CD38-PE and HLA-DR-APC. and these are applied to all of the patient's samples.
228
ord blo id 1 month 3 months
JSI' 9" '65
]
00,
~
- 0--. 027 025
I 1000
L~ H...A-ORAPC <FL8> HLA·OR APC
Figu re .I·t Plac m nt of gat, n 2-dimcn ional dot plots.
ell D hi. I otypes were used to set
) ilh L' ncuativ C UH f II.r Pt: and FIT . the gate were then applied to all of the
229
Data management system
More then 2000 flow cytometry standard (FCS) files were collected during this study.
The large volume of data presented challenges for data storage, organisation, and
retrieval. Oxford's Computational Biology Research Group (CBRG) provided
invaluable assistance in the construction of data management systems for this project.
This section outlines the flow of data from flow cytometer instrument to the final
statistical analysis software.
Processing of FCS Jiles
FCS files were collected on the CyAn flow cytometers. The size of FCS files
depends on the number of events acquired (cells counted), the number of lasers used,
and the number of parameters collected. For the multicolour experiments, a minimum
of 50,000 cells and a maximum of 1 million cells were acquired in each file, file sizes
ranged from about 1-20 MB. The total memory volume taken up by the FCS files
was20.5 GB.
The large file sizes collected in this study restricted options for analysis software.
Summit (Dako) software was used for data acquisition on the flow cytometers, but
was not suitable for the analysis of large or multiple files. FlowJo (Tree Star, Inc.
Olten, Switzerland) was selected for analysis because it was the only software
available at the time that allowed easy batch analysis of large numbers of samples of
large file size. Following the software developer's recommendations, FlowJo v.8.5.3
software was run on a MacPro dual-core processor with 3 GB of RAM.
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FCS files were compensated with FlowJo, organised into groups based on antibody
panels. gated. compiled as FlowJo tables, and exported as text files containing cell
frequencies and MFls. These text files were re-formatted using a PERL (Practical
Extraction and Report Language) script. The PERL script automates important
functions that allow the data to be more easily accessible to the user, for example,
complex FCS file names such as CTL-BI-00I-CORD-PANEL-A are broken down
into separate variables (STUDY (CTL or MIP), CTLCODE (mother or baby), IDNUM,
VISIT, PANEL) based on the "_h delimiter. Data is also transposed by the script such
that I00+ columns of data are reduced to 15 columns of data (by creating grouping
variables), which greatly facilitates downstream movement and analysis of data. The
reformatted files are then uploaded into a laboratory information management system
(LlMS) database for further management (Figure 7.15).
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FACS L1JIS Database
The FACS LlMS database was designed for this study by Stephen Taylor of the
CBRG. The database was designed using Microsoft Access (Microsoft Corporation,
Seattle. WA). FACS LIMS is a Relational Database Management System (RDMS)
containing clinical. laboratory. and research data collected from the cohorts. The
tables contained in the database are shown in Figure 7.16. All tables are joined by the
variables STUDY CTLCODE. ID. and VISIT which when combined uniquely identify
each line of data in a table. This simple relationship allows the user to easily extract
and combine data from multiple tables for export as text files.
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Figure 7.16. Table in the FACS LIMS database.
linical. laboratory and research data files generated from the cohorts are combined
in the FAC LIM databa e. Each file appears as a table in the cohort, which is
linked to all other table by the unique identifier combination of variables: STUDY,
CTLCODE. ID. and VI. 'IT.
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The Panel Query (Figure 7.17) forms the centre of the data extraction system for the
phenotyping study. This query is organised in a tree-like structure that emulates the
gating trees found in FlowJo's workspace files. The Panel Table and its associated
query contain all of the frequency, MFI, and other data generated in FlowJo. The
query allows the user to extract data from any combination of gates desired and to
combine these data with other patient data from the database. The data set generated
for analysis can be as large (including all phenotypes) or as small as the user requires.
Additionally, the user can easily modify the query's design to add additional data
from linked tables (Figure 7.18). The files exported from the database were then
analysed using the statistical software STAT A (Stata Corp, College Station, TX).
STATA analysis programs were written to automate data cleaning, checking,
production of tables, and generation of figures. This greatly streamlined the analysis
as new samples were tested and added to the existing data set. A summary of the
flow of data from the CyAn to the final analysis is illustrated in Figure 7.19.
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Figure 7.17. er interface for the Panel Query.
The Panel query of the F C LI database allows the user to select subsets of
flow C) tornetrj data (cell frequency. channel statistics) and to export these with other
data fr m th hort. The user highlights the flow cytometry data in the tree-
like tructure on the left, then chooses a button (on the right) to select other patient
data to add to the tabl (viral load. CD4, time and peak of HIV viral load, infant
mortality. or d liv er) ). lternately. the "Query All" button adds all of these data to
the output table in ne, tep.
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Figure 7.19. Schematic diagram of the data management system used in the
study.
Data are collected on the CyAn instrument using Summit software. Files are analysed
with FlowJo software, exported as text files, and re-formatted with a PERL script, and
uploaded into the FACS LIMS database. FACS LIMS is used to integrate flow
cytometry data with other patient data from the NMI C cohort. These tables are
exported as text files and analysed with STATA statistical software.
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General conclusions
The aim of this chapter was to describe some of the control experiments performed in
the design and execution of the immunophenotyping experiments. Though these
experiments were performed specifically to refine and understand the current study
protocols. the data presented here are informative for other investigators who are
setting up large cohort studies using flow cytometry data.
Before the commencement of the study, great efforts were made to monitor and
control for possible sources of experimental error. Using frozen cells allowed
reduction of intra-patient variability because all specimens could be tested in the same
experiment. In an ideal experiment, all study specimens would be run concurrently,
but the large number of specimens examined in this study made this strategy
impractical. Between-subjects variability is the largest source of experimental error
in this study. The establishment of a fixed healthy donor (HD) bank of cells for use in
control experiments was invaluable in monitoring and controlling for the effects of
time, instrument and reagent variability. Stringent quality control measures to
monitor antibody stability were also an important aspect of reducing inter-assay
variation and ensuring the production of usable data. Careful titration of antibodies to
assure saturation of epitopes, consistency in compensation and PMT voltages were
also important in limiting inter-assay error.
The upgrading of the CyAn (replacement of filters, lasers, upgrading of optics) is
shown here to have significant effects upon the MFI data. These data highlight the
importance of instrument variability as a source of experimental error and the need for
close monitoring of this error to enable valid comparisons. Such analyses are
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especially relevant in clinical trials where data may be collected over a period of
months or years. during which time instruments may be serviced, upgraded or
replaced several times. Ideally the same instrument would be used for the duration
for the study but in practice this is not always possible. These control experiments
demonstrate that a simple linear transformation may enable comparisons between
different instruments.
Error introduced by manual gating remains the greatest challenge in flow cytometry
studies. In this study. isotype controls were used to standardise the process and
remove some of the subjectivity of the process. Auto-gating tools are useful with the
analysis of some data. but are not appropriate for gating continuous, disperse, or low
frequency populations. New methods of analysis are being developed which aim to
eliminate the need for compensation and gating; these include cluster-analysis and
principal components analysis. Data from the current cohort is being used to explore
some of these novel methods. in collaboration with CBRG and Professor Marie Reilly
of the Karolinska Institute in Sweden.
Investigators collecting large volumes of flow cytometry also face challenges in data
storage. management and retrieval. An integrated system is outlined here that
describes a streamlined process of data transfer from experiment to analysis. The
FACS UMS database is an excellent prototype for a ROMS to integrate laboratory
and clinical data from large trials.
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CHAPTER 8: DISCUSSION
The natural histol)' of HIV-l infection in Kenyan infants
Currently more than 2 million children are infected with HIV -1. Mortality is very
high in HIV-1 infected children during the first two years of life in the absence of
ARV therapy. In the CTL cohort, half of the children died before their second
birthday despite frequent visits to clinic and close monitoring by study paediatricians.
Mortality rates are likely to be even higher in rural areas of Kenya with less medical
infrastructure. The pattern of viral load and CD4 during infant HIV -1 infection was
strikingly different than observed in adults. The majority of infants experienced
persistently high levels of viraemia throughout the observation period without
reaching a "set-point" or steady state viral load. Additionally, rapid depletion of CD4
was observed. without the partial recovery observed in adults following acute
infection. Opportunistic infections were common during the first few months of life,
even in infants with CD4 counts above critical levels.
The current study highlights the importance of early diagnosis and treatment for HIV-
1 infected infants. In adults and older children, the decision to initiate ARV therapy is
made based on laboratory measurements and clinical indicators. However HIV-l
progresses so rapidly in infants that delaying the initiation of therapy could be fatal.
Since this study was completed. ARV therapy has become more widely available in
Kenya, but the majority of HIV -1 infected women are not accessing pMTCT
interventions. There is still a great need for the expansion of voluntary counselling
and testing facilities to capture more infected women before delivery, or more ideally,
before they become pregnant.
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Primary CMV iafection; A co-factor for HIV-l disease progression in African
incants?
Co-infection with CMV has long been associated with increased mortality during
AIDS in adults. SeveraJ reports also suggested an association with increased
mortality in co-infected infants. The current study addressed this question by
examining longitudinal CMV and HIV -I viral loads in HIV -I infected and exposed
uninfected infants. The pattern of CMV viraemia peak and decline was delayed in
HIV -I infected infants. and many continued to be viraemic at the end of observation.
Surprisingly. many of the HIV -I exposed uninfected infants also experienced
prolonged levels of plasma viraemia. suggesting that even in immunocompetent
infants systemic CMV replication may not be tightly contained. A similar study
should be performed in healthy HIV -I unexposed infants to determine if systemic
CMV replication observed here is a result of HIV-I exposure.
CMV viraJ load has been shown to predict survival in adults with low CD4 counts or
AIDS. In the current study. CMV viral load was not associated with survival in the
infants when controlling for HIV -I viral load. There may indeed be a predictive
effect that the current study was underpowered to detect because of the strong effect
of HIV -I viral load. The correlation between HIV -I and CMV viral load is likely to
be explained by immunosuppression facilitating CMV replication. In the current
study infants with HIV -I who acquired CMV before 1 month of age had an increased
risk of death. Interestingly, this effect was seen only in those children with relatively
lower levels of HIV - J viraemia, suggesting that CMV co-infection can significantly
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increase mortality in children who would otherwise have a better prognosis. Infants
co-infected with CMV at I month of age also had higher frequencies of activated
CD4 cells. Although the link between activation and mortality cannot be made from
this small study. it is plausible that the activation of CD4 T cells by CMV may
contribute to HIY - t disease. Both viruses can be transmitted to infants via the gut
mucosa. and dual infection in GALT could potentially accelerate C04 depletion.
These data illustrate the potential benefits of a neonatal CMV vaccine, and warrant
further investigations into the benefits of delaying or preventing CMV infection in
HIV -I exposed neonates. Co-infection with CMV and other pathogens early in life
are likely to contribute to the excess mortality observed in African infants compared
to European and American cohorts.
Lymphocyte redistributions during primary viral infection
The longitudinal study of T cell phenotype during primary HIV -1 and CMV infection
enabled the discrimination of virus-induced effects on lymphocyte distributions. Both
HIV -I and CMV had dramatic effects on the C08 subset, stimulating cellular
activation. apoptosis. and the development of effector and memory cells. In
comparison. remarkably subtle changes were observed during primary infection in the
CD4 subset. This is surprising in context of the very high levels of HIV -1 viraemia
and perhaps suggests tighter homeostatic control over CD4 activation during acute
infection. It is not possible to determine from the current study what proportion of
these changes can be attributed to virus-specific cells.
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"IV -1 specific CDS T cells
Tetramer-staining experiments on a subset of infants demonstrated that high
frequencies of HIV-I specific CD8 T cells could be generated early in life. In one
infant 3.8% of CD8 T cells were directed at a single HIV-I epitope. Changes in the
phenotype of HIV -I specific CD8 during post-acute infection were also similar to
patterns observed in adult infection. The altered expression of cellular markers
examined in the current study does not explain the failure of CTL to control viraemia
in infants. The dysfunction of neonatal T cells may be explained by impaired
cytokine production or cytotoxicity. IFN-y ELI Spot data from this cohort revealed
that HIV-I speci fie CD8 responses were rare in infants at 1 month of age (-15%) but
increased with age. By 3 months more than 50% of infants had a detectable response
to at least one peptide and the magnitude of responses increased with age. However,
neither the presence of a response, nor the magnitude or breadth of peptide-specific
responses correlated with HIV -1 viral load or mortality. Together these data suggest
that very young infants can indeed produce CD8 responses, but the in vivo priming of
these responses somehow fails to generate a T cell that is able to effectively limit viral
replication. Lack of CD4 help is likely to be a large component of this failure, and
may also explain why CD8 IFN-y production appears to improve with age. The
ability of the infants to generate HIV -I specific CD8 T cell responses is encouraging
for the potential benefit of a CTL-based vaccine in neonates.
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Concluding remarks
We offer our deepest thanks to the families who participated in these studies for the
benefit of the women and children of Africa. We hope the data presented here has
broadened our understanding of the processes governing HIV-1 pathogenesis in
infants.
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